CURRICULUM VITAE

JEFFREY L. CUMMINGS, M.D., Sc.D.

December 14, 2016 TABLE OF CONTENTS

PERSONAL HISTORY: ...... 2 EDUCATION: ...... 2 PROFESSIONAL EXPERIENCE: ...... 2 BOARD CERTIFICATION: ...... 3 MEDICAL LICENSURE: ...... 3 HONORS AND AWARDS: ...... 4 PROFESSIONAL ACTIVITIES: ...... 5 SOCIETIES AND AFFILIATIONS: ...... 5 MISCELLANEOUS: ...... 7 INTERNATIONAL POSITIONS: ...... 8 NIH ALZHEIMER'S CENTER GROUP: ...... 8 ALZHEIMER’S ASSOCIATION: ...... 9 INTERNATIONAL ADVISORY BOARDS: ...... 9 UCLA NEUROBEHAVIOR AND DEMENTIA FELLOWS: ...... 10 UCLA INTERNATIONAL SCHOLARS: ...... 10 CLEVELAND CLINIC LOU RUVO CENTER FOR HEALTH SCHOLARS: ...... 10 UCLA PH.D. DISSERTATION COMMITTEES: ...... 10 FOUNDATIONS: ...... 11 JOURNAL AND TEXTBOOK BOARDS AND SERVICES: ...... 11 PROPOSAL REVIEW SERVICES: ...... 14 FUNDED RESEARCH: ...... 14 INDUSTRY-SPONSORED RESEARCH AND CLINICAL TRIALS: ...... 15 FOUNDATION AND ALZHEIMER’S DISEASE COOPERATIVE STUDY (ADCS) TRIALS: ...... 17 INDUSTRY RELATED EXPERIENCE: ...... 18 PUBLICATIONS: ...... 19 Books ...... 19 Articles ...... 20 Multicenter Publications to which Dr. Cummings was a Contributor ...... 58 Cleveland Clinic Publications ...... 60 Chapters ...... 60 Monographs ...... 72 Abstracts ...... 72 Book Cover Citations...... 96 Book Reviews ...... 96 Forewords ...... 97 Other ...... 97 MEDIA/VIDEOS: ...... 99 SELECTED NATIONAL PRESENTATIONS/NAMED LECTURESHIPS: ...... 99 SELECTED INTERNATIONAL PRESENTATIONS: ...... 101

1

C U R R I C U L U M V I T A E

PERSONAL HISTORY:

NAME: JEFFREY L. CUMMINGS, M.D., Sc.D.

TITLE: Director, Cleveland Clinic Lou Ruvo Center for Brain Health Camille and Larry Ruvo Chair for Brain Health Cleveland Clinic Neurological Institute Las Vegas, Nevada; Cleveland, Ohio; Weston, Florida Professor of , Cleveland Clinic Lerner College of Medicine of Case Western University Adjunct Professor of Psychology, College of Liberal Arts, University of Nevada, Las Vegas Adjunct Clinical Professor of , University of Nevada Las Vegas School of Medicine

BUSINESS ADDRESS: Cleveland Clinic Lou Ruvo Center for Brain Health 888 W. Bonneville Avenue Las Vegas, NV 89106 T: 702.483.6029 F: 702.483.6028

EDUCATION:

Baccalaureate University of Wyoming, graduation with High Honors, Bachelor of Science (Zoology), l966 – l970

MD University of Washington School of Medicine, Seattle, Washington, M.D., l970 – 1974

ScD University of Wyoming Laramie, Wyoming Bestowed 2011

Internship Flexible Internship, Hartford Hospital, Hartford, Connecticut, 1974 – l975.

Residency Neurology, Boston University School of Medicine, Boston, Massachusetts, l975 – 1978

Fellowship I , Boston University School of Medicine, Boston, Massachusetts, l978 – 1979

Fellowship II Postgraduate studies in Neuropathology and , Institute of Neurology National Hospital for Neurological Queen Square, London, England, l980

DATE OF BIRTH: March 8, l948

PLACE OF BIRTH: Basin, Wyoming

CITIZENSHIP: United States

PROFESSIONAL EXPERIENCE:

2

Boston University School of Medicine 1978 – 1979 Chief Resident in Neurology, Instructor in Neurology, Boston University School of Medicine Instructor, Clinical Medicine (Neurology), Laboure Junior College, Boston, Massachusetts 1979 – 1980 Director of Behavioral Neurology, Boston University Medical Center; Assistant Professor of Neurology, Boston University School of Medicine Consultant in Neurology, VAMC Boston Coordinator, Wald Neurological Unit, Boston University Medical Center

Department of Veterans Affairs 1980 – 1990 Director, Neurobehavior Unit, West Los Angeles VAMC (Brentwood Division) 1981 – 1988 Chief of Medicine, West Los Angeles VAMC (Brentwood Division) 1984 – 1988 Assistant Clinical Director, Nursing Home Care Unit, West Los Angeles VAMC 1986 – 199l Co-Chief, Movement Disorders Laboratories, West Los Angeles VAMC (Brentwood Division) 1989 – 1996 Associate Chief of for Neurobehavior, West Los Angeles, VAMC 1992 – 1997 Director, VA Geriatric Neurology Fellowship, West Los Angeles VAMC 1996 – 1999 Consultant to the Neurobehavior Unit, Psychiatry Service, West Los Angeles VAMC

UCLA School of Medicine 1980 – 1986 Assistant Professor of Neurology in Residence, UCLA School of Medicine 1983 – 1994 Co-Director, UCLA Neurobehavior Training Program, Department of Neurology, UCLA School of Medicine 1985 – 199l Clinical Co-Director, Alzheimer's Disease and Disorders Clinic, UCLA School of Medicine 1986 – 1992 Associate Professor of Neurology in Residence, UCLA School of Medicine 1986 – 1992 Associate Professor of Psychiatry & Biobehavioral Sciences in Residence, UCLA School of Medicine 1988 – 199l Director, Dementia Research Program, UCLA School of Medicine 1991 – 1996 Director, UCLA Geriatric Behavioral Neurology Clinic 1991 – 2010 Director, UCLA Alzheimer's Disease Center 1992 – 2010 Professor of Neurology and of Psychiatry & Biobehavioral Sciences, UCLA School of Medicine 1994 – 2010 Director, UCLA Dementia and Neurobehavior Research Fellowship 1996 – 2010 The Augustus S. Rose Professor of Neurology 2002 – 2006 Vice Chair, Department of Neurology 2002 – 2008 Executive Vice Chair, Department of Neurology 2004 – 2010 Director, Deane F. Johnson Center for Neurotherapeutics at UCLA 2009 – 2010 Director, Mary S. Easton Center for Alzheimer’s Disease Research at UCLA

Cleveland Clinic 2010 – Present Director, Cleveland Clinic Lou Ruvo Center for Brain Health 2010 – 2012 The Andrea L. and Joseph F. Hahn MD Chair of Neurotherapeutics, Cleveland Clinic, Neurological Institute 2012 – Present The Camille and Larry Ruvo Chair for Brain Health

BOARD CERTIFICATION:

1975 National Board of Medical Examiners l979 American Board of Neurology and Psychiatry (Neurology)

MEDICAL LICENSURE:

1980 – Present California (G42655) 2010 – Present Nevada (13787) 2011 – Present Ohio (096992)

3

HONORS AND AWARDS:

1970 Phi Beta Kappa 1973 Epilepsy Foundation of American Student Fellowship; Epilepsy Clinic, University of Washington School of Medicine, AA Ward and JR Green, preceptors 1974 Thesis Award, University of Washington School of Medicine 1989 Arthur Cherkin Award (for contributions to and Gerontology at UCLA) 1990 Neurology Faculty Teaching Award; UCLA Department of Neurology 1992 Research Award, Los Angeles Chapter, Alzheimer's Association 1993 Psychiatry Senior Faculty Teaching Award; UCLA Department of Psychiatry 1993 Irving and Helga Cooper Award for Geriatrics Research 1993, 2001, Best Doctors in America (Neuropsychiatry Section) 2005, 2006 1996 Best Doctors in America (Neurology Section) 1996 NorAge - Pharmacia & Upjohn Award for paper "Frequency of dementia in Parkinson's disease" by D. Aarsland, E. Tandberg, JP Larsen, JL Cummings. 1996 The Augustus S. Rose Professor of Neurology; endowed chair 1996 Benjamin Wiesel Lectureship; Hartford, Connecticut 1997 Cyril B. Courville Memorial Lectureship; Loma Linda, California 1997 Honorary Member of the American Association of 1998 Alexander Nies Lecture; University of Vermont 1998 The Dolan Lecture; Arlington, Virginia 1999 Gold Hugo award for Video Communicating the Impact of Alzheimer’s Disease to Patients and Caregivers 2000 The Tobolowsky Lecture; Dallas, Texas 2000 Matthew and Marcia Simons Lectureship; Boston, Massachusetts 2000 “Cotzias Lecturer”, Spanish Neurological Society 2000 Honoree, Alzheimer Association of Orange County 2002 Elected to American College of 2003 23rd Srinivasan Orator; Chennai, India (with medal) 2005 Henderson Lectureship American Geriatric Society (Annual Meeting) 2005 Outstanding Alumni, University of Wyoming 2006 Sanford Meyerowitz Lectureship; Department of Neurology, Rochester, New York 2006 Rayport Lecture, Department of Psychiatry, University of Ohio, Toledo 2007 Ramasamy Udayar Oration in , Ramachandran University, Chennai, India (with medal) 2007 Mani Memorial Lecture, Bangalore Neurological Society, Bangalore, India 2007 Cheves Smythe Distinguished Lecture, Department of , University of Texas , Houston, Texas School; Houston, Texas 2007 Chosen for New York Times “2007 Year In Ideas” for publication on telephone screening for signs of dementia (part of project with the Alzheimer's Disease Cooperative Study) 2008 Research Award, John Douglas French Alzheimer's Research Foundation 2008 Ronald and Nancy Reagan Research Award, National Alzheimer's Association. 2009 Included in “Rock Stars of Science™” supported by Geoffrey Beene Foundation and featured in Gentlemen’s Quarterly (reproduced in Vanity Fair and Vogue) 2009 Connelly’s Best Doctor, 5 year award 2010 Distinguished Scientist Award, American Association of Geriatric Psychiatry 2010 Featured in Beverly Hills Lifestyle (article about Dr. Cummings and the UCLA Easton Alzheimer’s Center. 2010 Legacy Award; Tichi Wilkerson – Kessel Movement Foundation; Los Angeles, California 2010 OPICA Founders Award; Los Angeles, California 2010 Vikrit Viranuvatti Invited lecture; Royal Conference of ; Thailand 2010 Joseph Foley Lecture; Cleveland, OH 2010 Honorary Fellow Royal College of Physicians of Thailand (FRCP, Hon, Thailand) 2010 Andrea and Joseph Hahn Chair for Neurotherapeutics; Las Vegas, NV 2011 Honorary Doctorate (ScD), University of Wyoming 2011 Lifetime Achievement Award; Vegas Inc., Las Vegas, Nevada 2011 Distinguished Lecture, University of Wyoming 2012 America’s Top Doctors 2012 Vegas Dozen (honoring Leading Men of Las Vegas) 2012 Camille and Larry Ruvo Chair for Brain Health at the Neurological Institute of Cleveland Clinic 4

2012 George and Cynthia Woods Mitchell Lecture on Neurotherapeutics, University of Texas; Medical Branch, Galveston, Texas 2012 Peter Bassoe Keynote Address for the American Neuropsychiatric Association/Central Neuropsychiatric Association 2012 Leader of Industry, National Public Radio; Las Vegas, NV 2012 Distinguished Men and Women of Nevada, Distinguished Publishing Company; Las Vegas, NV 2013 Lifetime Achievement Award, Community Partners for Better Health; Las Vegas, NV 2013 Cleveland Clinic Innovation Award 2013 Desert Companion Best Doctor Award 2013 Ranked among top 400 most influential biomedical researchers and ranked #3 among Alzheimer’s disease researchers world-wide (Boyack K et al. Eur J Clin Invest 2013; 43:1339-1365) 2014 Castle Connolly’s America’s Top Doctors (published nationally and in Seven Magazine locally) 2014 Vegas Inc. Top Docs (in Neurology) 2014 Plenary Speaker, Cleveland Clinic Research Day 2014 Plenary Speaker, Inaugural meeting of TEDxUNLV 2014 Favorite Las Vegas male by Las Vegas premier newspaper (Review Journal) 2014 Desert Companion (NPR); Best Doctors 2014 Inspired Excellence in Healthcare Awards; Las Vegas HEALS 2015 Desert Companion Best Doctors (Neurology) 2015 Top Doc - Neurology, Vegas Seven Magazine – Spring 2016 Commencement Speaker, University of Wyoming, School of Health Sciences 2016 Top Doc- Neurology, Vegas Seven Magazine – Spring 2016 Leon Thal Memorial Lecture, University of California San Diego

PROFESSIONAL ACTIVITIES:

SOCIETIES AND AFFILIATIONS:

American Neurological Association 1992 – Present Member

American Academy of Neurology 1980 – Present Member 1989 – 1990 Course Director, American Academy of Neurology Neuropsychiatric aspects of Neurologic Disease 1990 – 1992 Member, American Academy of Neurology Self-Assessment for Neurologists Committee Behavioral Neurology Section 1991 – 1993 Member, Subcommittee on Syllabus preparation for Recertification (Behavioral Neurology) 1993 – 1995 Facilitator, panel on in Neurology; subcommittee of Therapeutics and Technology Assessment Committee 1993 Abstract Review Committee, Behavioral Neurology and Neuropsychiatry Sections 1994 – 1995 Abstract Review Committee, Neuropsychiatric Section 1995 – 1998 Abstract Review Committee, Aging and Geriatric Neurology 1980 – Present Member, Behavioral Neurology Section 1994 – 1996 President, Behavioral Neurology Section 1998 – 2000 Co-Chair, Panels on Dementia Recognition, Diagnosis and Treatment Guidelines 2001 – Present Fellow 2002 Abstract Review Committee, Session Co-Chair, Behavioral Neurology Section 2003 Co-Chair, Dementia Platform Abstract Session 2003 – 2006 Course Director, Non-Alzheimer Dementias 2004 Chair, Abstract Review Committee, Behavioral Neurology 2005 Course Member, Dementia 2006, 2007 Course Member, Management of Behavioral Aspects of Dementia; Behavioral Neurology of Dementia Syndromes 2011 Faculty Member, Dementia Update Course

International Neuropsychological Society 5 l985 – 2005 Member

Behavioral Neurology Society 1986 – Present Member 1992 – 1994 Counselor 1992 – 1997 Chair, Certification and Accreditation Committee 1994 – 1996 President

American Psychiatric Association 1983 – 2010 Member

Society of Biological Psychiatry 1985 – 2006 Member

American Geriatric Society 1993 – 2008 Member 1993 Abstract Review Committee

Movement Disorders Society 1987 – 2000 Member

American Neuropsychiatric Association 1990 – Present Member 1993 – 2006 Member Research Committee 1993 – 1996 Board of Directors 1996 Executive Director 1996 – 1998 Abstract Reviewer 2000 Fellow

American Association for the Advancement of Science 1988 – Present Member

American Medical Association 1997 – Present Member

American Association of Geriatric Psychiatry 1998 – Present Member (Honorary)

Neuropsychiatric Institute, UCLA (Peter Whybrow, Director) 1998 – 2010 Senior Research Scientist

Institute for Neurodegenerative Disease, UCSF (Stanley Prusiner, Director) 2000 – 2010 Member

International Psychogeriatric Association 2000 – Present Member

American College of Neuropsychopharmacology 2002 – Present Member (Limited elected membership)

American Society for Experimental Neurotherapeutics (ASENT) 2001 – Present Member

Egyptian Neurological Society 2000 – Present Honorary Member

6

Thai Neurological Society 2004 – Present Honorary Fellow

Asian Dementia Society 2009 – Present Advisor

Clark County Medical Society 2012 – Present Member

Nevada State Medical Association 2012 – Present Member

Department of Veterans Affairs 1981 – 1983 Medical Records Committee West Los Angeles VAMC (Brentwood Division) 1981 – 1988 Member, GRECC Advisory Committee West Los Angeles VAMC 1982 – 1987 Research and Development Committee West Los Angeles VAMC (Brentwood Division) 1982 – 1986 Therapeutic Agents and Committee West Los Angeles VAMC (Brentwood Division) 1983 – 1989 Director's Task Force for Development of VAMC West Los Angeles Nursing Home Care Unit 1984 – 1988 Mental Health Council, West Los Angeles VAMC, (Chairman, l988) 1987 – 1988 Chairman, Residency Commission West Los Angeles VAMC (Brentwood Division) 1989 – 1999 Member, Dean's Committee West Los Angeles VAMC 1993 – 1997 Chair, GRECC Advisory Committee, West Los Angeles VAMC 1995 – 1996 Member VACO Office of Geriatrics and Extended Care Dementia Workgroup 2007 – 2010 Member, GRECC Advisory Committee West Los Angeles VAMC

UCLA School of Medicine 1983 – 1990 Assistant Chief of Neurology, Neuropsychogeriatrics Division of Department of Psychiatry UCLA School of Medicine 1985 – 1986 Member, Geropsychiatry Cluster Planning Committee, Rural Affiliated Neuropsychiatric Cluster Hospital (RANCH), UCLA 1985 – 2000 Academic Geriatric Resource Center Committee UCLA School of Medicine, Member 1988 – 1990 Chairman, Priority 5 Committee UCLA Department of Neurology 1989 – Present Member, Residency Selection Committee UCLA Department of Neurology 1989 – 1991 Neuroscience Curriculum Work Group UCLA 1990 – 1992 Chairman, Medical Student Education Committee Department of Neurology, UCLA 1990 – 2000 Chairman, Thesis Committee Department of Neurology, UCLA 1990 – 1993 Member, Quality Assurance and Peer Review Committee, Department of Neurology, UCLA 1990 – 1993 Faculty Planning Committee Center for Aging, UCLA 1992 – 1999 Member, Geriatric Medicine Intensive Course Steering Committee 1993 – 1994 NPI Director's Policies and Resources Advisory Committee 1993 – 1996 Member, UCLA Faculty Executive Committee 1994 – 1995 Chair, UCLA Neurology Search Committee (4 Neuroscience Positions) 1995 Member, UCLA Chair of Psychiatry Search Committee 1995 – 2000 Member, Department of Neurology Promotions Committee 1996 Member, UCLA Center on Aging Director Search Committee 1997 – 2004 Brain Research Institute Steering Committee 1997 Member, UCLA 5-Year Review Committee (Department of Molecular and Medical Pharmacology) 1997 Brain Research Institute Review Committee (Chair 2000 – 2003) 2000 – 2003 Chair, Department of Neurology Promotions Committee 2000 – 2005 Member, Scientific Advisory Board, Center for Vulnerable Populations Research

Cleveland Clinic 2014 – Present Cleveland Clinic Philanthropy Committee 2015 Innovation Summit Steering Committee

MISCELLANEOUS:

1983 – 1990 Neurological Consultant, Los Angeles Chapter Association 7

1986 – 1990 Scientific Advisory Board Los Angeles Resource Center (For Adults with Brain Impairment and their Caregivers) 1990 – 1992 Consultant, California Athletic Commission 199l – 1995 Consultant, American Medical Association Drug Evaluations Text and Periodicals 1992 – 1993 Member, Sigma Tau Scientific Journalism Award (to judge and reward outstanding journalism concerning Alzheimer's disease) 2000 – 2008 Member, Scientific Advisory Board, Institute for the Study of Aging 2004 – 2008 Alzheimer’s Research Forum Board 2014 –present Member, Wyoming Governor’s University of Wyoming (UW), Top-Tier Science Programs and Facilities Task Force 2014- present Lead, FasterCures, Philanthropy Advisory Service, Alzheimer’s Disease Committee 2014- present Member, ACT AD Science Advisory Board 2015 – present Co-Chair, Global Alzheimer Program Network (GAP NET) 2015 Consultant, Coalition Against Major Diseases (CAMD)

STATE, NATIONAL AND INTERNATIONAL GOVERNMENTAL SERVICES:

Neurological Consultant and Lecturer for the Philippine Government (March, 1983) NIH Study Section Member (Human Development and Aging; HUD-2), 1988-1992 Reviewer, Medical Research Council of Canada (1989 - 1999) Invited participant, NINDS-AIREN Workshop on Vascular Dementia. Criteria for diagnosis developed (April, 1991) Consultant, DSM IV Cognitive Impairment Section. (1991 - 1994) Member, NIMH Task Force on the Neuropsychological Assessment of HIV encephalopathy (Nelson Butters, Chairman) Member, NIMH Work Group on Depression in the Elderly (George Nederhe, Chairman) National Institute's Health Reviewers Reserve (7/1/92 - 6/30/96) Reviewer, Canadian Alzheimer Association (1992 - present) NIA ad hoc Alzheimer's Disease Center reviewer (1994, 2000) Aging and Neuroscience Research in the VA. Presentation to Congress Members and Congressional Staff (1995) NIMH ad hoc Geriatric Psychiatry Center review (1996) Member, Scientific Advisory Board, Sophie and Abram Stuchynski Alzheimer Research and Treatment Center Ramat Gan, Israel (1999 - 2005) NIA, Special Review Panel (for ADRC’s), Chair (1999) Chair, NIA ad hoc Alzheimer's Disease Center reviewer (2000, 2001) Member, NIMH Work group on degeneration in Alzheimer’s disease (2002) Chair, NIA Review Committee of Pilot Studies of Treatment for Alzheimer’s disease (2002 – 2008) Chair, Alzheimer’s Disease Center Ad Hoc Review Committee (2004) Chair, NIA Review Committee for Alzheimer’s Disease Research Center (2004) Member, NINDS Treatment of Depression in Parkinson’s Disease (SAD-PD) DSMB (2004 – 2010) Member, NINDS Parkinson Disease Neuroprotective Therapy (NET-PD) Program Advisory Board (2005 – 2010) Advisor, Alzheimer’s Study Group (report submitted to Congress 2010) (2009 – 2010) Testimony, House Foreign Relations Committee, Global Health Subcommittee (2011) Senior China Consultant, Scientific Steering Committee, National Clinical Research Center of Neurological Diseases (2014) Testimony, PreHearing Senate Briefing on head injury and dementia (2014) Member of FDA-affiliated Critical Path Institute, Coalition Against Major Diseases (CAMD) Work Group on cognitive outcomes for clinical trials in mild cognitive impairment/prodromal AD (2014/2015) Member, Wyoming Governors’ University of Wyoming (UW) Top-Tier Science Program and Facilities Task Force (2014/2015) Member, UNLV School of Medicine Community Advisory Board (2014 - present)

INTERNATIONAL POSITIONS:

Advisor, Alzheimer's Disease Clinic, Jakarta, Indonesia (2000 – Present), (Buku Peringutan Hut RS Dharma Tava ke 29)

NIH ALZHEIMER'S DISEASE CENTER GROUP:

Member, Steering Committee (1999 – 2000) 8

Member, National Alzheimer's Coordinating Center Steering Committee (2000, 2001) Chair, Steering Committee (2001) Member, Uniform Data Set Task Force (2001 – 2004) External Advisory Board, Irvine Alzheimer’s Disease Research Center, Irvine, CA (2006 – present)

ALZHEIMER’S ASSOCIATION:

1983 - 2010 Member, Los Angeles Chapter Alzheimer's Association Scientific Advisory Committee 1997 - 2001 Chair, Los Angeles Chapter Alzheimer's Association Scientific Advisory Board 1997 - 2001 Research and Practice Advisory Board, National Alzheimer's Association 1998 - 2002 National Medical and Scientific Advisory Council 1998 - 2002 National Board of Directors 2000 - 2004 Board Member, LA Chapter 2001 - 2004 President, Board of Directors, LA Chapter 2010 - Present Member, Desert Southwest Chapter of the Alzheimer’s Association Scientific Advisory Committee

ALZHEIMER’S DISEASE COOPERATIVE STUDY:

1993 - 2004 Steering Committee 1993 - 2010 UCLA Lead Investigator 1999 - Present Instrument Committee 2004 - 2009 Primary Prevention International Protocol 2005 - 2010 Valproate Study Steering Committee 2010 – 2012 Project Selection Committee

ALZHEIMER’S TREATMENT RESEARCH INSTITUTE OF USC:

2015 – Present External Advisory Committee

ALZHEIMER’S FOUNDATION:

2010 – Present Research Scientific Advisory Committee

USAGAINST ALZHEIMER’S

2010 – Present Leaders Against Alzheimer’s Disease (LEAD) Group

GLOBAL ALZHEIMER’S PLATFORM – NETWORK (GAP-NET)

2015 – Present Co-Chairman 2015 – Present TRC-PAD Co-Investigator

INTERNATIONAL ADVISORY BOARDS:

Alzheimer’s International – 2005 Meeting (Istanbul, Turkey); 2011 Meeting (UK); 2012 Meeting (Taiwan) International Neuropsychiatric Association – 2006 Meeting (Sydney, Australia)

FASTER CURES (A Milken Family Foundation) 2005 Member, Philanthropy Advisory Service 2014-present Chair, Philanthropy Advisory Service, Alzheimer’s Disease Consortium

9

UCLA NEUROBEHAVIOR AND DEMENTIA FELLOWS:

1980 Ralph Lilly 1994 Kevin Gray (with Geriatric Psychiatry) 1982 Michael Frankel 1994 Katherine White 1982 Sandra Horowitz 1995 Mark Wright 1984 Steven Read (with Geriatric Psychiatry) 1996 Morgan Levy (with Geriatric Psychiatry) 1985 Mario Mendez 1996 Donna Masterman 1985 Bruce Miller 1996 Tomo Nakawatase 1986 Jeffrey Davis 1996 Terri Edwards-Lee 1987 Michael Mahler (with Geriatric Medicine) 1996 Tiffany Chow 1987 William Reichmann 1997 Seth Weingarten 1988 Stephen Signer 1997 John Ringman 1988 Adam Darkins 1997 Barry Jordan 1988 Artiss Powell 1997 Adrian Mirea 1988 Fred Flynn 1998 Yuri Bronstein 1988 Jeffrey Victoroff 1998 Julia Chung 1989 David Sultzer 1998 Verna Porter (with Geriatric Medicine) 1989 Donald Freidenberg 1999 Sylvia Askin-Edgar 1989 Keith McDaniel 1999 Mark Pippenger 1989 Webb Ross 2000 Susan Guy 1990 Greg Gorman 2001 Susan O’Connor 1990 John Absher 2001 David Clark 1991 Mace Beckson 2002 Margaret Swanberg 1991 Douglas Scharre 2002 Zakiya Wynn 1992 Michael Mega 2003 Liana Apostolova 1992 Dan Kaufer 2004 Gad Marshall 1993 Ann Craig 2005 Edmond Teng

UCLA INTERNATIONAL SCHOLARS:

1988 Judith Aharon- Peretz (Israel) 2002 TJ Hwang (Taiwan) 1989 Larry Dian (Canada) 2002 Fred Assal (Switzerland) 1992 C. K. Liu (Taiwan) 2003 Il-Seon Shin (South Korea) 1995 Dag Aarsland (Norway) 2003 Mei-Sian Chong (Singapore) 1996 Dean Foti (Canada) 2004 Solasinee Hemrungrojn (Thailand) 1997 Ziad Nasreddine (Canada) 2004 Darwin Dasig (Phillipines) 1998 Sibel Tekin (Turkey) 2005 Tuty Yeo (Indonesia) 1999 Nobuto Hirono (Japan) 2005 Encarnita Raya Ampil (Phillippines) 2000 Lyna S. Kiemas (Indonesia) 2005 Raphael M. Bonelli (Austria) 2000 Silvia Lumempouw (Indonesia) 2006 Qiang Yuan (China) 2000 F. C. Pang (Hong Kong) 2006 Hyun Jeong Han (South Korea) 2000 J-L Fuh (Taiwan) 2008 Suwit Charoensak, (Thailand) 2000 Cecile Henquet (Netherlands) 2009 Rujing Ren 2001 Vorapun Senanarong (Thailand)

CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH SCHOLARS:

2016 Aaron Ritter

UCLA Ph.D. DISSERTATION COMMITTEES:

1989 Rena Matteson, UCLA Department of Psychology 1991 Karen Jensen, UCLA School of Nursing 1995 Patti Lee, Modeling caregiver stress. UCLA School of Nursing 10

1997 Lise Abrams, Aging, orthographic overlap, and implicit versus explicit word retrieval. UCLA Department of Psychology 1997 Jill Shapira, Patient agitation in one surgical intensive care unit: cultural models of nurse caregiver UCLA Department of Anthropology 1997 Michael Mega, Histological in vivo imaging and behavioral correlates in Alzheimer's disease. UCLA Department of Neurosciences 2003 Allison Breggon, Prodromal changes in subjects of genitive siste for Alzheimer’s disease; Brain Imaging Center, UCLA Neurosciences 2004 Shebnam Shadenam, Linguistic change in Alzheimer’s disease and Parkinson’s Disease 2004 Christina Fales, Executive dysfunction in Parkinson’s disease; UCLA Department or Psychology

FOUNDATIONS:

Deane F. Johnson Foundation for Alzheimer’s Research 1999 – 2010 Medical Director

Sidell Kagan Foundation 2001 – 2010 Member, Board of Directors

John Douglas French Foundation for Alzheimer’s Research 1996 – Present Vice Chair, International Scientific Advisory Board 1990 – Present Member, Scientific Advisory Board

Tichi Wilkerson Kassel Parkinson’s Foundation 2003 – 2010 Medical Director

Leeza Gibbons Memory Foundation 2005 – Present Medical Director

Alzheimer Drug Discovery Foundation (ADDF) 2005 – Present Reviewer 2010 – Present Scientific Advisory Committee

JOURNAL AND TEXTBOOK BOARDS AND SERVICES:

CHAIR, EDITORIAL BOARD: Alzheimer’s Disease Management Today (1998 – 1999)

ASSOCIATE EDITOR: Yearbook of Geriatrics and Gerontology (1986 – 1991) Brain and Cognition (1986 – 1998) Journal of Neuropsychiatry and (1987 – Present) Psychosomatics (1988 - 2004) Current Psychiatry Report; editor for Neuropsychiatry (1999 – 2000) Journal of Alzheimer’s Disease (2009 – Present) Translational (2011 – Present)

EDITORIAL BOARD: Behavioral Neurology (1987 – 2000) Neuropsychiatry, Neuropsychology and Behavioral Neurology (1987 – 2003) Alzheimer's Disease and Associated Disorders (1988 – Present) Journal of Geriatric Psychiatry and Neurology (1990 – 2008) Journal of the American Geriatric Society (1992 – 1997) Neurology (1992 – 2003) Psychiatric Times (1992 – 2010) Textbook of Neuropsychiatry, 2nd Edition (1992), 3rd Edition (1997) Health in Mind and Body (1995 – 1998) Neuropsychology (1996) Neurocase (1997 – 2003) 11

Archivos de Neurociencias (1998 – Present) International Journal of Neuropsychopharmacology (1998 – 2003) CNS Spectrums (1998 – Present) Demenze (1998 – Present) Clinical Geriatrics (1999 – 2002) Long-Term Care Forum (1999 – 2004) The Economics of Neuroscience (1999 – 2001) Clinical Trial Magnifier (2009 – Present) Caring for the Ages (2000 – 2005) Current Psychiatry Report (2000 – 2004) Psychogeriatrics (2000 – Present) Journal of the American Medical Directors Association (2001 – 2004) Practical Neurology (2001 – Present) Trends in Evidence-Based Neuropsychiatry (2001 – 2004) Dementia and Geriatric Cognitive Disorders (2002 – Present) Internal Medicine Thailand (2002 – Present) Cognitive and Behavioral Neurology (2003 – Present) Middle-Eastern Journal of Age and Aging (2003 – Present) Middle-Eastern Journal of (2003 – Present) American Journal of Alzheimer’s Disease (2004 – 2006) Cognitive Sciences (2004) Neuropsychiatric Disease and Treatment (2004 – 2005) Clinical Neurology and (2005 – Present) Research and Practice in Alzheimer’s Disease (2005) Neurology Reviews (2006 – 2008) Translational Neuroscience (2009 – 2010) Clinical Trial Magnifier (2009 – 2012) Cleveland Clinic Neuroscience Pathways (2010 – Present) American Journal of Neurodegenerative Disease (2012 - Present) CNS Spectrums (2012 – Present) Touch Neurology.com US Editorial Board (2013-Present) Journal of the International Neuropsychological Society (2013 – Present) Journal for the Prevention of Alzheimer (2014 – Present)

ADVISORY BOARD: Neuropsychiatry and Raven Press (1989 – 1993) Mental Fitness (1997 – 1999) Recent Patents on CNS Drug Discovery (2005) Medscape Neurology (2012)

GUEST EDITOR:  Special Issue on Psychosis in Neurologic Disease. Neuropsychiatry Neuropsychol Behav Neurol (1991)

 Special Issue on Lewy Body Disease and Related Disorders. Brain Cogn (1995)

 Special Issue on Alzheimer's Disease Therapy. Behavior as an Efficacy Outcome. Alzheimer Dis Assoc Disord 11 (suppl 4) (1997)

 Special Issue of J Neuropsychiatry Clin Neurosci (1997) Salloway S, Malloy P, Cummings, JLL, editors

 Rabins P, Cummings JL, editors. Supplement to Am J Geriatr Psychiatry. Alzheimer’s disease management; the emerging standard of care. Based on the Proceedings of the Consensus Conference on Alzheimer’s Disease and Related Disorders (1997), and the AAGP 10th Annual Meeting (1997)

12

 Special Issues on Current Perspectives in Alzheimer's Disease. Neurology 1998: 51 (Suppl 1)

 Special Issue on Alzheimer's Disease. Primary Psychiatry 6:45 (April 1999)

 Special Report: Practical Alzheimer's Disease Management: A comparative review of new compounds, diagnosis, treatment, and outcomes assessment. Postgrad Med pp. 5-6 (May 1999)

 Special Issue on Alzheimer’s Disease. Int J Neuropsychopharmacol (2000)

 Special Section: Treatment of behavioral disturbances In Alzheimer’s disease. Dementia Geriatr Cog Providers (2003)

 Supplement Editor: Galantamine treatment of Alzheimer’s disease in long-term care. J Am Med Directors Assoc. (2003)

 Special Issue: Parkinson’s disease and dementia with Lewy bodies; J Geriatr Psychiatry Neurology (2004 with Dag Aarsland, M.D.)

 Pathogenetic implications and clinical guidelines for the treatment of Alzheimer’s disease. Drugs & Aging 2005; 22: S1-40

 Supplement Editor: Transdermal Exelon treatment of Alzheimer’s disease; Neurology (2007)

 Supplement Editor: Alzheimers Disease Summit; CNS Spectrums (2008)

SECTION EDITOR: Comprehensive Textbook of Psychiatry, 6th Edition. Kaplan, Sadock B editors. Section - Neuropsychiatry (l994)

Current Psychiatry Reports: Neuropsychiatric Disorders (1999)

Current Psychiatry Reports: Neuropsychiatric Disorders (October 2000)

JOURNAL REFEREE: Dr. Cummings reviewer relatively infrequent due to competing time demands.

Alzheimer's Disease and Associated Disorders American Journal of Psychiatry American Journal of Geriatric Psychiatry Annals of Neurology Archives of Neurology Archives of General Psychiatry Biological Psychiatry Dementia and Geriatric Cognitive Disorders General Hospital Psychiatry International Psychogeriatrics Journal of Clinical Psychiatry Journal of Geriatric Psychiatry and Neurology Journal of the International Neuropsychological Society Journal of Neurology, Neurosurgery and Psychiatry Journal of the American Geriatrics Society Journal of the American Medical Association Journal of Neuroscience Lancet Movement Disorders NeuroImage Neurology Neuron Neuropsychiatry, Neuropsychology, and Behavioral Neurology New England Journal of Medicine Science Stroke

COLUMNIST: Psychiatric Times (Brain and Behavior column appears 4-6 times/year) (1988 – 1996; occasional contributor 1996 – 2010)

13

PROPOSAL REVIEW SERVICES:

National Institute of Health Review Group (1989 – 1993) French Foundation for Alzheimer Research (1990 – Present) Department of Veteran’s Affairs (1992 – 1996) Medical Research Council of Canada (1992 – 2004) National Institute of Aging Ad Hoc Review Committee (1992 – 1994) Wellcome Foundation, London, England (1993 – 2000) Alzheimer’s Association (1996 – 2003) Alzheimer Society of Canada (1997 – 2002) Swiss National Science Foundation (1998 – 2002) National Institute on Aging Special Review Panel, Chair (1999, 2004) National Institute on Aging, Pilot Clinical Trials Review Committee, Chair (2002 – 2005) National Institute on Aging, Alzheimer’s Disease Research Center Ad Hoc Review Chair (2004)

FUNDED RESEARCH:

Obsessions and Compulsions Funded by Gatepost Foundation and Tourette in Tourette Syndrome Syndrome Association M Frankel, JL Cummings, and DF Benson; 1982 ($18,000).

Alzheimer’s Disease Grant from the LA Alzheimer’s Association JL Cummings and DF Benson; 1985 ($1,000).

MRI and PET Studies in Veterans Administration Grant Schizophrenia and Dementia S Marder, B Oldendorf, JL Cummings, W Blahd, HC Padgett, and MA Mandelkern l985 ($15,000) for this subproject; (Project total was $75,000 plus MRI purchase and installation).

Language Changes in John Douglas French Foundation, JL Cummings, PI; Alzheimer’s Disease 1985 – 1987 ($30,000).

Intraventricular Bethanechol SL Read (PI), JL Cummings, and JG Frazee in Dementia of the Alzheimer Funded by the John Douglas French Foundation; 1985 ($30,000).

Speech and Language JL Cummings (PI), DF Benson, and MA Hill Alterations in the Dementias Funded by the John Douglas French Foundation; 1985 ($30,000).

Alzheimer’s Disease: JL Cummings (PI) and D Van Lancker Insight into CNS Mediation Southern California Alzheimer’s Disease Consortium; 1987 ($6,000). Of Language

Neurological Imaging in ME Mahler (PI), JL Cummings, et al (Co-Investigators) VA Merit Multi-Infarct Dementia Review Grant; 1987 – 1990 ($124,000).

HIV-Related CNS W Van Gorp (PI), CJ Frederich (Co-PI), JL Cummings et al Abnormalities (Co-Investigators) VA Research Program; 1987 – 1990 ($266,500).

Tardive Dyskinesia: JL Cummings (PI), W Wirshing, R Liber Electromechanical Measures (Co-Investigators) Merit Review Award; VA Research Program; 1988 – 1990 ($76,000).

Dementia and Geriatric D Frank Benson, Director; JL Cummings, Behavioral Neurology Co-Director NIA Training Grant, Research Fellowship 1988 – 2002, Director, 1995 – 2002.

Mental illness in the elderly: A Leuchter, PI; JL Cummings et al, Co-Investigators 14 diagnostic testing NIA Rol MH 4070504; 1989 – 1996.

Depression in Dementia of JL Cummings, PI; French Foundation Grant; the Alzheimer type 7/1/89 – 6/30/90 ($30,000).

PET Studies in Persons at Risk G Small, PI; JL Cummings et al, Co-Investigators, State of California for Alzheimer’s Disease 1989 – 1990 ($50,000)

Cholinergic Treatment of JL Cummings (sponsor), DG Gorman (Co-Investigator) Behavioral Disturbances in French Foundation for Alzheimer’s Research; Alzheimer’s Disease 7/1/90 – 6/30/92 ($30,000/year).

PET Studies in Persons at G Small, PI; JL Cummings et al (Co-Investigators) Risk for Alzheimer’s Disease NIMH FIRST Award; 1990 – 1995.

Mental Illness in Aging: G Small, PI; and JL Cummings, Co-PI, NIMH, 1990 – 1996. Early Diagnosis R 29 MH 46424-05

UCLA Alzheimer’s JL Cummings, PI; National Institute on Aging Disease Research Center 1991 – 2009. (AG POD 16470)

VA Geriatric JL Cummings, PI; Funding for training of 2 Neurologists Neurology Fellowship in Geriatric Neurology; 1992 – 1996.

Los Angeles Area JL Cummings, PI; National Institute on Aging Alzheimer Outreach 1992 – 1997; ($100,000/year).

Neuropsychiatric JL Cummings, PI; Irving and Helga Cooper Award for Geriatrics Research Inventory 1993 – 1994 ($20,000)

UCLA Alzheimer’s JL Cummings, PI; State of California. Disease Research 1998 – 2009 Center of California

UCLA Collaborative JL Cummings, PI; State of California Alzheimer’s Disease Center 2009 – 2010

Center of Biomedical Research JL Cummings, PI; Cleveland Clinic Lou Ruvo Center for Brain Health Excellence (COBRE); Center for 2015 - 2019 Neurodegeneration and Translational Neuroscience

INDUSTRY-SPONSORED RESEARCH AND CLINICAL TRIALS:

Acetyl-l-carnitine in Alzheimer’s Disease JL Cummings, PI; Double-blind efficacy trial sponsored by Sigma Tau Pharmaceutical Company; 199l – 1993.

DuP 996 in Alzheimer’s Disease JL Cummings, PI; Open label safety study sponsored by DuPont- Merck Pharmaceutical Company; 199l – 1993.

Amyloid precursors in CSF and serum in JL Cummings and B Miller, Co-PI’s; Investigation of CSF and serum Alzheimer’s Disease amyloid precursors; Athena Neuroscience; 1991 – 1993.

Cognex Access Program JL Cummings, PI; Safety study of tacrine sponsored by Parke-Davis; 1992 – 1994.

15

Ondansetron in Alzheimer’s Disease JL Cummings, PI; Double-blind study sponsored by Glaxo Pharmaceuticals; 1994.

Metrifonate in Alzheimer’s Disease JL Cummings, PI; Double-blind study sponsored by Miles-Bayer; 1995.

Milameline in Alzheimer’s Disease JL Cummings, PI; Double-blind study sponsored by Miles-Bayer; 1995 – 1996

Zoloft for Agitation in Alzheimer’s Disease JL Cummings, Co-PI; Double-blind study sponsored by Pfizer; 1997 – 1999.

Donepezil for behavioral disturbances in nursing JL Cummings and Stacey Wood, Co-PI’s; Double-blind study home patients sponsored by Pfizer; 1996 – 1998.

Cross-sectional study of Alzheimer’s Disease JL Cummings, PI: Pharmaco-economic study sponsored by Pfizer; 1996 – 1997.

Xanomeline in Alzheimer’s Disease JL Cummings, Co-PI; Double-blind study sponsored by Lilly; 1996 – 1998.

Olanzapine in Alzheimer’s Disease JL Cummings, Co-PI; Double-blind study sponsored by Lilly; 1996 – 1998.

ENA-713 in Alzheimer’s Disease JL Cummings, PI; Open-label study sponsored by Novartis; 1997 – 1998.

Aricept in vascular dementia JL Cummings, PI; Double-blind and open-label study sponsored by Eisai; 1998 – 2000.

Exelon in nursing home patients JL Cummings, PI; Open-label study of Exelon in patients in nursing homes Novartis; 1997 – 1998.

Cognitive, behavioral, and metabolic responses to JL Cummings, PI; Open-label study sponsored by Bayer; 1998 – Metrifonate 1999.

Donepezil Hcl (E2020) in patients with dementia JL Cummings, PI; A 30-week, open-label study sponsored by Eisai; Associated with MCI 1998 – 2001.

Donepezil for memory impairment in PD JL Cummings, PI; study sponsored by Pfizer, Inc. 1999 – 2002.

PET imaging responses to Galantamine treatment JL Cummings, PI; study sponsored by Janssen; 2001 – 2003.

Neotrofin in patients with probable AD JL Cummings, PI; placebo-controlled study sponsored by Neurotherapeutics; 2001 – 2002.

SR57746A in mild to moderate AD JL Cummings, PI; randomized, double blind, placebo-controlled trial sponsored by Sanofi-Synthelabo; 2001 – 2002.

CX516 in MCI JL Cummings, PI; study sponsored by Cortex, Inc.; 2002 – 2003.

Behavior cognition, function and quality of life JL Cummings, PI; Belmont Village; 2002 – 2005.

Biomarkers JL Cummings, PI; study sponsored by SynX; 2003 – 2004.

16

Efficacy and safely of Aricept in MCI JL Cummings, PI; study sponsored by Pfizer / Eisai; 2003 – 2006.

Bapineuzumab in AD ApoE non-carriers/ carriers JL Cummings, Sub-investigator; sponsored by Elan Pharmaceuticals, 2008 – 2012.

Long Term Safety & Tolerability Treatment of JL Cummings, Sub-investigator; sponsored by Elan Pharmaceuticals, Bapineuzumab 2009 – 2012.

FOUNDATION AND ALZHEIMER’S DISEASE COOPERATIVE STUDY (ADCS) TRIALS:

Melatonin for disturbance JL Cummings, Co-PI; Multicenter trial sponsored by ADCS; 1998 – 2000.

Melatonin for sleep disturbance in AD JL Cummings, PI; A multicenter, placebo-control study sponsored byADCS/NIH; 1998 – 2000.

Rofecoxib/Naproxen in patients in patients with JL Cummings, Co-PI; Multicenter trial sponsored by ADCS; 1999 – AD 2003.

Vitamin E and donepezil to prevent clinical JL Cummings, PI; study sponsored by ADCS; 1999 – 2005. progression in MCI

MCI – normal instrument study JL Cummings; PI; normal instrument study sponsored by ADCS; 1999 – 2005.

MCI – Imaging sub-study JL Cummings, PI; Imaging sub-study sponsored by the ADCS 1999 – 2005.

Divalproate sodium for agitation in dementia JL Cummings, PI; study sponsored by the ADCS; 2000 – 2002.

Primary prevention instrument protocol (PI) JL Cummings, Steering Committee: study sponsored by ADCS; 2001 – 2006.

Treatment of agitation and psychosis in JL Cummings, Co-PI; study sponsored by the ADCS’ 2003 – 2006. dementia/Parkinsonism (TAP/DAP)

Valproate to attenuate progression of AD (VN) JL Cummings, Steering Committee; study sponsored by the ADCS; 2003 – 2009.

Capacity to consent JL Cummings, Co-PI; study sponsored by the ARCC; 2004 – 2006.

Depression in AD JL Cummings, PI; Alzheimer Research Center of California; 2000 – 2007.

DHA in slowing the progression of AD JL Cummings; Alzheimer’s Disease Cooperative Study, National Institute on Aging 2007 – 2009.

Impact on biomarkers of antioxidant treatment of JL Cummings; Alzheimer’s Disease Cooperative Study, National AD (AX) Institute on Aging 2005 – 2009.

High dose supplements to reduce homocysteine and JL Cummings; Alzheimer’s Disease Cooperative Study, National slow the rate of cognitive decline in AD (HC) Institute on Aging, 2006 – 2008

17

Simvastatin to slow the progression of AD (LL) JL Cummings; Alzheimer’s Disease Cooperative Study, National Institute on Aging, 2006 – 2008

CERE-110 Gene Delivery in Subjects with AD ADCS, Ceregene, 2009 – 2010

Treatment with PF-04494700 (TTP488) in ADCS, Pfizer, 2008 – 2010 participants with AD (RI) Neudexta for Disinhibition in Neurodegenerative Avanir Pharmaceuticals, 2014 - 2015 Disorders (ND²) Trial

PHILANTHROPY SUPPORTED CLINICAL TRIALS:

Testosterone in AD and normal controls JL Cummings, Co-PI; Double-blind study sponsored by the French Foundation; 1999 – 2000

Curcumin in AD JL Cummings, Co-PI; pilot study sponsored by ISOA/French Foundation; 2003 – 2007. Axona in AD JL Cummings, sponsored by the French Foundation; 2010-2012.

Bexarotene amyloid treatment for Alzheimers Disease JL Cummings, donor sponsored; 2012 – 2015

Rasagiline rescue (R²) Trial for Alzheimers Disease JL Cummings, sponsored by the Alzheimers Drug Discovery Foundation (ADDF); 2014 - 2017

INDUSTRY RELATED EXPERIENCE:

Due diligence on preclinical candidates for clinical development Due diligence on clinical stage compounds Due diligence on clinical trial design with outcome choice Strategic planning for drug development Portfolio review of Alzheimer programs of major pharma Phase II and Phase III trial design Phase IV and life cycle management strategies Strategies for international and global drug development (especially Asia) Speaker training Slide deck preparation Investigator initiated studies, reviews Interpretation of trial outcomes Publication of primary trial outcomes, secondary analyses Launch preparation for new products and new formulations Data Safety Monitoring Boards (DSMB)(member and chair) Patent litigation (expert witness for innovator companies) Food and Drug Administration New Drug Application (NDA) preparation Food and Drug Administration Advisory Panel (psychosis in Alzheimer's disease panel member) Food and Drug Administration presentations Advisor to investment and private equity companies on drug development for Alzheimer's disease and related disorders Review of preclinical data and construction of bridge to clinical development plan Medical food assessment Clinical development and planning of two FD-approve compounds: /quinidine (Nuedexta™) and pimavanserin (Nuplazid ™) Presentations to pharma companies of clinical best practices at Cleveland Clinic Collaboration with Coalition Against Major Diseases (CAMD)

INVESTIGATIONAL NEW DRUG (IND) APPLICATIONS HELD

18

Physostigmine Galantamine Bexarotene

PUBLICATIONS:

Books 1. Cummings JL, Benson DF. Dementia: A Clinical Approach. Butterworths, Boston, 1983 (Japanese translation, 1986; Chinese Translation, 1987).

2. Cummings JL. Clinical Neuropsychiatry. Grune and Stratton, New York, l985.

3. Beck JC, Abrass I, Burton J, Small G, Cummings JL, Makinodon T editors. Yearbook of Geriatrics and Gerontology l988. Year Book Medical Publications, New York, l988.

4. Beck JC, Abrass I, Burton J, Small G, Cummings JL, Makinodon T editors. Yearbook of Geriatrics and Gerontology l989. Year Book Medical Publications, New York, l989.

5. Beck JC, Abrass I, Burton J, Small G, Cummings JL, Makinodon T editors. Yearbook of Geriatrics and Gerontology l990. Year Book Medical Publications, New York, l990.

6. Cummings JL, editor. Subcortical Dementia. Oxford University Press, New York, l990.

7. Cummings JL, Miller B, editors. Treatment and Long-Term Management of Alzheimer's Disease. Marcel Dekker, New York, 1990.

8. Beck JC, Abrass IB, Burton JR, Cummings JL, Makinodan T, Small GW editors. Yearbook of Geriatrics and Gerontology. Year Book Medical Publications, New York, l99l.

9. Beck JC, Abrass IB, Burton JR. Cummings JL, Makinodan T, Small GW editors. Yearbook of Geriatrics and Gerontology l992. Mosby Year Book, Chicago, l992.

10. Huber SJ, Cummings JL, editors. Parkinson's Disease: Neurobehavioral Aspects. Oxford University Press, New York, l992.

11. Cummings JL, Benson DF. Dementia: A Clinical Approach (Second Edition). Butterworths, Boston, 1992.

12. Coffey CE, Cummings JL, editors. Textbook of Geriatric Neuropsychiatry. American Psychiatric Press, Washington, D.C., 1994 (Italian translation, 2001).

13. Cummings JL, Trimble MR. Concise Guide to Neuropsychiatry and Behavioral Neurology. American Psychiatric Press, Washington, D.C., 1995 (Japanese translation, 1996).

14. Salloway S, Malloy P, Cummings JL, editors. The Neuropsychiatry of Limbic and Subcortical Disorders. American Psychiatric Press, Washington, DC, 1997.

15. Miller BL, Cummings JL, editors. The Human Frontal Lobes: Functions and Disorders. The Guilford Press, New York, 1999.

16. McKeith I, Cummings JL, Lovestone S, Harvey R, Wilkinson D. Outcome Measures in Alzheimer’s Disease. Martin Dunitz, London, 1999.

17. Bogousslavsky J, Cummings JL editors. Behavior and Mood Disorders in Focal Brain lesions. Cambridge University Press, Cambridge, England, 2000.

18. Coffey CE, Cummings JL, editors. Textbook of Geriatric Neuropsychiatry (Second Edition). American Psychiatric Press, Washington, D.C., 2000.

19. Gauthier S, Cummings JL editors. Alzheimer’s Disease and Related Disorders Annual. Martin Dunitz, London, 2000.

19

20. Lichter D, Cummings JL editors. Frontal-Subcortical Circuits in Psychiatric and Neurological Disorders. The Guilford Press, New York, 2001.

21. Gauthier S, Cummings JL editors. Alzheimer's Disease and Related Disorders Annual. Martin Dunitz, London, 2001.

22. Gauthier S, Cummings JL editors. Alzheimer’s Disease and Related Disorders Annual. Martin Dunitz, London, 2002.

23. Cummings JL, Trimble MR. Concise Guide to Neuropsychiatry and Behavioral Neurology (Second Edition). American Psychiatric Press, Washington, D.C., 2002 (Turkish translation, 2004; Greek Translation, 2009).

24. Mendez MF, Cummings JL. Dementia: A Clinical Approach (Third Edition). Butterworths, Boston, 2003.

25. Cummings JL. Neuropsychiatry of Alzheimer’s Disease and Related Dementias. Martin Dunitz, London, 2003.

26. Cummings JL, Mega M. Neuropsychiatry and . Oxford University Press, New York, 2003.

27. Gauthier S, Sheltens P, Cummings JL editors. Alzheimer’s Disease and Related Disorders Annual 2004. Martin Dunitz, London, 2004.

28. Cummings JL, Hardy J, Poncet M, Christen Y editors. Genotype-Proteotype-Phenotype Relationships in Neurodegenerative Diseases, Series: Research and perspectives in Alzheimer’s disease. Springer; Germany, 2005.

29. Gauthier S, Scheltens P, Cummings JL editors. Alzheimer’s Disease and Related Disorders Annual, 5. Taylor & Francis, London, 2006. Spanish Translation: Gauthier S, Scheltens P, Cummings JL. Enfermedad de Alzheimer y Trastornos Relacionados. Ars Medica, Barcelona, 2006.

30. Cummings JL editor. Progress in Neurotherapeutics and Neuropsychopharmacology. Cambridge University Press, London, 2006.

31. Ritchie CW, Ames D, Masters CL, Cummings JL editors. Therapeutic Strategies in Dementia. Clinical Publishing, Oxford, 2007.

32. Miller BL, Cummings JL, editors. The Human Frontal Lobes: Functions and Disorders (Second Edition). The Guilford Press, New York, 2007.

33. Cummings JL editor. Progress in Neurotherapeutics and Neuropsychopharmacology 2007 (Volume 2). Cambridge University Press, London, 2007.

34. Krishnamoorthy ES, Prince MJ, Cummings JL, editors. Dementia: A Global Approach. Cambridge University Press, New York, 2010.

35. Coffey CE, Cummings JL, editors. Textbook of Geriatric Neuropsychiatry (Third Edition). American Psychiatric Publishing, Inc., Washington, D.C., 2011.

36. Ravina B, Cummings J, McDermott M, Poole RM, editors. Clinical Trials in Neurology. Design, Conduct, Analysis. Cambridge University Press, New York, 2012.

37. Molinuevo JL, Cummings JL, Dubois B, Scheltens P, editors. Early Diagnosis and Intervention in Predementia Alzheimer’s Disease. Elsevier, Philadelphia, Pennsylvania, 2013.

38. Aarsland D, Cummings JL, Weintraub D, Chauduri R, editors. Neuropsychiatric and Cognitive Changes in Parkinson’s Disease and Related Movement Disorders: Diagnosis and Management. Cambridge University Press, Cambridge, 2013.

39. Cummings J, Zhang Z, Molineuvo JL, Wang H, Monsch A, Wei C, Wei W. China Memory Clinic Guidance Book. Fishawack Communications, Cheshire, UK, 2014.

Articles 1. Cummings JL. Spontaneous nystagmus: a clinical approach. Hartford Hosp Bull 1974;29:451-457. 20

2. Cummings JL, Sonntag VKH, Scott RM. Ascites complicating ventriculoperitoneal shunting in an adult. Surg Neurol 1976;6:136.

3. Cummings JL, Greenberg R. Sleep patterns in the "locked-in" syndrome. EEG Clin Neurophysiol 1977;43:270-27l.

4. Tarsy D, Mahoney JF, Cummings JL. Physostigmine in Wilson's disease. Ann Neurol 1978;3:372-373.

5. Cummings JL, Oppenheimer EY, Hochman HI. Tuberous sclerosis. Am J Dis Child 1978;132:1215-1216.

6. Cummings JL, Benson DF, Walsh MJ, Levine HL. Left to right transfer of cerebral dominance: case study. Neurology 1979;29:1547-1550.

7. Milberg W, Goodglass H, Cummings J, Kaplan E. A global sequential processing disorder following head trauma: possible role of the right hemisphere in serial order behavior. J Clin Neuropsychol 1979;1:213-225.

8. Landis T, Cummings JL, et Benson DF. Le transfert de la dominance du language de l'hemisphere gauche a l'hemisphere droite; une explication possible concernant la restruction tardive d'aphasie globale. Medicale de la Suisse Romande 1980;100:17l-178.

9. Cummings JL, Benson DF, LoVerme S, Jr. Reversible dementia: illustrative cases, definition, and review. JAMA 1980;243:2434- 2439.

10. Cummings JL, Hebben NA, Obler L, Leonard P. Nonaphasic misnaming and other neurobehavioral features of an unusual toxic encephalopathy: case study. Cortex 1980;16:315-323.

11. Trimble M, Cummings JL. Neuropsychiatric disturbances following brainstem lesions. Br J Psychiatry 1981;138:56-59.

12. Cummings JL, Gittinger W, Jr. Central dazzle: a thalamic syndrome? Arch Neurol 1981;38:372-374.

13. Cummings JL, Duchen LW. The Kluver-Bucy syndrome in Picks disease. Neurology 1981;3l:l4l5-l422.

14. Cummings JL, Syndulko K, Goldeberg F, Trieman D. Palinopsia reconsidered. Neurology 1982:32:444-447.

15. Benson DF, Cummings JL, Tsai SY. Angular gyrus syndrome simulating Alzheimer's disease. Arch Neurol l982; 39:616-620.

16. Cummings JL, Gosenfeld LF, Houlihan JP, McCaffrey T. Calcification of the basal ganglia: case report and review. Biol Psychiatry 1983;18:59l-60l.

17. Cummings JL, Benson DF, Houlihan JP, Gosenfeld LF. Mutism: loss of neocortical and limbic vocalization. J Nerv Ment Dis 1983;4:255-259.

18. Lilly R, Cummings JL, Benson DF, Frankel M. Clinical features of the human Kluver-Bucy syndrome. Neurology 1983;33:1141- 1145.

19. Benson DF, Kuhl DE, Hawkins RA, Phelps ME, Cummings JL, Tsai SY. The fluorodeoxyglucose l8Fscan in Alzheimer's disease and multi-infarct dementia. Arch Neurol 1983;40:714.

20. Frankel M, Cummings JL. Neuro-ophthalmic abnormalities in Gilles de la Tourette syndrome: functional and anatomic complications. Neurology 1984;34:359-361.

21. Cummings JL. Dementia definition, classification and differential diagnosis. Psychiatry Ann 1984;14:85-89.

22. Cummings JL, Tomiyasu U, Read S, Benson DF. Amnesia with hippocampal lesions after cardiopulmonary arrest. Neurology 1984;34:679-681.

23. Cummings JL, Mendez F. Secondary mania with focal cerebrovascular lesions. Am J Psychiatry 1984;141:1084-1087.

24. Cummings JL, Benson DF. Subcortical dementia: review of an emerging concept. Arch Neurol 1984:41:874-879. 21

25. Mendez MF, Cummings JL, Benson DF. Epilepsy: psychiatric aspects and use of psychotropics. Psychosomatics 1984; 25:883-879.

26. Cummings JL, Benson DF, Hill MA, Read S. Aphasia in dementia of the Alzheimer type. Neurology 1985;35:394-397.

27. Cummings JL. Organic delusions: phenomenology, anatomical correlations and review. Br J Psychiatry 1985; 146: 184-197.

28. Cummings JL. Psychosomatic aspects of movement disorders. Adv Psychosomatic Med (Interface between neurology and psychiatry), M. Trimble, ed. 1985;13:111-132.

29. Cummings JL. Treatable dementias: differential diagnosis and obstacles to recognition. Clin Ther 1985;7:480-486.

30. Cummings JL, Benson DF. How to differentiate among dementia syndromes. Diagnosis 1985;7:103-l08.

31. Cummings JL, Benson DF. Which symptoms of impairment point to Alzheimer's? Diagnosis 1985;7:36-50.

32. Cummings JL, Frankel M. Gilles de la Tourette syndrome and the neurologic basis of obsessions and compulsions. Biol Psychiatry l985;20:1117-1126.

33. Cummings JL. Language alterations in Alzheimer's disease. Bull Clin Neurosci 1985;50:3-4.

34. Landis T, Cummings JL, Benson DF, Palmer P. Loss of topographic familiarity: an environmental agnosia. Arch Neurol 1986;43:132-136.

35. Cummings JL. Organic psychoses: secondary mania and schizophrenia-like disorders. Psychiatr Clin North Am. (Neuropsychiatry), Restak R, ed. 1986;9:378-382.

36. Frankel M, Cummings JL, Robertson MM, Trimble MR, Hill MA, Benson DF. Obsessions and compulsions in Gilles de la Tourette syndrome. Neurology 1986;36:378-382.

37. Cummings JL, Benson DF. Dementia of the Alzheimer type: an inventory of diagnostic clinical features. J Am Geriatr Soc l986;34:12-19.

38. Miller BL, Jenden DJ, Cummings JL, Read S, Rice K, Benson DF. Abnormal erythrocyte choline and influx in Alzheimer's disease. Life Sci 1986;38:485-490.

39. Shapira J, Schlesinger R, Cummings JL. Distinguishing dementias. Am J Nurs 1986;86:698-702.

40. Miller BL, Benson DF, Cummings JL, Neshkes R. Late-life paraphrenia: an organic delusional syndrome. J Clin Psychiatry 1986;47:204-207.

41. Davis J, Cummings JL, Malin BD, Garrick T. Prolonged psychosis with first rank symptoms following metrizamide myelography. Psychosomatics 1986;27:373-375.

42. Cummings JL, Benson DF, Arthur RJ. Neuropsychiatry and behavioral neurology in the VA: the Brentwood model. VA Practitioner 1986;3:62-7l.

43. Landis T, Cummings JL, Christen L, Bogen JE, Imhof HG. Are unilateral right posterior cerebral lesions sufficient to cause prosopagnosia? Clinical and radiological findings in six additional patients. Cortex l986;22:243-252.

44. Mendez MF, Cummings JL, Benson DF. Depression in epilepsy: significance and phenomenology. Arch Neurol 1986; 43:766-770.

45. Cummings JL, Barrett C, Horan M. Delusions induced by procaine penicillin: case report and review of the syndrome. Int J Psychiatry Med 1986-l987;16:163-168.

46. Cummings JL, Houlihan JP, Hill MA. The pattern of reading deterioration in dementia of the Alzheimer type observations and implications. Brain Lang 1986;29:315-323. 22

47. Cummings JL. Subcortical dementia: neuropsychology, neuropsychiatry, and pathophysiology. Br J Psychiatry 1986; 149:682-697.

48. Altshuler L, Cummings JL, Mills MJ. Mutism: review, differential diagnosis, and report of twenty-two cases. Am J Psychiatry 1986;143:1409-1414.

49. Miller BL, Cummings JL, McIntyre H, Ebers G, Grode M. Hypersexuality or altered sexual preference following brain injury. J Neurol Neurosurg Psychiatry 1986;49:867-873.

50. Mendez MF, Cummings JL, Benson DF. Psychotropic drugs and epilepsy. Stress Med l986;2:325-332.

51. Cummings JL, Benson DF. The role of the nucleus basalis in the dementias: review and reconsideration. Alzheimer Dis Assoc Disord l987;l:l28-l45.

52. Mahler ME, Cummings JL, Benson DF. Treatable dementias. West J Med l987;40:705-7l2.

53. Read LS, Cummings JL. Alzheimer's disease: past, present, and future. Hosp Ed 1987;(Supplement):63-84.

54. Cummings J, Miller LB. Visual hallucinations: clinical occurrence and use in differential diagnosis. West J Ed 1987;l46:46-5l. Reprinted in part in Emerg Med and reviewed on National Physician's Radio.

55. Cummings JL. Multi-infarct dementia: diagnosis and management. Infarctions produce 20% to 35% of severe dementia cases. Psychosomatics 1987;28:117-119, 123-126.

56. Mahler M, Cummings JL, Tomiyasu U. Atypical dementia syndrome in an elderly man. J Am Geriatr Soc 1987;35: lll6-ll26.

57. Signer SF, Cummings JL. De Clerambault's syndrome in organic affective disorder: two cases. Br J Psychiatry 1987;l5l:404-407.

58. Cummings JL. Dementia syndromes: neurobehavioral and neuropsychiatric features. J Clin Psychiatry 1987;48:3-8.

59. Cummings JL, Miller BL, Hill MA, Neshkes R. Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer type. Arch Neurol 1987;44:389-393

60. Cummings JL. Obsessions and compulsions in Gilles de la Tourette syndrome. Prog Clin Neurosci 1987;2:l3l-l40.

61. Cummings JL, Benson DF. Dementia principles of diagnosis and management. The Older Patient 1987;23-28.

62. Cummings JL, Zarit J. Probable Alzheimer's disease in an artist. JAMA 1987;258:2731-2734. Reprinted in Chinese JAMA 1988;6:88-92. Partially reprinted in the New York Times, International Tribune, and Der Spiegel.

63. Cummings JL, Read SL. Multi-infarct dementia. Hosp Med 1988;25-42.

64. Cummings JL, Benson DF. Psychological dysfunction accompanying subcortical dementias. Ann Rev Med 1988;39: 53-6l.

65. Cummings JL. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988;l:24-36.

66. Cummings JL. The dementias of Parkinson's disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type. Europ Neurol 1988;28:l5-23.

67. Friedlander AH, Mills MJ, Cummings JL. Consent for dental therapy in severely ill patients. Oral Surg Oral Med Oral Pathol 1988;65:l79-l82.

68. Van Lancker DR, Cummings, JL, Kreiman J, Dobkin BH. Phonognosia: a dissociation between familiar and unfamiliar voices. Cortex 1988;24:l95-209.

23

69. Trautner R, Cummings JL, Read S, Benson DF. Idiopathic basal ganglia calcification and organic mood disorder. Am J Psychiatry 1988;l45:350-353.

70. Cummings JL, Darkins A, Mendez M, Hill MA, Benson DF. Alzheimer's disease and Parkinson's disease: comparison of speech and language alterations. Neurology 1988;38:680-684.

71. Powell AL, Cummings JL, Hill MA, Benson DF. Speech and language alterations in multi-infarct dementia. Neurology 1988;38:7l7-7l9.

72. Altshuler L, Cummings JL, Bartzokis G, Hill MA, May PPA. Lateral asymmetries of tardive dyskinesia in schizophrenia. Biol Psychiatry 1988;24:83-86.

73. Cummings JL, Wirshing W. Brentwood Movement Disorders Laboratory: Quantitative neuropsychiatry in the service of patient care. VA Practitioner 1988;5:99-l04.

74. Reichman WE, Cummings JL. Dementia syndromes clinical features and differential diagnosis. World J Psychosynth l987/88; l8:l5-22.

75. Mahler M, Cummings JL. Dementia: look for a treatable cause. Diagnosis 1988;l0:64-76.

76. Cummings JL. Movement disorders: causes, effects, treatments. The Older Patient 1988;2:2l-26.

77. Cummings JL. Organic psychosis. Psychosomatics 1988;29:l6-26.

78. Schwartz J, Cummings JL. Psychopathology and epilepsy: a consultation liaison experience. Psychosomatics 1988;29:295-300.

79. Aharon-Peretz J, Cummings JL, Hill MA. Vascular and Alzheimer's type dementias: comparison of ventricular measures and leuko- araiosis. Arch Neurol 1988;45:7l9-72l.

80. Davis RJ, Cummings JL. Clinical variants of tardive dyskinesia. Neuropsychiatry Neuropsychol Behav Neurol 1988; l:3l-38.

81. Flynn FG, Cummings JL, Tomiyasu U. Altered behavior associated with damage to the ventromedial hypothalamus: a distinctive syndrome. Behav Neurol 1988;l:49-58.

82. Davis JL, Cummings JL, Hierholzer RW. Tardive dystonia: clinical spectrum and novel manifestations. Behav Neurol 1988;l:4l-47.

83. Petry S, Cummings JL, Hill MA, Shapira J. Personality alterations in dementia of the Alzheimer type. Arch Neurol 1988;45:ll87- ll90.

84. Cummings JL. Focal and asymmetric presentations of Alzheimer's disease. Bull Clin Neurosci 1988;53:5-9.

85. Sultzer D, Cummings JL. Drug-induced mania: causative agents, clinical characteristics and management. A retrospective analysis of the literature. Med Toxicol 1988;4:l27-l43.

86. Van Lancker DR, Kreiman J, Cummings J. Voice perception deficits: neuroanatomical correlates of phonagnosia. J Clin Exp Neuropsychol 1989;ll:665-674.

87. Friedenberg D, Cummings JL. Parkinson's disease, depression, and the on-off phenomenon. Psychosomatics 1989; 30:94-99.

88. Cummings JL, Van Lancker DR. Alexia and agraphia after Luria. J Neuroling 1989;4:95-lll.

89. Shapira J, Cummings JL. Alzheimer's disease: changes in sexual behavior. Med Aspects Hum Sex 1989;23:32-36.

90. Friedlander A, Cummings JL. Temporal lobe epilepsy: its association with psychiatric impairment and appropriate dental management. Oral Surg Oral Med Oral Pathol 1989;68:288-292.

24

91. Bartzokis G, Wirshing W, Hill A, Cummings JL, Altshuler L, May PRA. Comparison of electromechanical measures and observer ratings of tardive dyskinesia. Psychiatry Res 1989;27:l93-l98.

92. McDaniel KD, Cummings JL, Shain S. The "Yips": a focal dystonia of golfers. Neurology 1989;39:l92-l95. Briefly represented in the New York Times; reported on Cable News Network, etc.

93. Signer S, Cummings JL, Benson DF. Delusions and mood disorders in patients with chronic aphasia. J Neuropsychiatry Clin Neurosci 1989;l:40-45.

94. Cummings JL. Depression in vascular dementia. Hillside J Clin Psychiatry 1989;l0:209-23l.

95. Wirshing WC, Cummings JL. Extrapyramidal syndromes in the elderly: diagnosis and management. Geriatrics 1989;44:47-54.

96. Bartzokis G, Hill MA, Altshuler L, Cummings JL, Wirshing W, May PRA. Tardive dyskinesia in schizophrenic patients: correlation with negative symptoms. Psychiatry Res 1989;28:l45-l5l.

97. Wirshing WC, Freidenberg DL, Cummings JL, Bartzokis G. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced Parkinsonism. J Clin Psychopharmacol 1989;9:407-4ll.

98. Van Gorp WG, Mitrushima M, Cummings JL, Satz P, Modesitt J. Normal aging and the subcortical encephalopathy of AIDS: a neuropsychological comparison. Neuropsychiatry Neuropsychol Behav Neurol 1989;2:5-20.

99. Cummings JL, Wirshing WC. Recognition and differential diagnosis of tardive dyskinesia. Int J Psychiatry Med 1989;l9:l33-l44.

100. Buchwald JS, Erwin RJ, Read S, Van Lancker D, Cummings JL. Midlatency auditory evoked responses: Differential abnormality of Pl in Alzheimer's disease. EEG Clin Neurophysiol 1989;74:378-384.

101. Van Gorp W, Cummings JL. Assessment of mood, affect, and personality in neuropsychological evaluation of the elderly. Geriatr Clin North Am 1989;5:44l-459.

102. Cummings JL. Dementia and depression: an evolving enigma. J Neuropsychiatry Clin Neurosci 1989;l:236- 242.

103. Friedenberg DL, Freeman D, Huber SJ, Perry J, Fischer A, Van Gorp WG, Cummings JL. Post-poliomyelitis syndrome: assessment of behavioral features. Neuropsychiatry Neuropsychol Behav Neurol 1989;2:272-28l.

104. Petry S, Cummings JL, Hill MA, Shapira J. Personality alterations in dementia of the Alzheimer type: a three-year follow-up study. J Geriatr Psychiatry Neurol 1989;2:l03-207.

105. Flynn FG, Cummings JL, Scheibel J, Wirshing W. Monosymptomatic delusions of parasitosis associated with ischemic cerebrovascular disease. J Geriatr Psychiatry Neurol 1989;2:l34-l39.

106. Cummings JL, Dian L, Petry S, Hill MA, Shapira J. Personality alterations in Alzheimer's disease and multi-infarct dementia. Neurology 1989;39:254.

107. Wirshing WC, Cummings JL. Tardive movement disorders. Neuropsychiatry Neuropsychol Behav Neurol 1990;(3): 23-35.

108. Cummings JL. Clinical features and treatment of Alzheimer's disease. Curr Opin Neurol Neurosurg 1990;3:90-97.

109. Cummings JL. Personality alterations in Alzheimer's disease: assessment techniques and quantitative observations. Bull Clin Neurosci 1990;54:80-87.

110. Cummings JL, Victoroff J. Noncognitive neuropsychiatric syndromes in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1990;3:140-l58.

111. Cummings JL, Petry S, Dian L, Shapira J, Hill MA. Organic personality disorder in dementia syndromes: an inventory approach. J Neuropsychiatry Clin Neurosci 1990;2:26l-267.

25

112. Dian L, Cummings JL, Petry S, Hill MA. Personality alterations in multi-infarct dementia. Psychosomatics 1990;3l:4l5-4l9.

113. Ross GW, Cummings JL, Benson DF. Speech and language alterations in dementia syndromes: Characteristics and treatment. Aphasiology 1990;4:339-352.

114. Read SL, Frazee J, Shapira J, Smith C, Cummings JL, Tomiyasu U. Intracerebroventricular bethanechol for Alzheimer's disease: variable dose-related responses. Arch Neurol 1990;47:l025-l030.

115. Gorman DG, Cummings JL. Organic delusional syndrome. Semin Neurol 1990;l0:229-238.

116. Reichman W, Cummings JL. Diagnosis of rare dementia syndromes: An algorithmic approach. J Geriatr Psychiatry Neurol 1990;3:73-84.

117. Hinkin C, Cummings JL, Van Gorp WG, Mitrushina M. Frontal/subcortical features of normal aging: an empirical analysis. Can J Aging 1990;9:l04-ll9.

118. Mahler ME, Cummings JL. Alzheimer's disease and the dementia of Parkinson disease: comparative investigations. Alzheimer Dis Assoc Disord 1990;4:l33-l49.

119. Cummings JL. The neurobehavior examination in dementia and other organic mental syndromes. Bull Clin Neurosci 1990;55:5-l6.

120. Mahler ME, Cummings JL. Behavioral neurology of multi-infarct dementia. Alzheimer Dis Assoc Disord 1991;5:l22-l30.

121. Miller B, Cummings JL. How brain injury can change sexual behavior. Med Aspects Hum Sex l99l;l:54-62.

122. Wirshing W, Cummings JL, Dencker J, May PRA. Electromechanical characteristics of tardive dyskinesia. J Neuropsychiatry Clin Neurosci 1991;3:10-17.

123. Beckson M, Cummings JL. Neuropsychiatric aspects of stroke. Int J Psychiatry Med 1991;2l:l-l5.

124. Cummings JL, Small G. Dealing with writer's block in an older man: Depression, Parkinson's disease, or both? Hosp Community Psychiatry 1991;42:l9-20.

125. Miller BL, Cummings JL, Villanueva-Meyers J, Boone K, Mena I. Frontal lobe degeneration: Clinical, neuropsychological, and SPECT characteristics. Neurology 1991;4l:l374-1382.

126. Flynn FG, Cummings JL, Gornbein J. Delusions in dementia syndromes: investigation of behavioral and neuropsychological correlates. J Neuropsychiatry Clin Neurosci 1991;3:364-377.

127. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39: 708-7l6.

128. Reichman WE, Cummings JL, McDaniel KD, Flynn F, Gornbein J. Visuoconstructional impairment in dementia syndromes. Behav Neurol 1991;4:l53-l62.

129. Cummings JL. Accuracy of clinical diagnosis of Alzheimer's disease: review of clinicopathologic investigations. Bull Clin Neurosci 1991;56:6-l6.

130. Osterweil D, Syndulko K, Cohen SN, Pettler-Jennings PP, Hershman JM, Cummings JL, Tourtellotte W, Solomon DH. Cognitive function in non-demented older adults with hypothyroidism. J Am Geriatr Soc 1992;40:325-335.

131. Cummings JL. Psychosis in neurologic disease: Neurobiology and pathogenesis. Neuropsychiatry Neuropsychol Behav Neurol 1992;5:l44-l50.

132. Beckson M, Cummings JL. Psychosis in basal ganglia disorders. Neuropsychiatry Neuropsychol Behav Neurol 1992;5:l26-l3l.

133. Friedlander A, Cummings JL. Dental management of patients with Gilles de la Tourette's syndrome. Oral Surg Oral Med Oral Pathol 1992;73:299-303.

26

134. Liu CK, Miller B, Cummings JL, Goldberg M, Merringer PM, Howng SL, Benson DF. A quantitative MRI study of vascular dementia. Neurology 1992;42:l38-l43.

135. Cummings JL, Cunningham K. Obsessive-compulsive disorder in Huntington's disease. Biol Psychiatry 1992;3l:263-270.

136. Kern RS, Van Gorp WG, Cummings JL, Brown WS, Osato S. Confabulation in Alzheimer's disease. Brain Cogn 1992(l9:l72-l82.

137. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;l49:443-454.

138. Absher J, Cummings JL. Dementia diagnosis and therapy in the elderly. Comp Therapy 1992;l8:28-33.

139. Gorman G, Cummings JL. Hypersexuality following septal injury. Arch Neurol 1992;49:308-3l0.

140. Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL. Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: The Neurobehavioral Rating Scale. J Am Geriatr Soc 1992;40:549-555.

141. Cummings JL. Subcortical dementia as a manifestation of cerebrovascula99r disease. New Issues in Neuroscience 1992;4:l5l-l58.

142. Engel P, Cummings JL, Villaneuva-Meyer J, Mena I. Single photon emission computed tomography in dementia syndromes: Relationship of perfusion and cognitive deficits. J Geriatr Psychiatry Neurol 1993;6:l44-l5l.

143. Roman GC, Tatemichi TK, Erkunjuntti T, Cummings JL, et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Work Group. Neurology 1993;43:250-260.

144. Gorman DG, Cummings JL. Neurobehavioral presentations of antiphospholipid antibody syndrome. J Neuropsychiatry Clin Neurosci 1993;5:37-42.

145. Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL. A comparison of psychiatric symptoms in vascular dementia and Alzheimer's disease. Am J Psychiatry 1993;l50:l806-l8l2.

146. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993;50:873-880.

147. Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates delusions in Alzheimer's disease. Biol Psychiatry 1993;33: 536-54l.

148. Cummings JL. Mini-Mental State Exam: Norm, normals, and numbers. JAMA 1993;269:2420-242l.

149. Cummings JL. The mental status examination. Hosp Practice 1993;28:56-68.

150. Strickland TL, Mena I, Villaneuva-Meyer J, Miller B, Mehringer M, Satz P, Cummings JL. Cerebral perfusion and neuropsychological consequences of chronic cocaine use. J Neuropsychiatry Clin Neurosci 1993;5:4l9-427.

151. Ortego N, Miller BL, Itahashi H, Cummings JL. Altered sexual behavior with multiple sclerosis: A case report. Neuropsychiatry Neuropsychol Behav Neurol 1993;6:260-264.

152. Gorman DG, Read S, Cummings JL. Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1993;6:229-234.

153. Cummings JL. of depression. J Clin Psychiatry 1993;54:l4-20.

154. Leuchter AF, Cook IA, Lufkin RB, Dunkin JT, Newton TF, Cummings JL, Mackey JK, Walter DO. Cordance: A new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography. Neuroimage 1994;1:208-219.

155. Cummings JL, Hegarty A. Neurology, Psychiatry, and Neuropsychiatry. Neurology 1994;44:209-2l3.

156. Drebbing CE, Moore LH, Cummings JL, Van Gorp W, Hinkin C, Perlman SL, Mahler ME, Cederbaum SD. Patterns of neuropsychological performance among forms of subcortical dementia: a case study approach. Neuropsychiatry Neuropsychol Behav Neurol 1994;7:57-66. 27

157. Ames D, Cummings JL, Wirshing WC, Quinn B, Mahler M. Repetitive and compulsive behavior in frontal lobe degenerations. J Neuropsychiatry Clin Neurosci 1994;6:l00-ll3.

158. Cummings JL. Delusions in Alzheimer's disease: clinical correlates, neurobiology, and management. Facts and Research in Gerontology 1994;(suppl):65-7l.

159. Leuchter A, Simon SL, Daly KA, Rosenberg-Thompson S, Abrams M, Dunkin JJ, Cook IA, Newton TF, Walker DO, Cummings JL. Quantitative EEG correlates of outcome in older psychiatric patients: Cross-sectional and longitudinal assessment of patients with dementia. Am J Geriatr Psychiatry 1994;2:200-209.

160. Salloway S, Cummings JL. Subcortical disease and neuropsychiatric illness. J Neuropsychiatry Clin Neurosci 1994;6:93-99.

161. Cummings, JL. Vascular subcortical dementias: clinical aspects. Dementia 1994;5:177-180

162. Leuchter AF, Cook IA, Mena I, Dunkin JJ, Cummings JL, Newton TF, Migneco O, Lufkin RB, Walker DO, Lachenbruch PA. Assessment of cerebral perfusion using quantitative EEG cordance. Psychiatry Research: Neuroimage 1994;55: 141-152.

163. Mega M, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994;6: 358-370.

164. Cummings JL. Depression in neurologic disease. Psychiatr Ann 1994;24:525-531.

165. McPherson S, Kuratani J, Shih J, Mischel PS, Vinters HV, Cummings JL. Creutzfeldt-Jakob disease with mixed transcortical aphasia: insights into echolalia. Behav Neurol 1994;7:197-203.

166. Sokolski KN, Cummings JL, Abrams, BI, Costa JL, Katz L, DeMet EM. Effects of substance abuse on hallucination rates and treatment responses in chronic psychiatric patients. J Clin Psychiatry 1994;55:380-387.

167. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44: 2308-2314.

168. Benjamin S, Cummings JL, Duffy JD, Fogel BS, Hegarty AM, Tucker G. Pathways to neuropsychiatry. J Neuropsychiatry Clin Neurosci 1995;7:96-101.

169. Absher J, Cummings JL. Neurobehavioral examination of frontal lobe functions. Physiology 1995;9:181-192.

170. Green RC, Benjamin S, Cummings JL. Fellowship programs in behavioral neurology. Neurology 1995;45:412-415.

171. Sultzer DL. Mahler ME, Cummings JL, Van Gorp WG, Hinkin CH, Brown C. Cortical abnormalities associated with subcortical lesions in vascular dementia: Clinical and positron emission tomographic findings. Arch Neurol 1995;52: 773-780.

172. Pahl JJ, Mazziotta JC, Bartzokis G, Cummings JL, Altschuler L, Mintz J, Marder SR, Phelps ME. Positron emission tomography (PET) in tardive dyskinesia. J Neuropsychiatry Clin Neurosci 1995;7:457-465.

173. Carmel R, Gott PS, Water CH, Carro K, Green R, Bondareff W, DeGiorgio CM, Cummings JL, Jacobsen DW, Buchwalter G, Henderson VW. The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities. Eur J Haemotol 1995;54:245-253.

174. Geschwind DH, FitzPatrick M, Mischel PS, Cummings JL. Sneddon's syndrome is a thrombotic vasculopathy: neuropathologic and neuroradiologic evidence. Neurology 1995;45:557-560.

175. Cheyette S, Cummings JL. Encephalitis lethargica: Lessons for contemporary neuropsychiatry. J Neuropsychiatry Clin Neurosci 1995;7:125-134.

28

176. Cummings JL, Ross W, Absher J, Gornbein J, Hadjiagha L. Depressive symptoms in Alzheimer disease: Assessment and determinants. Alzheimer Dis Assoc Disord 1995;9:87-93.

177. Cummings JL. Lewy body diseases with dementia: pathophysiology and treatment. Brain Cogn 1995;28:266-280.

178. Cummings JL. Anatomic and behavioral aspects of frontal-subcortical circuits. Ann NY Acad Sci 1995;769:1-13.

179. Sultzer DL, Mahler ME, Mandelkern MA, Cummings JL, Van Gorp WG, Hinkin CH, Berisford MA. Relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1995;7:476-484.

180. Cummings JL. Dementia: the failing brain. Lancet 1995;345:1481-1484.

181. Ponton MO, Darcourt J, Miller BL, Cummings JL, Schumann SW, Mena I. Psychometric and SPECT studies in Alzheimer's disease with and without delusions. Neuropsychiatry Neuropsychol Behav Neurol 1995;8:264-270.

182. Coffey CE, Cummings JL, Duffy JD, Fink M, Lauterbach EC, Lovell MR, Malloy P, Nussbaum PD, Royall DR, Salloway S. Assessment of treatment outcomes in neuropsychiatry: a report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 1995;7:287-289.

183. Mendez MF, Van Gorp W, Cummings JL. Neuropsychiatry, Neuropsychology, and Behavioral Neurology: A critical comparison. Neuropsychiatry Neuropsychol Behav Neurol 1995;8:297-302.

184. Aarsland D, Cummings JL, Kaufer D. Tacrine in Alzheimer's disease; which patients and which mental functions improve? Alzheimer Res 1995;1:133-136.

185. Chang L, Scharre DW, Miller B, Cummings JL, Vigo-Pelfry C, Schenk D. B-amyloid protein in cerebrospinal fluid of Alzheimer disease: correlations with Mini-Mental State Examination scores. Facts and Research in Gerontology 1995; 84-92.

186. Cummings JL. Neuropsychiatric assessment and intervention in Alzheimer's disease. Int Psychogeriatr 1996;8:25-30.

187. Mega M, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-135.

188. Yener GG, Leuchter AF, Jenden D, Read SL, Cummings JL, Miller BL. Quantitative EEG in frontal-temporal dementia. Clin Electroencephalogr 1996;27:61-68.

189. White K, Cummings JL. Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Comp Psychiatry 1996;37:188-195.

190. Aarsland D, Cummings JL, Yenner G, Miller B. The relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Am J Psychiatry 1996;153:243-247.

191. Cummings JL. Neuropsychiatry and society. J Neuropsychiatry Clin Neurosci 1996;8:104-109.

192. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.

193. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996;53:175-179.

194. Cummings JL. Differential diagnosis and medical management of dementia patients. Federal Practitioner 1996; (Suppl):10-15.

195. Salloway S, Cummings JL. Subcortical structures and neuropsychiatric illness. The 1996;2:66-75.

196. Cummings JL. Barriers to behavioral research on dementia. Int Psychogeriatr 1996;8:21-23.

29

197. Levy M, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996;153:1438-1443.

198. Jenike MA, Rauch SL, Cummings JL, Savage CR, Goodman WK. Recent developments in neurobiology of obsessive-compulsive disorder. J Clin Psychiatry, October, 1996;57:492-503. Condensed and presented in Psychiatry Digest, August, 1997.

199. Levy ML, Miller BL, Cummings JL, Fairbanks LA, Craig A. Alzheimer disease and frontotemporal dementias. Behavioral Distinctions. Arch Neurol 1996;53:687-690.

200. Litvan I, Mega M, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996;47:1184-1189.

201. Cummings JL, Kaufer DI. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996;47:876-883.

202. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996;53:538-542.

203. McPherson SE, Cummings JL. Neuropsychological aspects of vascular dementia. Brain Cogn 1996;31:269-282.

204. Wright MT, Cummings JL. Neuropsychiatric disturbances in Alzheimer's disease and other dementias: recognition and management. Neurologist 1996;2:207-218.

205. Cummings JL, Alexander M, Benson F, Delis DC, LaRue A, Meador K, Ponton NO, Shields WD, Stuss DJ, Whitney DK. Assessment: Neuropsychological testing of adults. Considerations for Neurologists. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996;47:592-59.

206. Mendez MF, Cherrier MM, Perryman KM, Pachana N, Miller BL, Cummings JL. Frontotemporal dementia versus Alzheimer's disease: differential cognitive features. Neurology 1996;47:1189-1194.

207. Cummings JL, Diaz C, Levy M, Binetti G, Litvan I. Neuropsychiatric syndromes in neurodegenerative diseases: frequency and significance. Semin Clin Neuropsychiatry 1996;1:241-247.

208. Craig AH, Cummings JL, Fairbanks L, Itti L, Miller BL, Li J, Mena I. Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996;53:1116-1120.

209. Pachana NA, Boone KB, Miller BL, Cummings JL, Berman N. Comparison of neuropsychological functioning in Alzheimer's disease and frontotemporal dementia. J Int Neuropsychol Soc 1996;2:505-510.

210. Levy ML, Cummings JL. Diagnosis of Alzheimer's disease in primary care. Primary Psychiatry 1996;Nov:30-40.

211. Aarsland D, Laake K, Cummings JL, Larsen JP. Course and prognostic significance of performance in reading, spelling and oral language in Alzheimer's disease. Alzheimer Res 1996;2:143-148.

212. Cummings JL. Theories behind existing scales for rating behavior in dementia. Int Psychogeriatr 1996;8:293-300.

213. Cummings JL, Mega M. Alzheimer's disease: etiologies and pathogenesis. The Consultant Pharmacist 1996;11:8-15.

214. Mega MS, Masterman DL, Benson DF, Vinters HV, Tomiyasu U, Craig AH, Foti DJ, Kaufer D, Scharre DW, Fairbanks L, Cummings JL. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology 1996;47:1403- 1409.

215. Cummings JL. Dementia: the behavioral aspects. Int Med 1996;12:75-80.

216. Cummings JL. Vascular dementia. Int Med 1996;12:81-88.

217. Van Gorp WG, Cummings JL. Dementia syndrome of depression: What cognitive functions are impaired? Neurocase 1996;2: 455-459. 30

218. Carmel R, Cairo K, Bondareff W, Gott PS, Cummings JL, Henderson VW. Spouses of demented patients with low cobalamin levels: a new risk group for cobalamin deficiency. Eur J Haematol 1996;57:62-67.

219. Cummings JL. Neuropsychiatric manifestations of right hemisphere lesions. Brain Lang 1997;57:22-37.

220. Kaufer DI, Miller BL, Itti L, Fairbanks LA, Li J, Fishman J, Kushi J, Cummings JL. Midline cerebral morphometry distinguishes frontotemporal dementia and Alzheimer's disease. Neurology 1997;48:978-985.

221. Weingarten SM, Cummings JL. Dementia: differentiating the treatable from the untreatable. Dementia 1997;19:13-32. Reproduced in Internal Medicine World Report.

222. Masterman DL, Mendez, Fairbanks LA, Cummings JL. Sensitivity, specificity, and positive predictive value of technetium 99- HMPAO SPECT in discriminating Alzheimer's disease from other dementias. J Geriatr Psychiatry Neurology 1997;10:15-21.

223. Miller BL, Ikonte C, Ponton M, Levy M, Boone K, Darby A, Berman N, Mena I, Cummings JL. A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations. Neurology 1997;48:937-942.

224. Cherrier MM, Mendez MF, Perryman KM, Pachana NP, Miller BL, Cummings JL. Frontotemporal dementia versus vascular dementia: differential features on mental status examination. J Am Geriatr Soc 1997;45:579-583.

225. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson's Disease. Arch Neurol 1997;54:625-630.

226. Miller BL, Darby A, Benson DF, Cummings JL, Miller MH. Aggressive, socially disruptive and antisocial behavior associated with frontotemporal dementia. Br J Psychiatry 1997;170:150-155.

227. Malloy PF, Coffey CE, Cummings JL, Duffy J, Fink M, Lauterbach E, Lovell M, Royall D, Salloway S. Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 1997;9:189-197.

228. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48:S10-S16.

229. Masterman DL, Cummings JL. Frontal-subcortical circuits: the anatomic basis of executive, social and motivated behaviors. J Psychopharmacol 1997;11:107-114.

230. Wright MT, Cummings JL, Mendez MF, Foti DJ. Bipolar syndromes following brain trauma. Neurocase 1997;3:111-118.

231. Edwards-Lee T, Miller BL, Benson DF, Cummings JL, Russell GL, Boone K, Mena I. The temporal variant of frontotemporal dementia. Brain 1997;120:1027-1040.

232. Trimble MR, Mendez MF, Cummings JL. Neuropsychiatric symptoms from the temporolimbic lobes. J Neuropsychiatry Clin Neurosci 1997;9:429-438.

233. Mega MS, Cummings JL, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic, and clinical perspective. J Neuropsychiatry Clin Neurosci 1997;9:315-330.

234. Homma A, Brodaty H, Bruno G, Cummings JL, Gilman S, Gracon S, McKeith IG. Clinical trials of treatment for noncognitive symptoms of dementia. Position paper from the International Working Group on harmonization of dementia drug guidelines. Alzheimer Dis Assoc Disord 1997;11:54-55.

235. Cummings JL. Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic for Alzheimer's disease. Alzheimer Dis Assoc Disord 1997;11:S1-S9.

236. Cummings JL, Mendez MF. Alzheimer's disease: cognitive and behavioral pharmacotherapy. Conn Med 1997;6:543-552.

31

237. Mendez MF, Perryman KM, Miller BL, Swartz JR, Cummings JL. Compulsive behaviors as presenting symptoms of frontotemporal dementia. J Geriatr Psychiatry Neurology 1997;10:154-157.

238. Salloway S, Malloy P, Cummings JL. Introduction to the neuropsychiatry of limbic and subcortical disorders. J Neuropsychiatry Clin Neurosci 1997;9:313-314.

239. Cummings JL. Degeneraciones frontales. Neuro-psique 1997;1:6-13.

240. Barbosa ER, Limongi JCP, Cummings JL. Parkinson's disease. Psychiatr Clin North Am. Neuropsychiatry of the Basal Ganglia 1997;20:769-791.

241. Haddad MS, Cummings JL. Huntington's disease. Psychiatr Clin North Am. Neuropsychiatry of the basal ganglia. 1997;20:791- 807.

242. Prichard JW, Cummings JL. The insistent call from functional MRI. Neurology 1997;48:797-800.

243. Cummings JL. Alzheimer's disease: comprehensive treatment approach. Neurology Reviews 1997;5-6.

244. Wetherall J, Yener G, Dorman AS, Earleywine M, Darby A, Emerson K, Cummings JL, Miller BL. The Mini-Mental State Examination in frontotemporal dementia and Alzheimer's disease. Int J Rehab Health 1997;3:253-265.

245. Cummings JL. Introduction: Alzheimer’s disease management. J Clin Psychiatry 1998;59:1-16.

246. Kaufer D, Cummings JL, Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998;10:55-63.

247. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998;6:S64-S78.

248. Cummings JL, Coffey CE, Duffy J, Lauterbach E, Lovell M, Malloy P, Royall DR, Rummans T, Salloway S. The clinician-scientist in neuropsychiatry: A position statement from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 1998;10:1-9.

249. Cummings JL. Metrifonate: overview of safety and efficacy. Pharmacotherapy 1998;18:43S-46S.

250. Mega MS, Thompson PM, Cummings JL, Back CL, Xu ML, Zohoori S, Goldkorn A, Moussai J, Fairbanks L, Small GW, Toga AW. Sulcal variability in the Alzheimer's brain: correlations with cognition. Neurology 1998;50:145-151.

251. Tom T, Cummings JL. Depression in Parkinson's disease: Pharmacological characteristics and treatment. Drugs Aging 1998;12:55- 74.

252. Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, MacMillan A, Ketchel P, DeKosky ST. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998;46:210-215.

253. Tom T, Cummings JL, Pollak J. Posterior cortical atrophy: unique features. Neurocase 1998;4:15-20.

254. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B, Metrifonate Study Group. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50:1214-1221.

255. Masterman DL, Cummings JL. Parkinson's disease update. Part I: Clinical features, neuropathology, and treatment. Clin Geriatrics 1998;6:61-69.

256. Masterman DL, Cummings JL. Parkinson’s disease update. Part II: Neuropsychiatric aspects. Clin Geriatrics 1998;6:76-80.

257. Chow T, Cummings JL. Treatment of depression in the patient with Parkinson's disease. Clin Geriatrics 1998;6:34-46. 32

258. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998;51:S2-S17.

259. Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Paulsen JS, Litvan I. Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998;10:314-419.

260. Cummings J, Masterman DL. Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease. J Clin Psychiatry 1998;59:23-30.

261. Cummings JL. On: frontal-subcortical circuits and human behavior. J Psychomat Res 1998;44:627-628.

262. Tom T, Cummings JL. Drug treatment for Alzheimer's disease. West J Med 1998;168:264.

263. Miller BL, Cummings J, Mishkin F, Boone K, Prince F, Ponton M, Cotman C. Emergence of artistic talent in frontotemporal dementia. Neurology 1998;51:978-982.

264. Litvan I, Paulsen JS, Mega MS, Cummings JL. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch Neurol 1998;55:1313-1319.

265. Lauterbach EC, Cummings JL, Duffy J, Coffey CE, Kaufer D, Lovell M, Malloy P, Reeve A, Royall DR, Rummans T, Salloway S. Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington’s, Wilson’s, and Fahr’s diseases. A report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 1998;10:249-266.

266. Chen ST, Sultzer DL, Hinkin CH, Mahler ME, Cummings JL. Executive dysfunction in Alzheimer’s disease: association with neuropsychiatric symptoms and functional impairment. J Neuropsychiatry Clin Neurosci 1998;10:426-432.

267. Geschwind D, Cummings JL, Hollander E, DiMauro S, Cook EH, Lombard J, Stefanotos G, Sprouse CA, Jensen P, Mott SH. Autism screening and diagnostic evaluation: CAN consensus statement. CNS Spectrums 1998;3:40:47-49.

268. Binetti G, Mega MS, Magni E, Padovani A, Rozzini L, Lussignoli G, Bianchetti A, Trabucchi M, Cummings J. Behavioral disorders in Alzheimer's disease: a transcultural perspective. Arch Neurol 1998;55:539-544.

269. Cummings JL. Clinical science and clinical practice: understanding the interface. Clin Geriatrics 1998;6:15-16.

270. Mendez MF, Perryman KM, Miller BL, Cummings JL. Behavioral differences between frontotemporal dementia and Alzheimer’s disease: a comparison on the BEHAVE-AD rating scale. Int Psychogeriatr 1998;10:155-162.

271. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings JL, Benson DF. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.

272. Cummings JL. On: Motility, behavior and the brain. J Psychomat Res 1998;44:643-644.

273. Thompson PM, Moussai J, Zohoori S, Goldkorn A, Khan AA, Mega, MS, Small GW, Cummings JL, Toga AW. Cortical variability and asymmetry in normal aging and Alzheimer’s disease. Cerebral Cortex 1998;8:492-509.

274. Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998;65:717-721.

275. Cummings JL. D. Frank Benson, M.D. Biography and overview of contributions. Aphasiology 1999;13:3-11.

276. Diaz-Olavarrieta C, Cummings JL, Velazquez J, Garcia de al Cadena C. Neuropsychiatric manifestations of multiple sclerosis. J Neuropsychiatry Clin Neurosci 1999;11:51-57.

33

277. Gifford DR, Cummings JL. Evaluating dementia screening tests: methodologic standards to evaluate their performance. (editorial). Neurology 1999;52:224-227.

278. Wood S, Cummings JL. Measuring outcomes in Alzheimer’s disease research: assessment of the effectiveness of interventions. Dis Manag Health Outcomes 1999;5:1-12.

279. Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer’s disease. Gerontology 1999;45:15-22.

280. Cummings JL. Understanding Parkinson disease. (editorial). JAMA 1999;81:376-378.

281. Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW. Apolipoprotein E genotype and non-cognitive symptoms in Alzheimer's disease. Biol Psychiatry 1999;45:422-425.

282. Frisoni GB, Rozzini L, Binetti G, Zanetti O, Bianchetti A, Trabucchi M, Cummings JL. Behavioral syndromes in Alzheimer’s disease: Description and correlates. Dementia 1999;10:130-138.

283. Fillit H, Knopman D, Cummings JL, Appel F, and the Alzheimer’s Disease Managed Care Advisory Council. Opportunities for improving managed care for individuals with dementia: part 1 – the issues. Am J Manag Care 1999;5:309-315.

284. Fillit H, Knopman D, Cummings JL, Appel F, and the Alzheimer’s Disease Managed Care Advisory Council. Opportunities for improving managed care for individuals with dementia: part 2 – a framework for care. Am J Managed Care 1999;5:309-315.

285. Cummings JL. Anti-dementia drugs: what difference do they make? (editorial). Reviews in Clinical Gerontology 1999;8:279-280.

286. Cummings JL. Diagnosis and treatment of Alzheimer's disease. (editorial). Clin Geriatrics 1999;7:25-29.

287. Rummans TA, Lauterbach EC, Coffey CE, Royall DR, Cummings JL, Salloway S, Duffy J, Kaufer D. Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials: a report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 1999;11:176-189.

288. Aarsland D, Larsen JP, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999;56:595-601.

289. Cummings JL, Fairbanks L, Masterman DL. Strategies for analysing behavioral data in clinical trials involving patients with Alzheimer's disease. Int J Neuropsychopharmacol 1999;2:59-66.

290. Bartzokis G, Cummings JL, Perlman S, Hance DB, Mintz J. Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999;56:569-574.

291. Cummings JL, Masterman DL. Neuroscience, neurology, and neuropsychiatry: responding to an aging population. Clin Geriatrics 1999;7:74-78.

292. Cummings JL. D-3 receptor agonists: combined action neurologic and neuropsychiatric agents. (editorial). J Neurol Sci 1999;163:2-3.

293. Cummings JL. Alzheimer's disease: neurobiology and clinical manifestations. Postgrad Med: A Special Report 1999;13-18.

294. Ringman JM, Cummings JL. Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. Exp Opin Invest Drugs 1999;8:463-471.

295. Cummings JL. Managing psychosis in patients with Parkinson's disease. (editorial). N Engl J Med 1999;340:801-803.

296. Cummings JL. Principles of neuropsychiatry: towards a neuropsychiatric epistemology. Neurocase 1999;5:181-188.

297. Cummings JL, Jeste DV. Alzheimer's disease and its management in the Year 2010. Psychiatr Serv 1999;50:1173-1177. 34

298. Desmond DW, Erkinjuntti T, Sano M, Cummings JL, Bowler JV, Pasquier F, Moroney JT, Ferris SH, Stern Y, Sachdev PS, Hachinski VC. The cognitive syndrome of vascular dementia: implications for clinical trials. Alzheimer Dis Assoc Disord 1999;13:S21-S29.

299. Mendez MF, Ottowitz W, Brown CV, Cummings JL, Perryman KM, Mandelkern MA. Dementia with leukoaraiosis: clinical differentiation by temporoparietal hypometabolism on 18FDG-PET imaging. Dement Geriatr Cogn Disord 1999;10:518-525.

300. Mendez MF, Perryman KM, Ponton MO, Cummings JL. Bilingualism and dementia. J Neuropsychiatry Clin Neurosci 1999;11):411-412.

301. Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciokas LJ, Tishler TA, Marder SR, Mintz J. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 1999;17:213-222.

302. Wood SA, Cummings JL, Barclay T, Hsu MA, Allahyar M, Schnelle JF. Assessing the impact of neuropsychiatric symptoms on distress in professional caregivers. Aging Ment Health 1999;3:241-245.

303. Wood S, Cummings JL, Hsu M-A, Barclay T, Wheatley MV, Yarema KT, Schnelle JF. The use of the Neuropsychiatric Inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry 2000;8:75-83.

304. Di Patre PL, Read SL, Cummings JL, Tomiyasu U, Vartavarian LM, Vinters HV. Progression of clinical deterioration and pathologic changes in Alzheimer patients evaluated at and . Arch Neurol 1999;56:1254-1261.

305. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388-1393.

306. Aarsland D, Larsen JP, Lim NH, Janvin C, Karlsen K, Tandberg E, Cummings JL. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:492-496.

307. McPherson S, Back C, Buckwalter JG, Cummings JL. Gender-related cognitive deficits in Alzheimer's disease. Int Psychogeriatr 1999;11:117-122.

308. Cummings JL, Knopman D. Advances in the treatment of behavioral disturbances in Alzheimer's disease. (editorial). Neurology 1999;53:899-901.

309. Hirono N, Cummings JL. Neuropsychiatric aspects of dementia with Lewy bodies. Curr Psychiatry Rep 1999;1:85-92.

310. Jeste V, Alexopoulos GS, Bartels SJ, Cummings JL, Gallo JJ, Gottlieb GL, Halpain MC, Palmer BW, Patterson TL, Reynolds CF, Lebowitz BD. Consensus statement on the upcoming crisis in geriatric mental health. Arch Gen Psychiatry 1999;56:848-853.

311. Menzin J, Lang K, Friedman M, Neumann P, Cummings JL. The economic cost of Alzheimer's disease and related dementias to the California Medicaid program ("Medi-Cal") in 1995. Am J Geriatr Psychiatry 1999;7:300-308.

312. Ringman JM, Cummings JL. Metrifonate: update on a new antidementia agent. J Clin Psychiatry 1999;60:776-782.

313. Van Lancker D, Cummings JL. Expletives: neurolinguistic and neurobehavioral perspectives on swearing. Brain Res Rev 1999;31:83-104.

314. Fillit H, Cummings JL. Practice guidelines for the diagnosis and treatment of Alzheimer’s disease in a managed care setting: Part I- Early detection and diagnosis. Manag Care Interface 1999;12:53-62.

315. Van Gorp WG, Marcotte TD, Sultzer D, Hinkin C, Mahler M, Cummings JL. Screening for dementia: comparison of three commonly used instruments. J Clin Exp Neuropsychol 1999;21:29-38.

316. Cummings JL, Masterman DL. Depression in patients with Parkinson’s disease. Int J Geriatr Psychiatry 1999;14:711-718.

35

317. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O’Brien JT, Ballard CG. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology 2000;54:1616-1625.

318. Fillit H; Cummings J. Practice guidelines for the diagnosis and treatment of Alzheimer’s disease in a managed care setting: Part II-- Pharmacologic therapy. Manag Care Interface 2000;13:51-56.

319. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;(157):4-15.

320. Hou C, Miller BL, Cummings JL, Goldberg M, Mychack P, Bottino V, Benson DF. Autistic Savants. Neuropsychiatry Neuropsychol Behav Neurol 2000;13:29-38.

321. Mega MS, Lee L, Dinov ID, Mishkin F, Toga AW, Cummings JL. Cerebral correlates of psychotic symptoms in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2000;69:167-171.

322. Kaufer DI, Cummings Jl, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000;12:233-239.

323. Cummings Jl, Donohue JA, Brooks RL. The relationship between donepezil and behavioral disturbances in patients with Alzheimer’s disease. Am J Geriatr Psychiatry 2000;8:134-140.

324. Cummings JL, Chung J. Differential diagnosis and management of psychotic disorders in the elderly. Directions in Psychiatry 2000;20:1-14.

325. Cummings JL, Askin-Edgar S. Evidence for psychotropic effects of acetylcholinesterase inhibitors. CNS Drugs 2000;13) 385-395.

326. Hirono N, Mega MS, Dinov ID, Mishkin F, Cummings JL. Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. Arch Neurol 2000;57:861-866.

327. Cummings JL. A window on the role of dopamine in disorders. J Neurol Neurosurg Psychiatry 2000;68:404.

328. Small GW, Ercoli LM, Silverman DHS, Huang S-C, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon Nl, Mazziotta JC, Sexena S, Wu HM, Mega MS, Cummings Jl, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A 2000;97:6037-6042.

329. Cummings JL. The role of cholinergic agents in the management of behavioral disturbances in Alzheimer’s disease. Int J Neuropsychopharmacol 2000;3:S21-S29.

330. Edwards-Lee T, Cook I, Fairbanks L, Leuchter A, Cummings JL. Quantitative electroencephalographic correlates of psychosis in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 2000;13:163-170.

331. Mega MS, Dinov ID, Lee L, O’Connor SM, Masterman DM, Wilen B, Mishkin F, Toga AW, Cummings JL. Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2000;12:209-218.

332. Cummings JL. Clinical Trials Report. Curr Psychiatry Rep 2000;2:419-420.

333. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000;57:968-976.

334. Bartzokis G, Sultzer D, Cummings JL, Holt LE, Hance DB, Henderson VW, Mintz J. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 2000;57:47-53.

335. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG. The clinician assessment of fluctuation and the one day fluctuation assessment scale: two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177: 252-256. 36

336. Cummings JL. Cholinesterase inhibitors: expanding applications. Lancet 2000;356:2024-2025.

337. Chung JA, Cummings JL. Neurobehavioral and neuropsychiatric symptoms in Alzheimer’s disease; characteristics and treatment. Neurol Clin 2000;18:829-846.

338. Cummings JL. New tests for dementia. Neurology 2000;55:1601-1602.

339. Miller BL, Boone K, Cummings JL, Read SL, Mishkin F. Functional correlates of musical and visual ability in frontotemporal dementia. Br J Psychiatry 2000;176:458-463.

340. Cummings JL. Cognitive and behavioral heterogeneity in Alzheimer’s disease: seeking the neurological basis. Neurobiol Aging 2000;21:845-861.

341. Cummings JL. Cognitive and behavioral heterogeneity in Alzheimer’s disease: seeking the neurological basis. Response to commentaries. Neurobiol Aging 2000;21:875-877.

342. Cummings JL, Masterman DL. Reconsidering outcomes in Alzheimer disease clinical trials. Econ Neurosci 2000;2:50-54.

343. Leon J, Neumann PJ, Hermann RC, Hsu MA, Cummings JL, Doraiswamy PM, Marin D. Health related quality of life and service utilization in Alzheimer’s disease. Am J Alzheimer Dis Other Demen 2000;15:94-108.

344. Chow TW, Ross L, Fox P, Cummings JL, Lin K-M. Utilization of Alzheimer’s disease community resources by Asian-Americans in California. Int J Geriatr Psychiatry 2000;15:838-847.

345. Cummings JL. in the dementia assessment: Is it necessary? J Am Geriatr Soc 2000;48:1345-1346.

346. Lindau M, Almkvist O, Kushi J, Boone K, Johansson SE, Wahlund LO, Cummings JL, Miller BL. First symptoms—frontotemporal dementia versus Alzheimer’s disease. Dement Geriatr Cogn Disord 2000;11:286-293.

347. Tekin S, Fairbanks LA, O’Connor S, Rosenberg S, Cummings JL. Activities of daily living in Alzheimer’s disease; neuropsychiatric, cognitive, and medical illness influences. Am J Geriatr Psychiatry 2001;9:81-86.

348. Thompson PM, Mega MS, Woods RP, Zoumalan CI, Lindshield CJ, Blanton RE, Moussai J, Holmes CJ, Cummings JL, Toga AW. Cortical change in Alzheimer’s disease detected with a disease-specific population-based brain atlas. Cereb Cortex 2001;11:1-16.

349. Mega MS, Cummings JL, O’Connor SM, Dinov ID, Reback E, Felix J, Masterman DL, Phelps ME, Small GW, Toga AW. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:63-68.

350. Cummings JL, Chow TC, Masterman D. Encephalitis lethargica: lessons for neuropsychiatry. Psychiatr Ann 2001;31;165-169.

351. Tekin S, Mega MS, Masterman DL, Chow T, Garakian J, Vinters HV, Cummings JL. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001;49:355-361

352. Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson’s disease with dementia and Alzheimer’s disease. Int J Geriatr Psychiatry 2001;16:184-191

353. Cummings JL, Senanarong V. Geriatric neuropsychopharmacology: Unmet needs. Psychogeriatrics 2001;1:14-26

354. Fuh J-L, Liu C-K, Mega MS, Wang S-J, Cummings JL. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. Int Psychogeriatr 2001;13:121-128

355. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-1142

37

356. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-1153

357. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-1166

358. Cummings JL, Mega M, Masterman D. Behavioral responses to cholinesterase inhibitors. CPD Bull Old Age Psychiatry 2001;2: 71-75.

359. Cummings JL. Introduction. Clin Cornerstone 2001;3:iv

360. Cummings JL. Treatment of Alzheimer's disease. Clin Cornerstone 2001;3:27-39

361. Pippenger MA, Cummings JL. Treatment of Alzheimer’s disease. Psychiatr Clin North Am Ann Drug Ther 2001; 8:237-253.

362. Cummings JL, Nadel A, Masterman D, Cyrus PA. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol 2001;14:101-108

363. Cummings JL, McPherson S. Neuropsychiatric assessment of Alzheimer’s disease and related dementias. Aging Clin Exp Res 2001;13:240-246

364. Leung VP, Lam LC, Chiu HF, Cummings JL, Chen QL. Validation study of the Chinese version of the Neuropsychiatric Inventory (CNPI). Int J Geriatr Psychiatry 2001;16:789-793

365. Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington’s disease. J Neurol Neurosurg Psychiatry 2001;71:310-314

366. Hirono N, Mega MS, Dinov ID, Mishkin F, Cummings JL. Neuroimaging correlates of aggressive behavior in dementia patients. Res Pract Alzheimer Dis 2001;5:27-32.

367. Tekin S, Cummings JL. Depression in dementia. Neurologist 2001;7:252-259

368. Silverman DH, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME. Positron emission tomography in evaluation of dementia. JAMA 2001;286:2120- 2127.

369. Swanberg MM, Cummings JL. Therapeutic approaches to Alzheimer’s disease. Alzheimer Care Q 2001;2:8-16

370. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E. A randomized, double-blind, placebo- controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-1599

371. Geschwind DH, Robidoux J, Alarcon M, Miller BL, Wilhelmsen KC, Cummings JL, Nasreddine ZS. Dementia and neurodeveopmental predisposition: cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia. Ann Neurol 2001;50:741-746

372. Kulisevsky J, Litvan I, Berthier ML, Pascual-Sedano B, Paulsen JS, Cummings JL. Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders. Mov Disord 2001;16:1098-1104

373. Doraiswamy PM, Leon J, Cummings J, Marin D, Neumann P. Prevalence and impact of medical comorbidity in Alzheimer’s disease. J Geronotol 2002;57:M173-M177

38

374. Chow TW, Cummings JL, Leung VPY, Chiu HFK, Lam LCW, Chen QL, Liu CK, Tai CT, Chen L-W, Wang SJ, Fuh JL. Neuropsychiatric symptoms of Alzheimer’s disease differ in Chinese and American patients. Int J Geriatr Psychiatry 2002;17:22-28.

375. Pang FC, Chow TW, Cummings JL, Leung VP, Chiu HFK, Lam LCW, Chen QL, Tai CT, Chen LW, Wang SJ, Fuh JL. Effect of neuropsychiatric symptoms of Alzheimer’s disease on Chinese and American caregivers. Int J Geriatr Psychiatry 2002;17:29-34.

376. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2002;13:67-73.

377. Senanarong V, Vannasaeng S, Poungvarin N, Ploybutr S, Udompunthurak S, Jamjumras P, Fairbanks L, Cummings JL. Endogenous estradiol in elderly individuals: cognitive and noncognitive associations. Arch Neurol 2002;59:385-389.

378. Wood S, Cummings JL, Schnelle B, Stephens M. A videotape-based training method for improving the detection of depression in residents of long-term care facilities. Gerontologist 2002;42:114-121.

379. McPherson S, Fairbanks L, Tiken S, Cummings JL, Back-Madruga C. Apathy and executive function in Alzheimer’s disease. J Int Neuropsychol Soc 2002;8:373-381.

380. Cummings JL, Cole G. Alzheimer disease. JAMA 2002;287:2335-2338.

381. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Ranga Rama Krishman K, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF, Rovner BW, Steffens DC, Tariot PN, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry 2002; 10:125-128.

382. Ringman JM, Diaz-Olavarrieta C, Rodriguez Y, Fairbanks L, Cummings JL. The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson’s disease in Mexico. Neuropsychiatry Neuropsychol Behav Neurol 2002;15:99-105.

383. Rosen HJ, Hartikainen KM, Jagust W, Kramer JH, Reed BR, Cummings JL, Boone K, Ellis W, Miller C, Miller BL. Utility of clinical criteria in differentiating frontotemporal lobar degeneration (FTLD) from AD. Neurology 2002;58:1608-1615.

384. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, Mittman B. Guidelines for managing Alzheimer’s disease: part I. Assessment. Am Fam Physician 2002;65:2263-2272.

385. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, Mittman B. Guidelines for managing Alzheimer’s disease: part II. Treatment. Am Fam Physician 2002;65:2525-2534.

386. Swanberg MM, Cummings JL. Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug Safety 2002;25:511-523.

387. Chow TW, Miller BL, Boone K, Mishkin F, Cummings JL. Frontotemporal dementia classification and neuropsychiatry. Neurologist 2002;8:263-269.

388. Sultzer DL, Chen ST, Brown CV, Mahler ME, Cummings JL, Hinkin CH, Mandelkern MA. Subcortical hyperintensities in Alzheimer’s disease: associated clinical and metabolic findings. J Neuropsychiatry Clin Neurosci 2002;14:262-269.

389. Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Current Opin Neurol 2002;15:445-450.

390. Fuh J-L, Mega MS, Binetti G, Wang, SJ, Magni E, Cummings JL. A transcultural study of agitation in dementia. J Geriatr Psychiatry Neurol 2002;15:171-174.

391. Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 2002;53:647-654.

392. Aarsland D, Cummings JL. Depression in Parkinson’s disease. Acta Psychiatrica Scand 2002;106:161-162.

39

393. Back-Madruga C, Boone K, Briere J, Cummings J, McPherson S, Fairbanks L, Thompson E. Functional ability in executive variant Alzheimer’s disease and typical Alzheimer’s disease. Clin Neuropsychol 2002;16:331-340.

394. Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rummans TA, LaFrance WC, Coffey CE. Executive control function: a review of its promise and challenges for clinical research. J Neuropsychiatry Clin Neurosci 2002;14:377-405.

395. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Jeste DV, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Lii CF, Rovner BW, Steffens DC, Unützer J, Lebowits BD. Provisional diagnostic criteria for depression of Alzheimer’s disease: description and review. Expert Rev Neurother. 2013;3:99-106

396. Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D, Cummings JL, Effros RB. Telomere shortening in T cells correlates with Alzheimer’s disease status. Neurobiol Aging 2003;24:77-84.

397. Cummings JL. 2-deoxy-2-[18F] fluoro-d-glucose positron emission tomography in Alzheimer’s diagnosis: time for technology transfer. Mol Imag Bio 2003;4:385-386.

398. Sultzer DL, Brown CV, Mandelkern MA, Mahler ME, Mendez MF, Chen ST, Cummings JL. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer’s disease. Am J Psychiatry 2003;160:341-349.

399. Cummings JL. Alzheimer’s disease: from molecular biology to neuropsychiatry. Semin Clin Neuropsychiatry 2003; 8:31-36.

400. Boyle PA, Malloy PF, Salloway S, Cahn-Weiner DA, Cohen R, Cummings JL. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003;11:214-221.

401. Sobrido MJ, Abu-Khalil A, Weintraub S, Johnson N, Quinn B, Cummings JL, Mesulam MM, Geschwind DH. Possible association of the tau H1/H1 genotype with primary progressive aphasia. Neurology 2003;60:862-864.

402. Bartzokis G, Cummings JL, Sultzer D, Henderson VW, Nuechterlein KH, Mintz J. White matter structural integrity in healthy aging adults and patients with Alzheimer disease. Arch Neurol 2003;60:393-398.

403. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-145.

404. Clark DG, Cummings JL. Dementia diagnosis and management: an update. Intern Med J Thai 2003;19:61-68.

405. Porter VR, Buxton WG, Fairbanks LA, Strickland T, O’Connor SM, Rosenberg S, Cummings JL. Frequency and characteristics of anxiety among patients with Alzheimer’s disease and related dementias. J Neuropsychiatry Clin Neurosci 2003;15:180-186.

406. Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Smith GE, Geda YE, Cummings JL, Petersen RC, Sunderland T. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer’s disease. Am J Psychiatry 2003;160:857-866.

407. Senanarong V, Harnphadungkit K, Prayoonwiwat N, Poungvarin N, Sivasariyanonds N, Printarakul T, Udompunthurak S, Cummings JL. A new measurement of activities of daily living for Thai elderly with dementia. Int Psychogeriatrics 2003;5:135-148.

408. Cummings JL, Jeste D. Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: definitional and regulatory aspects. Econ Neurosci 2003;5;36-40.

409. Swanberg MM, Cummings JL. Diagnosis and treatment of Alzheimer’s disease. Econ Neurosci 2003;5;55-62.

410. Cummings JL. The impact of depressive symptoms on patients with Alzheimer’s disease. Alz Dis Assoc Disorders 2003;17:61-62.

411. Cummings JL. Toward a molecular neuropsychiatry of neurodegenerative diseases. Ann Neurol 2003;54:147-154.

40

412. Solomon DH, Wenger NS, Saliba D, Young RT, Adelman AM, Besdine RK, Blazer DG, Cassell CK, Cummings JL, Katz PR, Kitzman DW, Lavizzo-Mourey RJ, Mondoux LC, Popuvich R, Pories WJ, Wenger N. Appropriateness of quality indicators for older patients with advanced dementia and poor prognosis. J Am Geriatric Soc 2003;51:902-907.

413. Cole GM, Yang F, Lim GP, Cummings JL, Masterman DL, Frautschy SA. A rationale for curcuminoids for the prevention or treatment of Alzheimer’s disease. Curr. Med. Chem. – Imun., Endoc. & Metab. Agents 2003;3:15-25.

414. Mendez M, Clark DG, Shapira JS, Cummings JL. Speech and language in progressive nonfluent aphasia compared with early Alzheimer’s disease. Neurology 2003;61;1108-1113.

415. Tractenberg RE, Singer CM, Cummings JL, Thal LJ. The sleep disorders inventory: an instrument for studies of sleep disturbance in persons with Alzheimer’s disease. J Sleep Res 2003;12:331-337.

416. Gustavson A, Cummings JL. Cholinesterase inhibitors in non-Alzheimer’s dementias. J Am Med Directions Assoc 2003;6:S165- S169.

417. Cummings JL. Out of the pipeline: . Current Psychiatry 2004;3:64-77.

418. Cummings JL. Advances in the neuropsychopharmacologic management behavioral alterations in Alzheimer’s disease. Dement Geriatr Cogn Disord 2004;17:54.

419. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer’s disease. Dement Geriatr Cogn Disord 2004;17:100-108.

420. Fu C, Chute DJ, Farag ES, Garakian J, Cummings JL, Vinters HV. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med 2004;128:32-38.

421. Silverman DHS, Truong CT, Kin SK, Chang CY, Chen W, Kowell AP, Cummings JL, Czernin J, Small GW, Phelps ME. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison of quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Molec Gen Metab 2003;80:350-355.

422. Senanarong V, Cummings JL, Fairbanks L, Mega M, Masterman DM, O’Connor SM, Strickland TL. Agitation in Alzheimer’s disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord 2004;17:14-20.

423. Cummings JL, Schneider L, Tariot P, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am J Psychiatry 2004;161:532-538.

424. Cummings JL. The one-minute mental status examination. Neurology 2004;62:534-535.

425. Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord 2004;18:17-22.

426. Chong MS, Vinters HV, Gustavson AR, Cummings JL. Dementia with Parkinsonism: what is the diagnosis? Rev Neurol Dis 2004;1:41-44.

427. Cummings JL. Reconsidering diagnostic criteria for dementia with Lewy bodies. Rev Neurol Dis 2004;1:31-34.

428. Cummings JL. Fluctuations in cognitive function in dementia with Lewy bodies. Lancet Neurology 2004;3:266.

429. Swanberg MM, Tractenberg RE, Mohs R, Thal LJ, Cummings JL. Executive dysfunction in Alzheimer’s disease. Arch Neurol 2004;61:556-560.

430. Cummings JL. Long-term treatment for patients with Alzheimer’s disease. Alzheimer Dis Assoc Disord 2004;18:S1.

431. Cummings JL. Alzheimer’s Disease. N Engl J Med 2004;351:56-67.

41

432. Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cummings JL. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging 2004;25:843-851.

433. Cummings JL. Treatment of Alzheimer’s disease: Current and future therapeutic approaches. Rev Neurol Dis 2004; 1:60-69.

434. Senanarong V, Jamjumras P, Harmphadunhkit K, Klubwongs M, Udomphanthurak S, Poungvarin N, Vannasaeng S, Cummings JL. A counseling intervention for caregivers: effect on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2004;19:781-788.

435. Chong MS, Klement IA, Vinters HV, Cummings JL. Dementia with parkinsonism. Rev Neurol Dis 2004;2:97-101.

436. Cummings JL, Tractenberg RE, Gamst A, Teri L, Masterman D, Thal LJ. Regression to the mean: implications for clinical trials of psychotropic agents in dementia. Current Alzheimer Research 2004;1:323-328.

437. Assal F, Alarcon M, Solomon EC, Masterman D, Geschwind DH, Cummings JL. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer’s disease. Arch Neurol 2004;61:1249-1253.

438. Waltz JA, Knowlton BJ, Holyoak KJ, Boone KB, Back-Madruga C, McPherson S, Masterman D, Chow T, Cummings JL, Miller BL. Relational integration and executive function in Alzhiemer’s disease. Neuropsychology 2004;18:296-305.

439. Kang SJ, Choi SH, Lee BH, Jeong Y, Hahm DS, Han IW, Cummings JL, Na DL. Caregiver-administered neuropsychiatric inventory (CGA-NPI). J Geriatr Psychiatry Neurol 2004;17:32-35

440. Bartzokis G, Tishler T, Shin I-S, Lu PH, Cummings JL. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Annals of New York Academy of Sciences 2004;1012:224-236.

441. Cummings JL. Dementia with Lewy bodies: molecular pathogenesis and implications for classification. J Geriatr Psychiatry Neurol 2004;17:112-119.

442. Cummings JL. Searching for methods to detect, prevent, and treat Alzheimer’s disease. Am J Psychiatry 2005; 162:645-647.

443. Tractenberg RE, Weiner MF, Cummings JL, Patterson MB, Thal LJ. Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer’s disease: A factor analytic approach. J Neuropsychiatry Clin Neurosci 2005;17:51-60.

444. Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O’Connor SM, Carter MF, Amezcua H, Cummings JL. Metabolic patterns associated with the clinical response to galantamine therapy. Arch Neurol 2005;62:721-728.

445. Senanarong V, Poungvain N, Jamjumras P, Sriboonroung A, Danchaivijit C, Udomphanthuruk S, Cummings JL. Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer’s disease. International Psychogeriatrics 2005;17:81-90.

446. Shin IS, Carter M, Masterman D, Fairbanks L, Cummings JL. Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Ger Psychiatry 2005;13:469-474.

447. Ringman, JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res 2005;2:131-136.

448. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collins I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53:695-699.

449. Cummings JL. Cholinesterase inhibitors for treatment of dementia associated with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2005;76:903-904.

450. Morris JC, Cummings JL. Mild cognitive impairment (MCI) represents early-stage Alzheimer’s disease. J Alzheimer’s Disease 2005;7:235-239.

42

451. Fuh JL, Wang S-J, Cummings JL. Neuropsychiatric profiles in patients with Alzheimer’s disease and vascular dementia. J Neurol Neurosurg Psychiatry 2005;76:1337-1341.

452. Cummings JL. Neuropsychiatric and behavioral alterations and their mangment in moderate to severe Alzheimer disease. Neurology 2005;65:S18-S24.

453. Cummings JL, Koumaras B, Chen M, Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Ger Pharmacotherapy 2005;3:137-148.

454. McKeith I, Cummings JL. Behavioural changes and psychological symptoms on dementia disorders. Lancet Neurol 2005;4:735-742.

455. Cummings JL. The neuropsychiatric burden of neurological diseases in the elderly. International Psychogeriatrics 2005;17:341-351.

456. Boada M, Tarraga L, Modinos G, Lopez OL, Cummings JL. Neuropsychiatric Inventory-Nursing Home version (NPI-NH): validacion española. Neurologia 2005;20:665-673.

457. Cummings JL. Behavioral and neuropsychiatric outcomes in Alzheimer’s disease. CNS Spectr 2005;10:22-25.

458. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien, Feldman H, Cummings JL, Duda JE, Lippa C,. Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VMY, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M for the Consortium on DLB.Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology 2005;65:1863-1872.

459. Cummings JL. Clinical evaluation as a biomarker for Alzheimer’s disease. J Alzheimer Dis 2005;8:327-337.

460. Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shonghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GW, Phelps ME. Serotonin 1A receptors in the living brain of Alzheimer’s disease patients. Proc Natl Acad Sci USA. 2006;103:702-707.

461. Cummings JL. What can we learn from open-label extensions of randomized clinical trials? Arch Neurol 2006;63:18-19.

462. Lu PH, Masterman DA, Mulnard R, Cotman C, miller b, Yaffe K, Reback E, Porter V, Swerdloff, Cummings JL. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol 2006;63:177-185.

463. Bartzokis G, Lu PH, Geschwind DH, Edwards N, Mintz J, Cummings JL. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals. Arch Gen Psychiatry 2006;63:63-72.

464. Cummings JL, Zhong K. Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nature Drug Discovery 2006;5:64-74.

465. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disor 2006;21:144-147.

466. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of activities of daily living in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:56-59.

467. Cummings JL. Alzheimer’s disease clinical trials: where are we now? Can J Neurol Sci 2006;33:5.

468. Marsh L, McDonald WM, Cummings JL, Ravina B, NINDS/NIMH Work Group on Depression and Parkinson’s Disease. Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Movement Disorders 2006;21:148-158.

469. Gauthier S, Reisberg B, Zaudig M, Peterson RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B, on behalf of the participants 43

of the International Psychogeriatric Association Expert Conference on Mild Cognitive Impairment. Mild cognitive impairment. Lancet 2006;367:1262-1270.

470. Apostolova LG, Dutton ID, Lin J, Toga AW, Cummings JL, Thompson PM. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol 2006;63:693-699.

471. Cummings JL, McRae T, Zhang R, The Donepezil-Sertraline Study Group. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006;17:605-612.

472. Cummings JL, Schneider E, Tariot PN, Graham SM, Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer’s disease patients receiving donepezil treatment. Neurology 2006;67:57-63.

473. Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer’s disease clinical trials. Alzheimer’s and Dementia 2006;2:263-271.

474. Apostolova LG, Klement I, Bronstein Y, Vinters HV, Cummings JL. Multiple system atrophy presenting with language impairment. Neurology 2006;67:726-727.

475. Tractenberg RE, Aisen PS, Weiner MF, Cummings JL, Hancock GR. Independent contributions of neural and “higher-order” deficits to symptoms in Alzheimer’s disease: A latent variable modeling approach. Alzheimer Dement 2006; 2:303-313.

476. Cummings JL, Arciniegas DB, Brooks BR, Herndon RM, Lauterbach EC, Pioro EP, Robinson RG, Scharre DW, Schiffer RB, Weintraub D. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr 2006;1:1S1-S7.

477. Ortiz F, Fitten LJ, Cummings JL, Hwang S, Fonseca M. Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2006;21:263-273.

478. Ringman JM, Cummings JL. Current and emerging pharmacological treatment options for dementia. Behav Neurol 2006;17:5-16.

479. Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ, Alzheimer’s Disease Cooperative Study Group. ADCS prevention instrument project: overview and initial results. Alzheimer Dis Assoc Disord 2006;20:S109-S123.

480. Salmon DP, Cummings JL, Jin S, Sano M, Sperling RA, Zamrini E, Petersen RC, Edland SD, Thal LJ, Ferris SH, the Alzheimer’s Disease Cooperative Study. ADCS prevention instrument project: development of a brief verbal memory test for primary prevention clinical trials. Alzheimer Dis Assoc Disord 2006;20:S139-S146.

481. Cummings JL, Raman R, Ernstrom K, Salmon D, Ferris SH, the Alzheimer’s Disease Cooperative Study Group. ADCS prevention instrument project: behavioral measures in primary prevention trials. Alzheimer Dis Assoc Disord 2006;20:S147-S151.

482. Fuh JL, Lam L, Hirono N, Senanarong V, Cummings JL. Neuropsychiatric inventory workshop: behavioral and psychologic symptoms of dementia in Asia. Alzheimer Dis Assoc Disord 2006;20:314-317.

483. Morris JC, Cummings JL. Workshop reports from the third Asia-Pacific regional meeting of the International Working Group on harmonization of dementia drug guidelines. Alzheimer Dis Assoc Disord 2006;20:313.

484. Sano M, Egelko S, Jin S, Cummings J, Clark CM, Pawluczyk S, Thomas RJ, Schittini M, Thal LJ, the members of the Alzheimer’s Disease Cooperative Study. Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials. Alzheimer Dis Assoc Disord 2006;20:232-241.

485. Apostolova LG, Lu PH, Rogers S, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. 3D mappings of Mini-mental State Examination performance in clinical and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:224-231.

486. Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis Assoc Disord 2006;20:210-216.

44

487. Maurer K, McKeith I, Cummings J, Ames D, Burns A. Has the management of Alzheimer’s disease changed over the past 100 years? Lancet 2006;368:1619-1621.

488. Apostolova LG, Dinov ID, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer’s disease. Brain 2006;129:2867-2873.

489. Van Lancker SD, Pachana N, Cummings JL, Sidtis JJ. Dysprosodic speech following basal ganglia insult: toward a conceptual framework for the study of the cerebral representation of prosody. Brain Lang 2006;97:135-153.

490. Murrell J, Ghetti B, Cochran E, Macias-Islas MA, Medina L, Varpetian A, Cummings JL, Mendez MF, Kawas C, Chui H, Ringman JM. The A431E mutation in PSEN1 causing familial Alzheimer’s disease originating in Jalisco State, Mexico: an additional fifteen families. 2006;7:277-279.

491. Tsang SW, Pomakian J, Marshall GA, Vinters HV, Cummings JL, Chen CP, Wong PT, Lai MK. Disrupted muscarinic M(1) receptor signaling correlates with loss of protein kinase C activity and deficit in Alzheimer’s disease. Neurobiol Aging 2007;28:1381-1387.

492. Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78:36-42.

493. Kennedy GJ, Golde TE, Tariot PN, Cummings, JL. Amyloid-based interventions in Alzheimer’s disease. CNS Spectr 2007;12:S1- S14.

494. Cummings JL. Measuring disease modification in Alzheimer’s disease. CNS Spectr 2007;12:11-14.

495. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer’s disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol 2007;20:29-33.

496. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R. A six-month double- blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-467.

497. Teng E, Lu PH, Cummings JL. Deficits in facial emotion processing in mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:271-279.

498. Rosen HJ, Cummings JL. A real reason for patients with pseudobulbar affect to smile. Ann Neurol 2007;61:92-96.

499. Kurlan R, Cummings JL, Raman R, Thal L. Quetiapine for agitation or pyschosis in patients with dementia and parkinsonism. Neurology 68 2007;1356-1362.

500. Rabins PV, Cummings JL. Involuntary emotional expression disorder. CNS Spectr 2007;2:S5.

501. Cummings JL. Involuntary emotional expression disorder: definition, diagnosis, and measurement scales. CNS Spectr 2007;12:S11- S16.

502. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings JL, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6:501-512

503. Teng E, Lu PH, Cummings JL. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:253-259

504. Cummings JL, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007;69:S510-S513

505. Cummings JL. A transdermal patch in Alzheimer disease. Neurology 2007;69:2-3

45

506. Tsang SW, Vinters HV, Cummings JL, Wong PT, Chen CP, Lai MK. Alterations in NMDA receptor subunit densities and ligand binding to recognition sites are associated with chronic anxiety in Alzheimer's disease. Neurobiol Aging 2008;29:1524-1532

507. Apostolova LG, Lu P, Rogers S, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. 3D mapping of language networks in clinical and pre-clinical Alzheimer's disease Journal. 2008;104:33-41

508. Ringman JM, O'Neill J, Geschwind D, Medina L, Apostolova LG, Rodriguez Y, Schaffer B, Varpetian A, Tseng B, Ortiz F, Fitten J, Cummings JL, Bartzokis G. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 2007;130:1767-1776

509. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22:1689-1707

510. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007;120:388-397

511. Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 2007;64:1015-1020

512. Cummings JL Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. Rev Neurol Dis 2007;4:57-62

513. Apostolova LG, Akopyan GG, Partiali N, Steiner CA, Dutton RA, Hayashi KM, Dinov ID, Toga AW, Cummings JL, Thompson PM. Structural correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:91-97

514. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J Alzheimers Dis 2007;11:509-519

515. Bonelli RM, Cummings JL. Frontal-subcortical circuitry and behavior. Dialogues Clin Neurosci 2007;9:141-151

516. Cummings JL, Jeste DV. Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: definitional and regulatory aspects. Psychopharmacol Bull 2007;40:89-98

517. Apostolova LG, Steiner CA, Akopyan GG, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch Neurol 2007;64:1489-1495

518. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology 2007;69:1622-1634

519. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-746

520. Bonelli RM, Cummings JL. Frontal-subcortical dementias. Neurologist. 2008;14:100-107

521. Cummings JL, Winblad B. A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia. Expert Rev Neurotherapeutics. 2007;7:1457-1463

522. Cummings, JL, Golde TE, Sano M, Tariot PN. Looking to the future of Alzheimer’s disease: Anti-amyloid disease-modifying therapies. CNS Special Edition 2007;91-101

523. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23:537-545

524. Cummings JL, MacKell J, Kaufer, D. Behavioral effects of current Alzheimer’s disease treatments: A descriptive review. Alzheimers Dement 2008;4:49-60

46

525. Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord 2008;25:115-126

526. Ringman JM, Romano JD, Medina LD, Rodriguez-Agudelo Y, Schaffer B, Varpetian A, Ortiz F, Fitten LJ, Cummings JL, Baloh RW. Increased prevalence of significant recurrent headache in preclinical familial Alzheimer’s disease mutation carriers. Dement Geriatr Cogn Disord 2008;25:380-384

527. Cummings JL, Miller BL, Christensen DD, Cherry D. Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease. CNS Spectr 2008 (suppl 2);13:S1-S20.

528. Farlow MR, Cummings JL. A modern hypothesis: The distinct of dementia associated with Parkinson’s disease versus Alzheimer’s disease. Dement Geriatr Cogn Disord 2008;25:301–308

529. Fillit HM, Simon ES, Doniger GM, Cummings JL. Practicality of a computerized system for cognitive assessment in the elderly. Alzheimers Dement 2008;4:14-21

530. Cummings, JL. The Black Book of Alzheimer’s Disease, Part 1. Prim Psychiatry 2008;15:66-76

531. Cummings, JL. The Black Book of Alzheimer’s Disease, Part 2. Prim Psychiatry 2008;15:69-90

532. Cummings, JL. Update on Alzheimer’s disease: one hundred years after Dr. Alois Alzheimer. CNS Spectr 2008;13:S4-S6

533. Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer’s disease. Alzheimers Dement 2008;4:65-79

534. Cummings, JL. Optimizing phase II of drug development for disease-modifying compounds. Alzheimers Dement 2008 (suppl 1);4:S15-S20

535. Salzman C, Jeste DV, Meyer RE, Cohen-Mansfield J, Cummings J, Grossberg GT, Jarvik L, Kraemer HC, Lebowitz BD, Maslow K, Pollock BG, Raskind M, Schultz SK, Wang P, Zito JM, Zubenko GS. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 2008;69:889-898

536. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement 2008;4:156-163

537. Teng E, Ringman JM, Ross LK, Mulnard RA, Dick MB, Bartzokis G, Davies HD, Galasko D, Hewett L, Mungas D, Reed BR, Schneider LS, Segal-Gidan F, Yaffe K, Cummings JL; Alzheimer's Disease Research Centers of California-Depression in Alzheimer's Disease Investigators. Diagnosing depression in Alzheimer disease with the National Institute of Mental Health provisional criteria. Am J Geriatr Psychiatry 2008;16:469-477

538. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008;71:85-92

539. Cummings J. Primary progressive aphasia and the growing role of biomarkers in neurological diagnosis. Ann Neurol 2008;64: 361-364.

540. Cummings JL. Integrating symptomatic and disease-modifying treatments. CNS Spectr 2008;13 (suppl 16):28-30.

541. Schaffer BA, Bertram L, Miller BL, Mullin K, Weintraub S, Johnson N, Bigio EH, Mesulam M, Wiedau-Pazos M, Jackson GR, Cummings JL, Cantor RM, Levey AI, Tanzi RE, Geschwind DH. Association of GSK3B with Alzheimer disease and frontotemporal dementia. Arch Neurol 2008;65:1368-1374

47

542. Cummings JL. Controversies in Alzheimer's disease drug development. Int Rev Psychiatry 2008;20:389-395

543. Connor D, Sabbagh M, Cummings JL. Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials. Alzheimers Dement 2008;4:390-394

544. Cummings JL. Alzheimer's disease summit. Translating research advances into clinical practice. Introduction. CNS Spectr 2008;13 (suppl 16):4-5

545. Harvey PD, Ferris SH, Cummings JL, Wesnes KA, Hsu C, Lane RM, Tekin S. Evaluation of dementia rating scales in Parkinson's disease dementia. Am J Alzheimers Dis Other Demen 2010;25:142-148

546. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, Lyketsos CG. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009;5:245-255

547. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement 2009;5:85-92

548. Cummings JL. Commentary on "A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Establishing a national biomarker database: utility and incentives.” Alzheimers Dement 2009;5:108-113

549. Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D, Peskind E, Dietrich W, Beekly DL, Kukull WA, Morris JC. The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord 2009;23:91-101

550. Woods DL, Bushnell B, Kim H, Geschwind D, Cummings J. Apolipoprotein 4 status is associated with behavioral symptoms in nursing home residents with dementia. Int Psychogeriatr 2009;21:722-728

551. Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL; Alzheimer's Disease Cooperative Study Group. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 2009;72:2115-2121

552. Cummings NA, O’Donohue WT, Cummings JL. The financial dimension of integrated behavioral/primary care. J Clin Psychol Med Settings 2009;16:31-39

553. Chow TW, Binns MA, Cummings JL, Lam I, Black SE, Miller BL, Freedman M, Stuss DT, van Reekum R. Apathy symptom profile and behavioral associations in frontotemporal dementia vs dementia of Alzheimer type. Arch Neurol 2009;66:888-893

554. Cummings JL. Axona for Alzheimer’s Disease: A Clinician’s Perspective. Neurol Rev 2009;17(Suppl 1):1-7

555. Apostolova LG, Thompson PM, Rogers SA, Dinov ID, Zoumalan C, Steiner CA, Siu E, Green AE, Small GW, Toga AW, Cummings JL, Phelps ME, Silverman DH. Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly. Mol Imaging Biol 2010;12:218-224

556. Ringman JM, Medina LD, Rodriguez-Agudelo Y, Chavez M, Lu P, Cummings JL. Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. Curr Alzheimer Res 2009;6:341-346

557. Teng E, Tingus KD, Lu PH, Cummings JL. Persistence of neuropsychological testing deficits in mild cognitive impairment. Dement Geriatr Cogn Disord 2009;28:168-178

558. Alva G, Cummings JL. Relative tolerability of Alzheimer’s disease treatments. Psychiatry (Edgmont) 2008;5:27-36

559. Cummings JL. Defining and labeling disease-modifying treatments for Alzheimer's disease. Alzheimers Dement 2009;5:406-418

48

560. Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT. Rivastigmine transdermal patch skin tolerability: Results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clin Drug Investig 2010;30:41-49

561. Cummings JL. Commentary on: L-Methylfolate, methylcobolamine, and n- in the treatment of Alzheimer’s disease- related cognitive decline. CNS Spect 2010;15(Suppl 1):7

562. Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, Arnold SE, Mann DM, Pickering-Brown SM, Seelaar H, Heutink P, van Swieten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Hodges J, Spillantini MG, Gilman S, Lieberman AP, Kaye JA, Woltjer RL, Bigio EH, Mesulam M, Al-Sarraj S, Troakes C, Rosenberg RN, White CL 3rd, Ferrer I, Lladó A, Neumann M, Kretzschmar HA, Hulette CM, Welsh-Bohmer KA, Miller BL, Alzualde A, de Munain AL, McKee AC, Gearing M, Levey AI, Lah JJ, Hardy J, Rohrer JD, Lashley T, Mackenzie IR, Feldman HH, Hamilton RL, Dekosky ST, van der Zee J, Kumar-Singh S, Van Broeckhoven C, Mayeux R, Vonsattel JP, Troncoso JC, Kril JJ, Kwok JB, Halliday GM, Bird TD, Ince PG, Shaw PJ, Cairns NJ, Morris JC, McLean CA, DeCarli C, Ellis WG, Freeman SH, Frosch MP, Growdon JH, Perl DP, Sano M, Bennett DA, Schneider JA, Beach TG, Reiman EM, Woodruff BK, Cummings J, Vinters HV, Miller CA, Chui HC, Alafuzoff I, Hartikainen P, Seilhean D, Galasko D, Masliah E, Cotman CW, Tuñón MT, Martínez MC, Munoz DG, Carroll SL, Marson D, Riederer PF, Bogdanovic N, Schellenberg GD, Hakonarson H, Trojanowski JQ, Lee VM. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010;42:234-239

563. Cummings JL, Emre M, Aarsland D, Tekin S, Dronamraju N, Lane R. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. J Alzheimers Dis 2010;20:301-311

564. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI. PBT2 rapidly improves cognition in Alzheimer's disease: Additional phase II analyses. J Alzheimers Dis 2010;20:509-516

565. Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR Jr, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp 2010;31:786-797

566. Apostolova LG, Morra JH, Green AE, Hwang KS, Avedissian C, Woo E, Cummings JL, Toga AW, Jack CR Jr, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative. Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. Neuroimage 2010;51:488-499

567. Cummings JL, Ringman J, Metz K. Mary S. Easton Center of Alzheimer's Disease Research at UCLA: Advancing the Therapeutic Imperative. J Alzheimers Dis 2010;19:375-388

568. Fuh JL, Cummings JL. Top cited papers in International Psychogeriatrics: 6b. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. Int Psychogeriatr. 2009;21:1031-1036

569. Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones RW, Gauthier S, Lopez OL, Cummings JL, Xu Y, Feldman HH. Effectiveness of donepezil in reducing clinical worsening in patients with mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 2009;28:244-251

570. Cummings, JL, Ferris SH, Farlow MR, Olin JT, Meng X. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impresion of change in Alzheimer’s disease: A retrospective analysis. Dement Geriatr Cogn Disord 2010;29:406-412

571. Cummings, JL, Jones R, Wilkinson D, Lopez O, Gauthier S, Waldemar G, Zhang R, Xu Y, Sun Y, Richardson S, Mackell J. Effect of donepezil on cognition in severe Alzheimer’s disease: A pooled data analysis. J Alzheimers Dis 2010;21:843-851

572. Apostolova LG, Beyer M, Green AE, Hwang KS, Morra JH, Chou YY, Avedissian C, Aarsland D, Janvin CC, Larsen JP, Cummings JL, Thompson PM. Hippocampal, caudate and ventricular changes in Parkinson’s disease with and without dementia. Mov Disord 2010;25:687-695

573. Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimer’s disease. Expert Rev Neurother 2010;10: 711-728.

574. Gauthier S, Cummings JL, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C. Management of behavioral problems in 49

Alzheimer's disease. Int Psychogeriatr 2010;22:346-372

575. Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on cognitive domains in mild to moderate Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2010;25:347-52

576. Cummings JL. Biomarkers in Alzheimer’s Disease. US Neurology 2010;1:23-27

577. Ringman JM, Medina LD, Braskie M, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Cummings JL, Bookheimer S. Effects of risk genes on bold activation in presymptomatic carriers of familial Alzheimer’s disease mutations during a novelty encoding task. Cereb Cortex 2011;21:877-883

578. Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga LW, Trojanowski JQ, Shaw LM, Jack CR, Petersen RC, Aisen PS, Jagust WJ, Koeppe RA, Mathis CA, Weiner MW, Thompson PM. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 2010;31:1284-1303

579. Cummings JL. Integrating ADNI results into Alzheimer’s disease drug development programs. Neurobiol Aging 2010;31:1481-1492

580. Fillit H, Cummings JL, Neumann P, McLaughlin T, Salvatore P, Leibman C. Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer’s disease. J Nutr Health Aging 2010;14:640-647

581. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossmor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol 2010;9:1118-27

582. Pioro EP, Brooks BR, Cummings JL, Schiffer R, Thisted RA, Wynn D, Hepner A, Kaye R. Safety, tolerability and efficacy results trial of AVP-923 in PBA investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010;68:693-702

583. Gauthier S, Lopez O, Waldemar G, Jones R, Cummings JL, Zhang R, Schindler R, Schwam E. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer’s disease. Int Psychogeriatr 2010;22,973-983

584. de Medeiros K, Robert P, Gauthier S, Stella F, Politis A, Leoutsakos J, Taragano F, Kremer J, Brugnolo A, Porsteinsson AP, Geda YE, Brodaty H, Gazdag G, Cummings JL, Lyketsos C. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr 2010;22:984-994

585. Teng E, Becker B, Woo E, Knopman D, Cummings JL, Lu PH. Utility of the Functional Activities Questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer’s disease. Alzheimer Dis Assoc Disord 2010;24:348-353

586. Teng E, Becker BW, Woo E, Cummings JL, Lu PH. Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 2010;30:189-197

587. Lopez O, Schwam E, Cummings JL, Gauthier S, Jones R, Wilkinson D, Waldemar G, Zhang R, Schindler R. Predicting cognitive decline in Alzheimer’s disease: An integrated analysis. Alzheimers Dement 2010;6:431-439

588. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P; Alzheimer’s Disease Genetics Confortium, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W. Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 2012 ;67:1473-84

589. Cummings JL. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer’s disease? Biol Psychiatry 2010;68:876-878

590. Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings JL, Lopez O, Zhang R, Xu Y, Sun Y, Knox S, Richardson S, Mackell J. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer’s disease. Int J Geriatr Psychiatry 2011;26:150-157

50

591. Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 2011:1-21

592. Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement. 2011;7:e13-44. [Epub ahead of print]

593. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011;43: 436-441.

594. Cummings, JL. Alzheimer disease: clinical trials and the amyloid hypothesis. Ann Acad Med Singapore 2011;40:304-306

595. Apostolova LG, Hwang KS, Medina LD, Green AE, Braskie MN, Dutton RA, Lai J, Geschwind DH, Cummings JL, Thompson PM, Ringman JM. Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer’s disease. Dement Geriatr Cogn Disord 2011;32:118-125

596. Sabbagh M, Cummings JL. Progressive cholinergic decline in Alzheimer’s disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurology 2011;11:2-6

597. Cummings JL, Reynders R, Zhong K. Globalization of Alzheimer’s disease clinical trials. Alzheimer’s Research & Therapy 2011; 3:24-32

598. Fleisher AS, Truran D, Mai JT, Langbaum JBS, Aisen PS, Cummings JL, Jack CR, Weiner MW, Thomas RG, Schneider LS, Tariot PN. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 2011;77:1263-1271

599. Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porteinsson A, Weiner M, Jack CR, Thal L, Aisen PS. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011;68:853-861

600. Jones R, Wilkinson D, Lopez OL, Cummings J, Waldemar G, Zhang R, Mackell J, Gauthier S. Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer’s disease. Trials 2011;12:233-265

601. Medina LD, Rodriguez-Agudelo Y, Geschwind DH, Gilbert PE, Liang LJ, Cummings JL, Ringman JM. Propositional density and apolipoprotein E genotype among persons at risk for familial Alzheimer’s disease. Dement Geriatr Cog Disord. 2011;32:188-9

602. Cummings JL. Alzheimer’s disease clinical trials: changing the paradigm. Curr Psychiatry Rep. 2011;50:1265-74

603. Walker Z, Cummings J. [¹²³I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies. Alzheimer’s & Dementia 2011;8:74-83

604. Doody R, Cummings J, Farlow M. Reviewing the role of donepezil in the treatment of Alzheimer’s disease. Current Alzheimers Res 2011;9:773-81

51

605. Andrawis JP, Hwang KS, Green AE, Kotlerman J, Elashof D, Morra JH, Cumings JL, Toga AW, Thompson PM, Apostolova LG. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging 2012;33:856-866

606. Braskie MN, Medina LD, Rodriquez-Agudelo Y, Geschwind DH, Macias-Islas MA, Cummings JL, Bookheimer SY, Ringman JM. Increased fMRI signal with age in familial Alzheimer’s disease mutation carriers. Neurobiol Aging 2012;33:424.e11-21

607. Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, Cole G, Sokolow S, Gylys K, Geschwind DH, Cummings JL, Wan HI. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol 2012;69:96-104

608. Andrawis J, Hwang K, Green A, Kotlerman J, Elashoff D, Morra J, Cummings J, Toga A, Thompson P, Apostolova L. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging. 2012;33:856-866

609. Bernick C, Cummings J, Raman R, Sun X, Aisen P. Age and rate of cognitive decline in Alzheimer disease: Implications for clinical trials. Arch Neurol 2012;69:901-905

610. Ringman JM, Coppola G, Elashoff D, Rodriguez-Agudelo Y, Medina LD, Gylys K, Cummings JL, Cole GM. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer’s disease. Dement Geriatr Cogn Disord 2012;33:1-5

611. Ringman JM, Fithian AT, Gylys K, Cummings JL, Coppola G, Elashoff D, Pratico D, Moskovitz J, Bitan G. Plasma methionine sulfoxide in persons with familial Alzheimer’s disease mutations. Dement Geriatr Cogn Disord 2012;33:219-225

612. Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM. Plasma signaling protiens in persons at genetic risk for Alzheimer disease: Influence of APOE genotype plasma biomarkers and AD genetic risk. Arch Neurol 2012;69:757-64

613. Cummings J. Food for thought: Souvenaid® in mild Alzheimer’s disease. J Alzheimers Dis 2012;31:237-238

614. Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, Kressig RW, Downs P, Caputo A, Strohmaier C. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm) in Alzheimer’s disease. Dement Geriatr Cogn Disord 2012;33:341-353

615. Cummings, J. Alzheimer’s disease diagnostic criteria: practical applications. Alzheimers Res Ther 2012;4:35-41

616. Ringman J, Frautschy S, Teng E, Begum A, Bardens J, Beigi M, Gylys K, Badmaev V, Heath D, Apostolova L, Porter V, Vanek Z, Marshall G, Hellemann G, Sugar C, Masterman D, Montine T, Cummings J, Cole G. Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controled study. Alzheimers Res Ther 2012;4:43-71

617. Cummings J, Gould H, Zhong K. Advances in designs for Alzheimer’s disease clinical trials. Am J Neurodegener Dis 2012;1:205- 206

618. Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2012;27:421-32

619. Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller BL, Cummings J. Frontotemporal degeneration, the next therapeutic frontier:Molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement 2012;9:176-188

620. Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier.) Alzheimers Dement 2012;9:189-198

52

621. Dubois B. Gauthier S, Cummings J. The utility of the new research diagnostic criteria for Alzheimer’s disease. Internat Psychogeriatr 2012;13:2-4

622. Trzepacz PT, Cummings J, Konechnick T, Forrester TD, Chang C, Dennehy EB, Willis BA, Shuler C, Tabas LB, Lyketsos C. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease. Int Psychogeriatr 2012;51:1-13

623. Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer’s disease discovered in repurposed agents. Dement Geriatr Cogn Disord 2013;35:1-22

624. Senanarong V, Harnphadungkit K, Poungvarin N, Vannasaeng S, Chongwisal S, Chakorn T, Jamjumrus P, Raksthaput A, Chiachanettee S, Aoonkaew N, Udompunthurak S, Doody RS, Cummings JL. The dementia and disability project in Thai elderly: rational, design, methodology and early results. BMC Neurol 2013;13:1-11

625. Kim HJ, Kang SJ, Kim C, Kim GH, Jeon S, Lee JM, Oh SJ, Kim JS, Choe YS, Lee KH, Noh Y, Cho H, Yoon CW, Chin J, Cummings JL, Lee JH, Na DL, Seo SW. The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments. Neurobiol Aging 2013;34:1913-20

626. Ferris S, Cummings J, Christensen D, Doody R, Farlow M, Sabbagh M, Liu L, Mackell J, Fain R. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer’s disease: evaluating the impact of baseline severity. Alzheimers Res Ther 2013;5:12

627. Cummings JL, Ihl R, Herrschaft H, Hoerr R, Tribanek M. Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia. Int Psychogeriatr 2013;25:431-8

628. Cummings JL Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alsheimer’s disease: drug profile and clinical guidelines. CNS Neurosci Ther 2013;19:294-301

629. Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Walsh RR, Zhong K. Alzheimer’s disease drug development: translational neuroscience strategies. CNS Spect 2013;18:128-138

630. Lauterbach EC, Cummings JL, Kuppuswamy PS. Toward a more precise, clinically-Informed pathophysiology of pathological laughing and crying. Neurosci Biobehav Rev 2013;37:1893-1916

631. Pillai JA, Cummings JL. Clinical trials in predementia stages of Alzheimer disease. Med Clin North Am 2013;97:439-57

632. Cummings JL, Dubois B, Molinuevo JL, Scheltens P. International work group criteria for the diagnosis of Alzheimer disease. Med Clin North Am 2013;97:363-8

633. Sabbagh JJ, Kinney JW, Cummings JL. Alzheimer’s disease biomarkers: Correspondence between human studies and animal models. Neurobiol Dis 2013;56:116-130

634. Trzepacz PT, Saykin A, Yu P, Bhamditipati P, Sun J, Dennehy EB, Willis B, Cummings JL, Alzherimer’s Disease Neuroimaging Initative. Subscale validation of the Neuropsychiatric Inventory questionnaire: Comparison of Alzheimer’s Disease Neuroimaging Initative and National Alzheimer’s Coordinating Center cohorts. Am J Geriatr Psychiatr 2013:21:607-622.

635. Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H. Performance of a shortened scale for assessment of positive symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord 2013;19:295-9

636. Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, Mackell J, Fain R. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effect of baseline features on treatment response. BMC Geriatr 2013;12:1-9

637. Apostolova LG, Babakchanian S, Hwang KS, Green AE, Zlatev D, Chou YY, Decarli C, Jack CR Jr, Petersen RC, Aisen PS, Cummings JL, Toga AW, Thompson PM. Ventricular enlargment and its clinical correlates in the imaging cohort from the ADCS MCI Donepezil/Vitamin E study. Alzheimer Dis Assoc Disord 2013;27:174-181

53

638. Grossberg G, Cummings J, Frölich L, Bellelli G, Molinuevo JL, Krahnke T, Strohmaier C. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease. J Alzheimers Dis 2013;28:583-591

639. Sabbagh JJ, Kinney JW, Cummings JL. Alzheimer’s disease biomarkers in animal models: closing the translational gap. Am J Neurodegener Dis 2013;21:108-20

640. Sabbagh JJ, Kinney JW, Cummings JL. Animal systems in the development of treaments for Alzheimer’s disease: challenges, methods, and implications. Neurobiol Aging 2013;34:169-83

641. Grill J, Di L, Lu P, Lee C, Ringman J, Apostolova L, Chow N, Kohannim O, Cummings J, Thompson P, Elashoff D. Estimating sample sizes for predementia Alzheimer’s trials based on the Alzheimer’s Disease Neuroimaging Initiative. Neurobiol Aging 2013;34:62-72

642. Salmon DP, Ferris SH, Thomas RG, Sano M, Cummings JL, Sperling RA, Petersen RC, Aisen PS. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology 2013;27:391-401

643. Apostolova LG, Babakchanian S, Hwang KS, Green AE, Zlatev D, Chou YY, Jack C, Petersen RC, Thal LJ, Aisen PS, Cummings JL, Toga AW, Thompson PM. Ventricular atrophy and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. Alzheimer Dis Assoc Disord 2013;27:174-181

644. Hwang KH, Beyer MK, Green AE, Thompson PM, Janvin C, Larsen JP, Cummings JL, Aarsland D, Apostolova LG. Mapping cortical atrophy in Parkinson’s disease patients with cognitive impairment and dementia. J Parkinsons Dis 2013;3:69-76

645. Hwang KS, Coppola G, Johnson S, Thompson PM, Lee JL, Cummings JL, Apostolova LG. Mapping the effects of TOMM40 and TOMM40 polyT polymorphism on hippocampal atrophy in cognitively normal elderly and mild cognitive impairment. Dement Geriat Cogn Disord, (In Press)

646. Cummings J, Zhong K. Biomarker-driven therapeutic management of Alzheimer’s disease: Establishing the foundations. Clin Pharmacol Ther 2013;95:67-77

647. Appleby BS, Cummings JL. Discovering new treatments for Alzheimer’s disease by repurposing approved . Curr Top Med Chem. 2013;13:2306-2327

648. Cummings J, Gilbart J, Andersen G. Pseudobulbar Affect – A disabling but under-recognised consequence of neurological disease and brain injury. Eur Neur Rev 2013;8:74-81

649. Braskie MN, Medina LD, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Thompson PM, Cummings JL, Bookheimer SY, Ringman JM. Memory performance and fMRI signal in presymptomatic familial Alzheimer’s disease. Hum Brain Mapp 2013;34:3308-3319

650. Cummings J, Zhong K, Bernick C. The Cleveland Clinic Lou Ruvo Center for Brain Health: Keeping Memory Alive. J Alzheimers Dis 2014;38:103-109

651. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson’s disease psychosis: a randomized, placebo-controlled phase 3 trial. Lancet, 2014;383:533-540

652. McLaughlin PM, Wright MJ, LaRocca M, Nguyen PT, Teng E, Apostolova LG, Ringman JM, Zhou Y, Cummings JL, Woo E. The “Alzheimer’s Type” profile of semantic clustering in amnestic mild cognitive impairment. J Internat Neuropsychol Soc 2014;20:402- 412

653. Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, Cummings J. The Alzheimer’s Disease Cooperative Study Prevention Instrument Project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Disord Extra 2014;4:509-516

654. Cummings JL, Zhong K. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. Expert Rev Clin Pharmacol 2014; 7:161-165

54

655. Apostolova LG, Di LJ, Duffy EL, Brooks J, Elashoff D, Tseng CH, Fairbanks L, Cummings JL. Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer’s disease. Dem Geriat Cog Disorders 2014;37:315-326

656. Pillai J, Bonner-Jackson A, Walker E, Mourany L, Cummings J. Higher working memory predicts slower functional decline in autopsy confirmed Alzheimer’s disease. Dem Geriat Cog Disorders 2014;38:224-233

657. Cummings JL, Fine M, Grachev ID, Jarecke CR, Johnson MK, Kuo PH, Oberdorf JA, Rezak M, Riley DE, Schaecher KL, Truong D. Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTSCAN™). Am J Managed Care 2014;20(Suppl):S97-S109

658. Cummings JL, Ringman J, Vinters HV. Neuropathologic correlates of trial-related instruments for Alzheimer’s disease. AM J Neurodegener Dis. 2014;3:45-9

659. Dubois B, Feldman HH, Javoca C, Hamel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert M, Jicha GA, Norberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;13:614-629

660. Miller JB, Banks SJ, Léger GC, Cummings JL. Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes. Transl Neurodegener. 2014;5:3-12

661. Ousset PJ, Cummings J, Delrieu J, Legrand V, Prins N, Winblad B, Touchon J, Weiner M.W, Vellas B. Is Alzheimer’s disease drug development broken? What must be improved? J Prev Alz Dis 2014;1:40-45

662. Shineman SW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, Fillit HW. Overcoming obstacles to repurposing for neurodegenerative disease. Ann Clin Transl Neurol 2014;1:512-518

663. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014;3:37

664. Cummings JL, Tribanek M, Hoerr R. Sensitivity to change of composite and frequency scores of the neuropsychiatric inventory in mild cognitive impairment. Alzheimers Res Ther 2014;3:1-4

665. Bloniecki V, Aarsland D, Cummings J, Blennow K, Freund-Levi Y. Agitation in dementia: Relation to core cerebrospinal fluid biomarker levels. Dement Geriatr Cogn Disord Extra 2014;4:335-343

666. Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack Jr C.R., Sperling R, Cummings J, Blennow K, O’Bryant S, Frisoni G.B., Khachaturian A, Kivipelto M, Klunk W, Broich K, Andrieu S, Theibaut de Schotten M, Mangin J.-F, Lammertsma A.A., Johnson K, Teipel S, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider L.S., Hampel H. The road ahead to cure Alzheimer’s disease: Development of biological markers and neuroimaging methods for prevention trials across all stages and target populations. J Prev Alzheimers Dis 2014;1:181-202

667. Vellas B, Sampaio C, Bateman R, Boxer A, Carrillo M.C., Cummings J, Dubois B, Hampel H, Katz R, Khachaturian Z, Gauthier S, Johnson K, Karlawish J, Mintun M, Petersen R, Rafii M, Robert P, Schneider L.S., Simers E, Sperling R, Tariot P, Touchon J, Weiner M, Andrieu S, Aisen P, Task Force Members. E.U./U.S. CTAD task force on Alzheimer’s trial populations. J Prev Alzheimer’s Dis 2014;1:110-116

668. Shen JH, Shen Q, Yu H, Lai JS, Beaumont JL, Zhang Z, Wang H, Kim SY, Chen C, Kwok T, Wang SJ, Lee DY, Harrison J, Cummings J. Validation of an Alzheimer’s disease assessment battery in Asian participants with mild to moderate Alzheimer’s disease. Am J Neurodegener Dis 2014;3:158-169

669. Cummings J, Isaacson R, Schmitt F, Velting D. A practical algorithm for managing Alzheimer’s disease: what, when, and why? Ann Clin Transl Neurol 2015;2:307-323

55

670. Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, Gauthier S, Howard R, Lanctôt K, Lyketsos CG, Peskind E, Porsteinsson AP, Reich E, Sampaio C, Steffens D, Wortmann M, Zhong K. Agitation in Cognitive Disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr 2015;27:7-17

671. Peterson RB, Lissemore FM, Appleby B, Aggarwal N, Boyatzis R, Casadesus G, Cummings J, Jack A, Perry G, Safar J, Sajatovic M, Surewicz W, Wang Y, Whitehouse P, Lerner A. From neurodegeneration to brain health: an integrated approach. J Alzheimers Dis 2015;46:271-283

672. Molinuevo JL, Frölich L, Grossberg G, Galvin JE, Cummings J, Krahnke T, Strohmaier C. Responder analysis of a randomized comparison of the 13.3 mg/24 hour and 9.5 mg/24 hour rivastigmine patch. Alz Res Ther 2015 March 8; 7:9-14

673. Cummings J, Friedman JH, Garibaldi G, Jones M, Macfadden W, Marsh L, Robert PH. Apathy in neurodegenerative diseases: recommendations on the design of clinical trials. J Geriatr Psychiatry Neurol 2015;28:159-173

674. Cummings J. New IPA criteria for agitation in cognitive impairment. J Prev Alz Dis 2015;2:160-162

675. Alva G, Cummings J, Galvin J, Meng X, Velting M. Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer’s disease. Int J Clin Pract 2015 May; 69:518-530

676. Henley D, Dowsett S, Chen Y, Liu-Seifert H, Grill J, Doody R, Aisen P, Raman R, Miller D, Hake A, Cummings J. Alzheimer’s disease progression by geographical region in a clinical trial setting. Alz Res Ther 2015 June 25; 7:43

677. Grill J, Raman R, Ernstrom K, Aisen P, Dowsett S, Chen Y, Liu-Seifert H, Hake A, Miller D, Doody R, Henley D, Cummings J. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials. Alz Res Ther 2015 June 25:7:39

678. Liu-Seifert H, Siemers E, Price K, Han B, Selzler K, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R, Alzheimer’s Disease Neuroimaging Initiative. Cognitive impairment precedes and predicts functional impairment in mild Alzheimer’s disease. J Alzheimers Dis 2015;47:205-214

679. Liu-Seifert H, Siemers E, Sundell K, Price K, Han Baoguang, Selzler K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive and functional decline and their relationship in patients with mild Alzheimer’s dementia. J Alz Dis 2015;43:949-955

680. Hui-Fen M, Chun-An K, Wen-Ni H, Cummings JL, Tzung-Jeng H. Values of the minimal clinically important difference for the neuropsychiatric inventory questionnaire in individuals with dementia. J Am Geriatr Soc 2015;63:1448-1452

681. Soto M, Abushakra S, Cummings J, Siffert J, Robert P, Vellas B, Lyketsos C, Task Force Members. Progress in treatment development for neuropsychiatric symptoms in Alzheimer’s disease: focus on agitation and aggression. A report from the EU/US/CTAD task force. J Prev Alz Dis 2015;2:184-188

682. Cummings J, Zhong K. Trial design innovations: clinical trials for treatment of neuropsychiatric symptoms in Alzheimer’s disease. Clin Pharmacol Ther 2015;98:483-485

683. Ritter A, Cummings J. Fluid biomarkers in clinical trials of Alzheimer’s disease therapeutics. Front Neurol 2015;6:186

684. Raskin J, Cummings J, Hardy J, Schuh K, Dean R. Neurobiology of Alzheimer’s disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr Alzheimer Res 2015;12:712-722

685. Cummings J, Lyketsos C, Peskind E, Porsteinsson A, Mintzer J, Scharre D, De La Gandara J, Agronin M, Davis C, Nguyen U, Shin P, Tariot P, Siffert J. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia. JAMA 2015;314:1242-1254

686. Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, Sundell K, Stern Y, Rentz DM, Dubois B, Jones RW, Cummings J, Aisen PS. A combined measure of cognition and function for clinical trials: the integrated Alzheimer’s disease rating scale (iADRS). J Prev Alz Dis 2015;2:227-241

56

687. Masters C, Bateman R, Blennow K, Rowe C, Sperling R, Cummings J. Alzheimer’s disease. Nature Reviews 2015;15056

688. Vogel SJ, Banks SJ, Cummings JL, Miller JB. Concordance of the Montreal cognitive assessment with standard neuropsychological measures. Alzheimers Dement: Diag, Assess & Dis Monit 2015;1:289-294

689. Arias JJ, Cummings J, Grant AR, Ford PJ. Stakeholders’ perspectives on preclinical testing for Alzheimer’s disease. J Clin Ethics 2015;26:297-305

690. Bradley, P, Akehurst R, Ballard C, Banerjee S, Blennow K, Bremner J, Broich K, Cummings J, Dening K, Dubois B, Klipper W, Leibman C, Mantua V, Molinuevo JL, Morgan S, Muscolo L, Nicolas F, Pani L, Robinson L, Siviero P, Van Dam J, Van Emelen J, Wimo A, Wortmann M, Goh L. Taking stock: a multi-stakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer’s disease. Alzheimer Dement 2015;11:455-461

691. Ringman, Liang L, Zhou Y, Vangala S, Teng E, Kremen S, Wharton D, Goate A, Marcus DS, Farlow M, Ghetti B, McDade E, Masters CL, Mayeux RP, Rossor M, Salloway S, Schofield PR, Cummings JL, Buckles V, Bateman R, Morris JC, and the Dominantly Inherited Alzheimer Network. Early behavioural changes in familial Alzheimer’s disease in the Dominantly Inherited Alzheimer Network. Brain 2015;138:1036-1045

692. Mao H, Kuo C, Huang W, Cummings JL, Hwang T. Values of the minimal clinically important difference for the Neuropsychiatric Inventory questionnaire in individuals with dementia. J Am Geriatr Soc 2015;63:1448-1452

693. Cummings J, Lai T, Hemrungrojn S, Mohandas E, Kim S, Nair G, Dash A. Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer’s disease and dementia with lewy bodies. CNS Neurosci Ther 2016;22:159-166

694. Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, Pontecorvo M, Devous M, Tang A, Bena J. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease. Alz Research & Ther 2016; 8:4

695. Aisen P, Touchon J, Andrieu S, Boada M, Doody R, Nosheny R, Langbaum J, Schneider L, Hendrix S, Wilcock G, Molinuevo JL, Ritchie C, Ousset PJ, Cummings J, Sperling R, DeKosky S, Lovestone S, Hampel H, Petersen R, Legrand V, Egan M, Randolph C, Salloway S, Weiner M, Vellas B, and Task Force Members. Registries and cohorts to accelerate early phase Alzheimer’s trials. A report from the EU/US/CTAD task force. J Prev Alz Dis 2016;3:68-74

696. Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, Dhadda S, Do I, Rabe M, Luthman J, Cummings J, Satlin A. ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry 2016;87:993-999

697. Dubois B, Hampel H, Feldman H, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni G, Gauthier S, Genthon R, Gouw A, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O’Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Rack CR, from the proceedings of the meeting of the International Working Group (IWG) and the American Alzheimer’s Associatio on “The Preclinical State of A”, Juy 23, 2015. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alz & Dem 2016;12:292-323

698. Yuan J, Zhang Z, Wen H, Hong X, Hong Z, Qu Q, Tang M, Wu J, Xu Q, Li H, Cummings JL. Incidence of dementia and subtypes: a cohort in four regions in China. Alzheimers Dement 2016;12:262-271

699. Cummings J, Aisen P, Barton R, Bork J, Doody R, Dwyer J, Egan JC, Feldman H, Lappin D, Truyen L, Salloway S, Sperling R, Vradenburg G for the GAP-NET Working Groups. Re-engineering Alzheimer clinical trials: Global Alzheimer’s Platform Network. J Prev Alz Dis 2016;3:114-120

700. Zhong K, Cummings J. Healthybrains.org: from registry to randomization. J Prev Alz Dis 2016;3:123-126

701. Kim H, Choi K, Kim S, Cummings J, Yang D. Validation study of the Korean version of the brief clinical form of the neuropsychiatric inventory. Dement Geriatr Cogn Disord Extra 2016;6:214-221

702. Cummings JL, Morstorf T, Lee G. Alzheimer’s drug development pipeline: 2016. Alzheimer Dement 2016;2:222-232

57

703. Cummings J, Aisen PS, DuBois B, Frolich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer’s disease: the path to 2025. Alz Res Ther 2016;8:39

704. Abushakra S, Porsteinsson A, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Hendrix S, Wang P, Shen L, Sampalis J, Tolar M. Clinical benefits of tramiprosate in Alzheimer’s disease are associated with higher number of APOE4 alleles: The “APOE4 gene- dose effect”. J Prev Alz Dis 2016;3:219-228

705. Sperling R, Cummings J, Donohue M, Aisen P. Global Alzheimer’s Platform trial ready cohorts for the prevention of Alzheimer’s dementia. J Prev Alz Dis 2016;3:185-187

706. Cummings J, Scheltens P, McKeith I, Blesa R, Harrison JE, Bertolucci P, Rockwood K, Wilkinson D, Wijker W, Bennett DA, Shah RC. Effect size analyses of Souvenaid in patients with Alzheimer’s disease. J Alz Dis 2017;55:1131-1139

707. Ismail Z, Brodaty H, Cieslak A, Fischer C, Gauthier S, Geda Y, Herrmann N, Kanji J, Lanctot K, Miller D, Mortby M, Onyike C, Aguera Ortiz L, Rosenberg P, Smith EE, Smith G, Sultzer D, Cummings J, Lyketsos C, for the NPS Professional Interest Area of the International Society to Advance Alzheimer’s Research and Treatment (NPS-PIA of ISTAART). The Mild Behavioral Impairment Checklist (MBI-C): A rating scale for neuropsychiatric symptoms in pre-dementia populations. J Alz Dis 2016; in press

Multicenter Publications to which Dr. Cummings was a Contributor

1. Foster NL, Wilhelmsen K, Sima AAF, Jones MZ, D'Amato CJ, Gilman S, Conference Participants. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997;41:706-715.

2. Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ, and the Alzheimer's Disease Cooperative Study. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S1-S12.

3. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ, and the Alzheimer's Disease Cooperative Study. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's disease assessment scale that broaden its scope. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S13-S21.

4. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH, and the Alzheimer's Disease Cooperative Study. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. Alzheimer Dis Assoc Disord 1997;11(Suppl 2): S22-S32.

5. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S, and the Alzheimer's disease cooperative study. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S33-S39.

6. Patterson MB, Mack JL, Mackell JA, Thomas R, Tariot P, Weiner M, Whitehouse PJ, and the Alzheimer's Disease Cooperative Study. A longitudinal study of behavioral across five levels of dementia severity in Alzheimer's disease: the CERAD behavior rating scale for dementia. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S40-S44.

7. Koss E, Weiner M, Ernesto C, Cohen-Mansfield J, Ferris SH, Grundman M, Schafer K, Sano M, Thal LJ, Thomas R, Whitehouse PJ, and the Alzheimer's Disease Cooperative Study. Assessing patterns of agitation in Alzheimer's disease patients with the Cohen- Mansfield agitation inventory. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S45-S50.

8. Mackell JA, Ferris SH, Mohs R, Schneider L, Galalsko D, Whitehouse P, Schmitt F, Sano M, Thal LJ, and the Alzheimer's disease cooperative study. Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S65-S69.

58

9. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury P, Alzheimer's Disease Cooperative Study. Clinical Dementia Rating training and reliability in multicenter studies: The Alzheimer's Disease Cooperative Study experience. Neurology 1997;48:1508-1510.

10. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang M-X, Phelps CH, Alzheimer's Disease Centers Consortium on APOE and Alzheimer's Disease. Utility of the Apolipoprotein-E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998;338:506-511.

11. Bronstein JM, DeSalles A, DeLong MR, Workshop Participants. Stereotactic pallidotomy in the treatment of Parkinson disease. An expert opinion. Arch Neurol 1999;56:1064-1069.

12. Grundman M, Sencakova D, Jack CR, Petersen RC, Kim HT, Schultz A, Weiner MF, DeCarli C, DeKosky ST, van Dyck C, Thomas RG, Thal LJ, for the Alzheimer’s Disease Cooperative Study. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci 2002;19:23-27.

13. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ, for the Alzheimer’s Disease Cooperative Study. A Multicenter, Placebo-controlled Trial of Melatonin for Sleep Disturbance in Alzheimer’s Disease. Sleep 2003;26:893-901.

14. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyke CH, Mintzer J, Zamrini EY, Cahn- Weiner D, Thal L, for the Alzheimer’s Disease Cooperative Study. Mild cognitive impairment can be distinguished from Alzheimer’s disease and normal aging for clinical trials. Arch Neurol 2004;61:59-66.

15. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Leon J, for the Alzheimer’s Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388.

16. DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, Thal LJ, Jin S, Jack CR, Scheltens P, for the Alzheimer’s Disease Cooperative Study Group. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 2007;64:108-115.

17. Tinklenberg JR, Kraemer HC, Yaffe K, Ross L, Sheikh J, Ashford JW, Yesavage JA, Taylor JL. Donepezil treatment and Alzheimer disease: Can the results of randomized clinical trials be applied to alzheimer disease patients in clinical practice? Am J Geriatr Psychiatry 2007;15:953-960.

18. Jack CR Jr, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D, Doody RS, Thal LJ; Members of the Alzheimer's Disease Cooperative Study (ADCS). Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 2008;29:1285-1295.

19. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr, Aisen PS, Thal LJ. Volumetric MRI vs clinical predictors of Alzheimer’s disease in mild cognitive impairment. Neurology 2008;70:191-199.

20. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, Alzheimer’s Disease Genetics Consortium, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD. Meta-analysis confirms CR1, CLU and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 2010;12:1473-1484.

21. Cruchaga C, Chakraverty S, Mayo K, Vallania FL, Mitra RD, Faber K, Williamson J, Bird T, Diaz-Arrastia R, Foroud TM, Boeve BF, Graff-Radford NR, St. Jean P, Lawson M, Ehm MG, Mayeux R, Goate AM. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families. PLoS One. 2012;7(2):e31039.

22. Richard IH, McDermott MP, Kurlan R, Lynes JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurol 2012:18(16):1229-36.

59

23. Elm JJ. Design innovations and baseline findings in a long-term Parkinson’s trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson’s Disease Long-Term Study-1. Mov Disord. 2012:27(12):1513-21.

24. Zou F, Younkin CS, Allen M, Crook J, Pankratz VS, Carrasquillo MM, Rowley CN, Nair AA, Middha S, Maharjan S, Nguyen T, Ma L, Malphrus KG, Palusak R, Lincoln S, Bisceglio G, Georgescu C, Kouri N, Kolbert CP, Jen J, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD; Alzheimer’s Disease Genetics Consortium, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet. 2012:8(6):e1002707

25. Jun G, Vardarajan BN, Buros J, Yu CE, Hawk MV, Dombroski BA, Crane PK, Larson EB, Alzheimer’s Disease Genetics Consortium, Mayeux R, Jaines JL. Lunetta KL, Pericak-Vance MA, Schellenberg GD, Farrer LA. Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. Arch Neurol 2012:69(10):1270-9

26. Holton P, Ryten M, Nalls M, Trabzuni D, Weale ME, Hernandez D, Crehan H, Gibbs JR, Mayeux R, Haines JL, Farrer LA, Pericak- Vance MA, Schellenberg GD, Alzheimer’s Disease Genetics Consortium, Ramirez-Restrepo M, Engel A, Myers AJ, Comeveaux JJ, Heuntelman MJ, Dillman A, Cookson Mr, Reiman EM, Singleton A, Hardy J, Guerreiro R. Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann Hum Genet. 2013;77:85-105

27. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert JE, Munro CA, Pelton G, Rabins PV, Rosenbert PG, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311:682-91

28. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Rasking M, Sabbagh M, Honig LS, Porteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnick B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Bapineuzumab, 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014:340:322-33

29. Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, Schneider LS, Aisen PS. Alzheimer’s disease cooperative study prevention instrument project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. JAGS. 2014:62:985-988

30. Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM, NET-PD Investigators. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol 2014;71:710-6

31. Drye LT, Spragg D, Devandand DP, Frangakis C, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, CitAD Research Group. Changes in QTc interval in the citalopram for agitation in Alzhermier’s disease (CitAD) randomized trial. PLoS One 2014;10: e98426. doi: 10.1371/journal.pone.0098426. eCollection 2014.

32. Vellas B, Bateman R, Blennow K, Frisoni G, Johnson K, Katz R, Langbaum J, Marson D, Sperling R, Wessels A, Salloway S, Doody R, Aisen P, Task Force Members. Endpoints for pre-dementia AD trials: A report from the EU/US/CTAD task force. J Prev Alz Dis 2015;2:128-135

Cleveland Clinic Publications 1. Cummings J, Zhong K. Immunotherapy: A new therapeutic approach to treating Alzheimer’s disease. Neuroscience Pathways 2011- 2012:6-7

2. Cummings J. Alzheimer’s disease redefined. Geriatric Times Fall 2011:3-5

3. Cummings JL, Zhong K. Bexarotene for Alzheimer disease: Innovative clinical trial could open the door to disease-modifying. Neuroscience Pathways 2013;4-5

60

Chapters 1. Alexander MP, Cummings JL, Albert ML. Higher visual functions. In: Neuro-, Vol. l. Lessell S and Van Dalen JTW editors. Excerpta Medica, Amsterdam, l980, pp. 78-94.

2. Pahl JJ, Bartzokis G, Mazziotta JC, Cummings JL, Altshuler L, Marder S, Phelps ME. In: Positron Emission Tomography (PET) in Schizophrenia Research. Springer Verlag Publishers, New York, l980-l987.

3. Feldman RG, Cummings JL. Treatable dementias. In: Geriatric Neurology. Slade WR editor. Futura Publishers, New York, l98l, pp. l73-l97. 4. Cummings JL. Cortical dementias. In: Psychiatric Aspects of Neurologic Disease, Vol 2. Benson DF, Blumer D editors. Grune and Stratton, New York, l982, pp. 93-l20.

5. Alexander MP, Cummings JL. Higher visual functions. In: Neuro-Ophthalmology, Vol. 2. Lessell S, Van Dalen JTW editors. Excerpta Medica, Amsterdam, l982, pp. 88-l07.

6. Cummings JL. Treatable dementias. In: Recent Advances in Neurology. The Dementias. Mayeux R, Rosen J editors. Raven Press, New York, l983, pp. l65-l83.

7. Alexander MP, Cummings JL. Higher visual functions. In: Neuro-Ophthalmology, Vol. 3. Lessell S, Van Dalen JTW editors. Excerpta Medica, Amsterdam, l983, pp. ll3-l27.

8. Benson DF, Cummings JL. Subcortical dementia. In: Brain Pathology, Vol. l. Pilleri G, Tagliavini F editors. Brain Anatomy Institute, Bern, Switzerland, l984, pp. 7l-90.

9. Benson DF, Cummings JL. Agraphia. In: Clinical Neuropsychology. Vol. l (45). Handbook of clinical neurology. Frederiks JAM editor. American Elsevier, New York, l985, pp. 457-472.

10. Cummings JL. Dementia: neuropathologic correlates of intellectual deterioration in the elderly. In: The Aging Brain: Communication in the Elderly. College-Hill Press, San Diego, l985, pp. 53-68.

11. Cummings JL. Hemispheric specialization: a history of current concepts. In: Clinical Management of Right Hemisphere Dysfunction. Burns M, Halper AS, and Mogil SI editors. Aspen Press, Rockland, Maryland, l985, pp. l-5.

12. Cummings JL. Clinical syndromes following right hemisphere injuries. In: Clinical Management of Right Hemisphere Dysfunction. Burns M, Halper AS, and Mogil SI editors. Aspen Press, Rockland, Maryland, l985, pp. 7-l5.

13. Cummings JL. Hemispheric asymmetries in visuospatial and visuo-perceptual function. In: The Dual Brain. Benson DF and Zaidel E editors. Guilford Press, New York, l985, pp. 233-246.

14. Benson DF, Cummings JL. Scheme for the diagnosis of dementia. In: Neuropsychiatric Dementias. Jeste DV editor. American Psychiatric Association, Washington, D.C., l986, pp. l-25.

15. Cummings JL. Dementia of the Alzheimer type: challenges of definition and clinical diagnosis. In: Neuropsychological Studies of Non-Focal Brain Damage: Dementia and Trauma. Whitaker H editor. Springer-Verlag Publishers, New York, l988, pp. 83-l02.

16. Alexander MP, Cummings JL. Higher visual functions. In: Current Ophthalmology. Lessell S, Van Dalen JTW editors. Yearbook Medical Publishers, New York, l988, pp. 86-l07.

17. Aharon J, Cummings JL. Subcortical dementia. In: Neuropsychology and the Elderly. Holden U editor. Croom Helm, London, l988, pp. 70-l20.

18. McDaniel K, Cummings JL. Visual hallucinations. In: Neuro-Ophthalmology Enters in the Nineties. Smith JS, Katz R editors. Dutton Press, Hiakoh, l988, pp. 26l-275.

19. Cummings JL, Small GW. Alzheimer's disease. In: Yearbook of Geriatrics and Gerontology. Beck JC et al editors. Yearbook Medical Publishers, Chicago, l988, pp. l9l-232.

61

20. Cummings JL. Geriatric neurology. In: Yearbook of Geriatrics and Gerontology. Beck JC et al editors. Yearbook Medical Publishers, Chicago, l988, pp. 233-240.

21. Cummings JL, Benson DF. Speech and language alterations in dementia syndromes. In: Brain Organization of Language and Cognitive Processes. Ardilla A, Ostrosky F editors. Plenum Press, New York, l989, pp. l07-l20.

22. Cummings JL. Clinical diagnosis of dementia of the Alzheimer's type. In: Caring for Alzheimer's Patients: A Guide for Family and Health Care Providers. Miner GD, Winters-Miner LA, Blaus JP, Richter RW, Valentine JL editors. Plenum Press, New York, l989, pp. 57-75.

23. Freidenberg DL, Van Gorp W, Cummings JL. Subcortical dementia. In: Neuropsychology of Senile Dementia. Katona C editor. Croom Helm Ltd Publishers, Beckenham, Kent, England, l989, pp. l04-l4l.

24. Cummings JL. Neuropsychiatric syndromes in the elderly: pharmacologic management. In: Psychiatric Consequences of Brain Disease in the Elderly. Conn D, Grek A, Sadavoy J editors. Plenum Publishing Company, New York, l989, pp. 59-84.

25. Cummings JL. Clinical diagnosis of Alzheimer's disease. In: Treatment and Management of Alzheimer's Disease. Cummings JL and Miller B editors. Marcel Dekker, New York, l989, pp. 3-l9.

26. Cummings JL. Higher visual functions. In: Current Neuro-Ophthalmology. Lessell S and Van Dalen JTW eds). Yearbook Medical Publishers, New York, l990, pp. 75-86.

27. Cummings JL. Epidemiology of Alzheimer's disease. In: Alzheimer's and Parkinson's Diseases: Recent Advances. Plenum Publishing Corporation, New York, l989, pp. l-l0.

28. Cummings JL. Geriatric neurology. In: Yearbook of Geriatrics and Gerontology. Beck JC et al editors. Yearbook Medical Publishers, Chicago, l989, pp. 20l-245.

29. Cummings JL. Dementing illnesses. In: Yearbook of Geriatrics and Gerontology. Beck JC et al editors. Yearbook Medical Publishers, Chicago, l990, pp. l75-2l4.

30. Cummings JL, Jarvik L. Dementia. In: Geriatric Medicine, 2nd ed. Cassel CK, Reisenberg DE, Sorensen LB, Walsh JR, editors. Springer-Verlag, New York, l990, pp. 428-448.

31. Cummings JL. Geriatric neurology. In: Yearbook of Geriatrics and Gerontology. Beck JC et al editors. Yearbook Medical Publishers, Chicago, l990, pp. 2l5-268.

32. Cummings JL. Pick's disease. In: Clinical Neurology. Swash M, Oxbury W editors. Churchill Livingstone, Edinburgh, l990, pp. 267-279.

33. Cummings JL. Introduction. In: Subcortical Dementia. Cummings JL, editor. Oxford University Press, New York, 1990, pp. 3-l6.

34. Stuss D, Cummings JL. Subcortical vascular dementia. In: Subcortical Dementia. Cummings JL editor. Oxford University Press, New York, l990, pp. l45-l63.

35. Heir D, Cummings JL. Rare acquired and degenerative subcortical dementias. In: Subcortical Dementia. Cummings JL editor. Oxford University Press, New York, l990, pp. l99-2l7.

36. Benson DF, Cummings JL. Subcortical mechanisms in human behavior and cognition. In: Subcortical Dementia. Cummings JL editor. Oxford University Press, New York, l990, pp. 25l-259.

37. Sultzer D, Cummings JL. Alzheimer's disease. In: Difficult Medical Management. Taylor RB editor. WB Saunders Co., Philadelphia, l99l, pp. l6-24.

38. Cummings JL, Mahler ME. Vascular dementia. In: Bornstein RA, Brown GG editors. Neurobehavioral Aspects of Cerebrovascular Disease. Oxford University Press, New York, l99l, pp. l3l-l49.

62

39. Cummings JL. Geriatric neurology. In: Yearbook of Geriatrics and Gerontology. Beck JC et al editors. Mosby Yearbook, Chicago, l99l, pp. l85-233.

40. Cummings JL. Neurobehavioral disorders. In: Geriatric Review Syllabus. Beck JC editor. American Geriatrics Society, New York, l99l, pp. l29-l34.

41. Ross GW, Cummings JL. Vascular dementias. In: Cognitive Disorders: Pathophysiology and Treatment. Thal LT, Gamzu ER, Moos WN editors. Marcel Dekker, New York, l992, pp. 27l-289.

42. Cummings JL. Neuropsychiatric aspects of Alzheimer's disease and other dementias. In: Textbook of Neuropsychiatry, 2nd ed. Yudofsky S, Hales R editors. American Psychiatric Press, Washington, D.C., l992, pp. 605-620.

43. Cummings JL. Neuropsychiatric complications of drug treatment of Parkinson's disease. In: Parkinson's Disease: Neurobehavioral New York, l992, pp. 3l3-324.

44. Ross WR, Mahler M, Cummings JL. Dementia in Parkinson's disease: Cortical and subcortical aspects. In: Parkinson's Disease: Neurobehavioral Aspects. Huber S, Cummings JL editors. Oxford University Press, New York, l992, pp. l32-l48.

45. Cummings JL. Parkinson's disease and parkinsonism. In: Movement Disorders in Neurology and Neuropsychiatry. Joseph A, Young R editors. Blackwell Scientific Publications, Oxford, l992, pp. l95-203.

46. Cummings JL, Wirshing W. Movement disorders in schizophrenia. In: Movement Disorders in Neurology and Neuropsychiatry. Joseph A, Young R editors. Blackwell Scientific Publications, Oxford, l992, pp. 407-4l3.

47. Cummings J. Geriatric neurology. In: Yearbook of Geriatrics and Gerontology. Mosby Yearbook, Chicago, l992, pp. l79-235.

48. Reichman WE, Cummings JL. Dementia. In: Practice of Geriatrics, 2nd ed. Calkins E, Ford AB, Katz PR editors. WB Saunders Co., Philadelphia, l992, pp. 295-304.

49. Cummings JL. Neurobehavioral disorders. In: Geriatric Review Syllabus. Rubin DB, Yoshikawa TT, Besdine RW editors. American Geriatric Society, New York, l993, pp. 665-695.

50. Cummings JL. Dementia. In: Geriatric Review Syllabus. Rubin DB, Besdine RW editors. American Geriatric Society, New York, 1993, pp. 575-6l5.

51. Cummings JL, Sultzer D. Depression in multi-infarct dementia. In: Depression in Neurological Diseases. Starkstein SE, Robinson RG editors. Johns Hopkins University Press, Baltimore, l993, pp. l65-l85.

52. Scharre D, Cummings JL. Dementia. In: Ambulatory Geriatric Care. Yoshikawa TT, Cobbs EL, Brummel-Smith K editors. Mosby, Chicago, l993, pp. 333-345.

53. Sultzer D, Cummings JL. Alzheimer's disease. In: Conn's Current Therapy. Rakel RE editor. WB Saunders Company, Philadelphia, l993, pp. 838-840.

54. Cummings JL. Amnesia and memory disturbances in neurologic diseases. In: Review of Psychiatry, Vol. l2. Oldham JM, Riba MB, Tusman A editors. American Psychiatric Press, Washington, D.C., l993, pp. 725-745.

55. Cummings JL. Psychosis in basal ganglia diseases. In: Mental Dysfunction in Parkinson's Disease. Wolters EC editor. Virje Universiteit, Amsterdam, 1993, pp. 257-268.

56. Absher JR, Cummings JL. Noncognitive behavioral alterations in dementia syndrome. In: Handbook of Neuropsychology, Vol 8. Spinner H, Boller F editors. Elsevier, New York, 1993, pp. 315-338.

57. Absher J, Cummings JL. Behavioral aspects of dementia syndromes. In: Dementia. Burns A, Levy R editors. Chapman and Hall, London, 1994, pp. 59-76 .

63

58. Ross GW, Cummings JL. Subcortical dementia. In: Dementia. Presentations, differential diagnosis, and nosology. Emery VOB, Oxman TE editors. Johns Hopkins University Press, Baltimore, l994, pp. l4l-l6l.

59. Cummings JL, Miller B. Disorders of sexual behavior in neurological disease. In: Sexual Function. Singer C, Weiner WJ editors. Futura, New York, 1994, pp. 199-218.

60. Gray KF, Cummings JL. Neuroimaging in dementia. In: Localizing and Neuroimaging in Neuropsychology. Kertesz A editor. Academic Press, New York, l994, pp. 62l - 65l.

61. Cummings JL. Neuropsychiatric aspects of Alzheimer's disease and other dementing illnesses. In: Synopsis of Neuropsychiatry. Yudofsky SC, Hales RT editors. American Psychiatric Association, Washington, D.C., 1994, pp. 469-482.

62. Cummings JL, Coffey CE. Geriatric neuropsychiatry. In: Textbook of Geriatric Neuropsychiatry. Coffey CE, Cummings JL editors. American Psychiatric Press, Washington, D.C., 1994, pp. 3-15.

63. Cummings JL, Coffey CE. Neurobiological basis of behavior. In: Textbook of Geriatric Neuropsychiatry. Coffey CE, Cummings JL editors. American Psychiatric Press, Washington, D.C., 1994, pp. 71-96.

64. Sultzer D, Cummings JL. Secondary dementias. In: Geriatric Neurology, 2nd edition. Albert ML, Knoefel JE editors. Oxford University Press, New York, 1994, pp. 379-395.

65. Masterman DL, Craig AH, Cummings JL. Alzheimer's Disease. In: Treatments of Psychiatric Disorders, 2nd ed. Gabbard G editor. American Psychiatric Press: Washington, DC, 1995, pp. 479-513.

66. Craig A, Cummings JL. Neuropsychiatric aspects of aphasia. In: Handbook of Neurological Speech and Language Disorders. Kershner H editor. Marcel Dekker, New York, 1995, pp. 483-498.

67. Cummings JL. Neuropsychiatry: Clinical assessment and approach to diagnosis. In: Comprehensive Textbook of Psychiatry VI. Kaplan HI, Sadock BJ editors. Williams and Wilkins, Baltimore, 1995, pp. 167-187.

68. Miller BL, Cummings JL, Mena I, Darcourt J. Neuroimaging in neuropsychiatric disorders. In: Comprehensive Textbook of Psychiatry VI. Kaplan HI, Sadock BJ editors. Williams and Wilkins, Baltimore, 1995, pp. 257-275.

69. Cummings JL. Neuropsychiatry. In: Manual of Psychiatric Disorders. Simpson G editor. Impact Medical Communications, Inc., New York, 1995, pp. 109-136.

70. Cummings JL. Geriatric neuropsychiatry in the Caribbean. In: McCardle PD, Quatrano LA, Rawlings SC editors. Proceedings of the workshop on social and psychosocial aspects of aging in the Caribbean. National Institutes of Health, Division of Research Grants, 1995.

71. Kaufer DI, Cummings JL. Personality alterations in degenerative brain diseases. In: Neuropsychiatry of Behavioral Disorders. Ratey J editor. Blackwell Scientific Publication, London, 1995, pp. 172-209.

72. Cummings JL. Behavioral and psychiatric symptoms associated with Huntington's disease. In: Advances in Neurology. Behavioral Neurology of Movement Disorders. Weiner WJ, Lang AE editors. Raven Press, New York, 1995, 65:179-186.

73. Hinkin CH, Cummings JL. Agraphia. In: Blackwell Dictionary of Neuropsychology. Beaumont JG, Kenealy PM, Rogers MJC editors. Basil Blackwell Limited, Oxford, 1996.

74. Cummings JL, Craig AH. Aphasia and behavioral neurology. In: Current Practice of Medicine. Bone RC editor 1996, 3:X10:1- X10.9.

75. Pachana NA, Cummings JL, Hinkin CH, Van Gorp WG. Experimental and advanced techniques for the assessment of dementia. In: Vascular Dementia: Current concepts. Prohovnik I, Wade J, Knezevic S, Tatemichi T, Erkinjunnti T editors. Wiley: New York, 1996, pp.179-218.

64

76. Mendez MF, Benson DF, Cummings JL. Aux confins de la neurologie et de la psychiatrie: déficit d'attention, crises d'aggressivité et atteintes traumatiques cérebrales lègéres. In: Neuropsychologie Clinique et Neurologie du Comportement, 2nd ed. Botez MI editor. Masson; Paris, 1996.

77. Mega MS, Cummings JL. Dementia. In: Psychiatric Care in the Nursing Home, Reichman WE, Katz P editors. Oxford University Press; New York, 1996, pp. 40-56.

78. Cummings JL, Khachaturian Z. Definitions and diagnostic criteria. In: Clinical Diagnosis and Management of Alzheimer's Disease. Gauthier S editor. Martin Dunitz; London, 1996, pp. 3-15.

79. Gray KF, Cummings JL. Dementia. In: Textbook of Consultation-Liaison Psychiatry. Rundell JR, Wise MG editors. American Psychiatric Press, Inc., Washington, DC, 1996, pp. 277-309.

80. Cummings JL, Burns MS. Hemispheric specialization: a history of current concepts. In: Clinical Management of Right Hemisphere Dysfunction, 2d ed. Halper AS, Cherney LR, Burns MS editors. Aspen Publishers, Inc., Gaithersburg, Maryland, l996, pp. l-8.

81. Cummings JL, Burns, MS. Neurological syndromes associated with right hemisphere damage. In: Clinical Management of Right Hemisphere Dysfunction, 2d ed. Halper AS, Cherney LR, and Burns MS editors. Aspen Publishers, Inc., Gaithersburg, Maryland, l996, pp. 9-20.

82. McPherson S, Cummings JL. Neuropsychological aspects of Parkinson's disease and Parkinsonism. In: Neuropsychological Assessment of Neuropsychiatric Disorders, 2d ed. Grant I, Adams KM editors. Oxford University Press, New York,1996, pp. 288- 311.

83. Cummings JL, Aarsland D, Jarvik L. Dementia. In: Geriatric Medicine, 3rd ed. Cassell CK, Cohen HJ, Larson EB, Meier DE, Resnick N, Rubenstein L, Sorensen LB editors. Springer-Verlag: New York, 1997, 897-916.

84. Cummings JL, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate in Alzheimer's disease: results of a dose-finding study. In: Alzheimer's Disease: Biology, Diagnosis and Therapeutics. Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM editors. Wiley, 1997, pp. 665-669.

85. Kaufer DI, Cummings JL. Dementia and delirium: an overview. In: Behavioral Neurology and Neuropsychology. Feinberg TE, and Farah MJ editors. McGraw-Hill, 1997, pp. 499-520.

86. Foti DJ, Cummings JL. Neurobehavioral aspects of movement disorders. In: Movement disorders. Neurologic principles and practice. Watts RL, Koller WC editors. McGraw-Hill, 1997, pp. 15-30.

87. Mendez MF, Cummings JL. Dementia. In: Contemporary Behavioral Neurology. Trimble MR, Cummings JL editors. Butterworth-Heinemann, Oxford, 1997, pp. 255-273.

88. Mega MS, Cummings JL. The cingulate and cingulate syndromes. In: Contemporary Behavioral Neurology. Trimble MR, Cummings JL editors. Butterworth-Heinemann, Oxford, 1997, pp. 189-214.

89. Mendez MF, Benson DF, Cummings JL. Neuropsychiatric aspects of aphasia and related disorders. In: The American Psychiatric Press Textbook of Neuropsychiatry, 3rd ed. Yudofsky SC, Hales RE editors. American Psychiatric Press, Washington, DC, 1997, pp. 471-483.

90. White KE, Cummings JL. Neuropsychiatric aspects of Alzheimer's disease and other dementing illnesses. In: The American Psychiatric Press Textbook of Neuropsychiatry, 3rd ed. Yudofsky SC, Hales RE editors. American Psychiatric Press, Washington, DC, 1997, pp. 823-854.

91. McPherson SE, Cummings JL. Vascular dementia: clinical assessment, neuropsychological features, and treatment. In: Handbook of Neuropsychology and Aging. Nussbaum PD editor. Plenum Press, New York, 1997, pp.177-188.

92. Nasreddine ZS, Cummings JL. Depression in neurological diseases. In: Depression: Neurobiological Psychopathological and Therapeutic Advances. Honig A, van Praag HM editors. John Wiley & Sons, Ltd., New York, 1997, pp. 309-323.

65

93. Chen ST, Cummings JL. Tratamiento de los trastornos conductuales en la demencia. In: Demencia Enfoque Multidisciplinario. Mangone CA, Allegri RF, Arizaga RL, Ollari JA editors. C.A. Mangone y otros, Buenos Aires, 1997, pp. 473-484.

94. Foti DJ, Cummings JC. Neurobehavioral aspects of movement disorders. In: Movement Disorders Neurologic Principles and Practice. Watts RL, Koller WC editors. McGraw-Hill, New York, 1997, pp. 15-30.

95. Salloway S, Malloy P, Cummings JL. Introduction to the neuropsychiatry of limbic and subcortical disorders. In: The Neuropsychiatry of Limbic and Subcortical Disorders. Salloway S, Malloy P, Cummings JL editors. American Psychiatric Press, Inc., Washington, DC, 1997, pp. 313-314.

96. Reichman WE, Cummings JL. Dementia. In: Practice of Geriatrics, 3rd ed. Duthie EH, Katz PR editors. W. B. Saunders Co., Philadelphia, 1998, pp. 267-278.

97. Scharre D, Cummings JL. Dementia. In: Practical Ambulatory Geriatrics, 2nd ed. Yoshikawa TT, Cobbs EL, Brummel-Smith K editors. Mosby, Chicago, l998, pp. 290-301.

98. Cherrier MM, Mendez MF, Cummings JL, Benson DF. Language and communication in non-Alzheimer's dementias. In: Handbook of . Stemmer B, Whitaker HA editors. Academic Press, New York, 1998, pp. 447-473.

99. Back C, Miller BL, Cummings JL. Neurobiological basis of behavioral changes in HIV-1 encephalopathy. In: Practitioner's Guide to the Neuropsychiatry of HIV/AIDS. Van Gorp WG, Buckingham SL editors. The Guilford Press, New York, 1998, pp. 42-64.

100. Cervenakova L, Brown P, Piccardo P, Cummings JL, Nagle J, Vinters HV, Kaur P, Ghetti B, Chapman J, Gajdusek DC, Goldfarb LG. 24-nucleotide deletion in the PRNP gene: analysis of associated phenotypes. In: Transmissible Subacute Spongiform Encephalopathies: Prion Diseases. Court L, Dodet B editors. Elsevier, Amsterdam, 1997, pp. 433-443.

101. McPherson SE, Cummings JL. The neuropsychology of the frontal lobes. In: Disorders of Brain and Mind. Ron MA and David AS. Cambridge University press, Cambridge, 1998, pp. 11-34.

102. Cummings JL. Behavioral neurology. In: The American Academy of Neurology: the First 50 Years, 1948 - 1998. Cohen MM editor. American Academy of Neurology, St. Paul, 1998, pp. 220-222.

103. Levy ML, Miller BL, Cummings JL. Frontal and frontotemporal dementia. In: The Dementias. Growdon JH, Rossor MN editors. Butterworth Heinemann, Boston, 1998, pp. 45-65.

104. Leiter FL, Cummings JL. Pharmacologic interventions in Alzheimer's disease. In: Cognitive : a Comprehensive Approach. Stuss DT, Winocur G, Robertson IH editors. Cambridge University Press, Cambridge, 1999, pp. 153-169.

105. Nasreddine ZS, Mendez MF, Cummings JL. Speech and language. In: Textbook of Clinical Neurology. Goetz CG, Pappert EJ editors. W.B. Saunders Company, Philadelphia, 1999, pp. 70-89.

106. Cummings JL. Neuropsychiatry of sexual deviations. In: Neuropsychiatry and Mental Health Services. Ovsiew F editor. American Psychiatric Press, Washington, D.C., 1999, pp. 363-384.

107. Chow TW, Cummings JL. Frontal-subcortical circuits. In: The Human Frontal Lobes: Functions and Disorders. Bornstein RA editor. The Guilford Press, New York, 1999, pp. 3-26.

108. Jordan B, Cummings JL. Mental status and neurologic examination in the elderly. In: Principles of Geriatric Medicine and Gerontology. Hazzard WR, Blass JP, Ettinger WH, Halter JB, Ouslander JG editors. McGraw-Hill, New York, 1999, pp. 1209- 1217.

109. Wright MT, Wirshing WC, Cummings JL. Movement disorders in schizophrenia. In: Movement Disorders in Neurology and Neuropsychiatry. Joseph AB, Young RR editors. Second Edition, Blackwell Science Ltd, Boston, 1999, pp. 383-389.

110. Levy ML, Cummings JL. Parkinson's disease and parkinsonism. In: Movement Disorders in Neurology and Neuropsychiatry. Joseph AB, Young RR editors. Second Edition, Blackwell Scientific Publications, Boston, 1999, pp. 171-179.

66

111. Cummings JL, Khachaturian ZS. Definitions and diagnostic criteria. In: Clinical Diagnosis and Management of Alzheimer's Disease, 2nd ed. Martin Dunitz Ltd, London, 1999, pp. 3-15.

112. Cummings JL. Neuropsychiatric symptoms. In: Outcome Measures in Alzheimer's Disease. McKeith I et al editors. Martin Dunitz Ltd., London, 1999, pp. 35-50.

113. Mendez MF, Cummings JL. Amnesia and aphasia. In: Cecil’s Textbook of Medicine. Goldman L, Claude Bennett J editors. W.B. Saunders Company, Philadelphia. 1999, pp. 2038-2039.

114. Nakawatase TV, Cummings JL. Alzheimer’s disease and related dementias. In: Cecil’s Textbook of Medicine. Goldman L, Claude Bennett J editors. W.B. Saunders Company, Philadelphia, 1999, pp. 2042.

115. Gray KF, Cummings JL. Dementia. In: Essentials of Consultation-Liaison Psychiatry. Rundell JR, Wise MG editors. American Psychiatric Press, Inc, Washington D.C., 1999, pp. 95-119.

116. Ringman JM, Cummings JL. Diagnosis of regional cerebral dysfunction. In: Cecil’s Textbook of Medicine, 21st. Goldman L, Claude Bennett J editors. W.B. Saunders Company, Philadelphia. 2000, pp. 2033-2047.

117. Cummings JL. Alzheimer’s disease. In World Book Encyclopedia. World Book, Inc, 2000.

118. Chow TW, Cummings JL. Depression in Parkinson’s disease: pharmacological characteristics and treatment. In: Depression in the Medically Ill Patient. Palmer K editor. Adis International, Auckland, 2000 pp. 31-52.

119. Chow TW, Cummings JL. Neuropsychiatry: clinical assessment and approach to diagnosis. In: Comprehensive Textbook of Psychiatry, 6th ed. Kaplan HI, Sadock BJ editors. Williams and Wilkins, Baltimore, 2000, pp. 221-242.

120. Levy ML, Cummings JL. Parkinson’s disease. In: Psychiatric Management in Neurological Disease. Lauterbach EC editor. American Psychiatric Press, Inc, Washington DC, 2000, pp. 41-69.

121. Mega MS, Thompson PM, Toga AW, Cummings JL. in dementia. In: Brain Mapping: The Disorders. Mazziotta JC, Toga AW, Frackowiak RSJ editors. Academic Press, San Diego, 2000, pp. 217-234.

122. McPherson S, Cummings JL. Neuropsychiatric symptoms in Alzheimer’s disease: assessment and management. In: Neurobehavior of Language and Cognition: Studies of Normal Aging and Brain Damage Connor LT, Obler LK editors. Kluwer Academic Publishers, Boston, 2000, pp. 327-346.

123. Bronstein YL, Cummings JL. Neuropsychiatric manifestations of dementia. In: Alzheimer’s Disease and Related Disorders Annual. Gauthier S, Cummings JL editors. Martin Dunitz, United Kingdom, 2000, pp. 179-197.

124. Edwards-Lee T, Cummings JL. Focal lesions and psychosis. In: Behavior and Mood Disorders in Focal Brain Lesions. Bogousslavsky J, Cummings JL editors. Cambridge University Press, 2000, pp. 419-436.

125. Ringman JM, Cummings JL. Alterations in sexual behavior following focal brain injury. In: Behavior and Mood Disorders in Focal Brain Lesions. Bogousslavsky J, Cummings JL editors. Cambridge University Press, 2000, pp. 437-464.

126. Cummings JL, Bogousslavsky J. Emotional consequences of focal brain lesions: an overview. In: Behavior and Mood Disorders in Focal Brain Lesions. Bogousslavsky J, Cummings JL editors. Cambridge University Press, 2000, pp. 1-20.

127. Longobardi PG, Cummings JL, Anderson-Haley C. Multicultural perspectives on the neuropsychological and neuropsychiatric assessment and treatment of the elderly. In: Handbook of Cross-Cultural Neuropsychology. Fletcher-Janzen E, Strickland T, Reynolds CR editors. Kluwer Academic/Plenum Publishers, New York, 2000, pp. 123-144.

128. Mirea A and Cummings JL. Neuropsychiatric aspects of dementia. In: Dementia, Second Edition. O'Brien J, Ames D, Burns A editors. Arnold Publishers, London 2000, pp. 61-79.

129. Chow TW, Cummings JL. The amygdala and Alzheimer's disease. In: The Amygdala: a Functional Analysis, 2nd ed. Aggleton JP editor. Oxford University Press, New York, 2000, pp. 655-679.

67

130. Cummings JL, Coffey CE. Neurobiological basis of behavior. In: Textbook of Geriatric Neuropsychiatry, 2nd ed. Coffey CE, Cummings JL editors. American Press, Washington, DC, 2000, pp. 81-105.

131. Cummings JL, Coffey CE. Introduction to geriatric neuropsychiatry. In: Textbook of Geriatric Neuropsychiatry, 2nd ed. Coffey CE, Cummings JL editors. American Psychiatric Press, Washington, DC, 2000, pp. 3-15.

132. Cummings JL, Litvan I. Neuropsychiatric aspects of corticobasal degeneration. Advances in Neurology 2000, pp. 47-152.

133. Mega MS, Thompson PM, Toga AW, Cummings JL. Hippocampal volume assessment in mild cognitive impairment. In: Drug Discovery and Development for Alzheimer’s Disease. Fillit HM, O’Connell AW editors. Springer Publishing Company, New York, 2000, pp. 33-41.

134. Weingarten SM, Cummings JL. Psychosurgery of frontal-subcortical circuits. In: Frontal-Subcortical Circuits in Psychiatric and Neurological Disorders. Lichter DG, Cummings JL editors. The Guilford Press, New York, 2001, pp. 421-435.

135. Masterman DL, Cummings JL. Alzheimer’s disease. In: Treatments of Psychiatric Disorders. Gabbard GO editor. American Psychiatric Publishing, Inc., Washington, DC, 2001, pp. 481-514.

136. Mega MS, Cummings JL. Frontal subcortical circuits, anatomy and function. In: The Frontal Lobes and Neuropsychiatric Illness. Salloway, SP, Malloy PF, Duffy JD editors. American Psychiatric Publishing, Inc., Washington, DC, 2001, pp. 15-32.

137. Lichter DG, Cummings JL. Introduction and overview. In: Frontal-Subcortical Circuits in Psychiatric and Neurological Disorders. Lichter DG, Cummings JL editors. The Guilford Press, New York, 2001, p.1.

138. Kumar A, Cummings JL. Depression in neurodegenerative disorders and related conditions. In: Alzheimer's Disease and Related Disorders Annual 2001. Gauthier S, Cummings JL editors. Martin Dunitz, London, 2001, pp. 123-141.

139. Cummings JL. Behavioral manifestations of Alzheimer’s disease. In: Contemporary Neuropsychiatry. Miyoshi K, Shapiro CM, Gaviria M, Morita Y editors. Springer, New York, 2001, pp. 84-88.

140. Cummings JL. Neuropsychiatry in the elderly. In: Contemporary Neuropsychiatry. Miyoshi K, Shapiro CM, Gaviria M, Morita Y editors. Springer, New York, 2001, pp. 107-115.

141. Cummings JL, Saul RE, Nakawatase T. The Difficult-to-Treat patient with dementia or traumatic brain injury. In: The Difficult-to- Treat Psychiatric Patient. Mantosh J. Dewan, Ronald W. Pies editors. American Psychiatric Publishing, Inc., Washington, DC, 2001, pp. 299-324.

142. Cummings JL, Chung JA. Neuropsychiatric assessment. In: Early-Onset Dementia: a multidisciplinary approach. John R. Hodges editors. Oxford University Press, New York, 2001, pp. 74-103.

143. Pippenger M, Cummings JL. Treatment of dementia. In: Handbook of Neuropsychology, 2nd ed. Boller F, Cappa SF editors. Elsevier Science, 2001, pp. 259-272.

144. Mega MS, Thompson PM, Toga AW, Cummings JL. Hippocampal volume assessment in mild cognitive impairment. In: Drug Discovery and Development for Alzheimer’s Disease. Fillit HM, O’Connell AW editors. Springer Publishing Company, New York, 2002, pp. 33-41.

145. Gray KF, Cummings JL. Dementia. In: The American Psychiatric Publishing Textbook of Consultation-Liaison Psychiatry, Second Edition. Wise MG, Rundell JR editors. American Psychiatric Publishing, Inc., 2002, pp. 273-306.

146. Chow TW, Masterman DL, Cummings JL. Depression. In: Parkinson’s Disease: Diagnosis and Clinical Management. Factor SA, Weiner WJ editors. Demos Medical Publishing, Inc., New York, NY, 2002, pp. 145-159.

147. Porter VR, Cummings JL. Dementia. In: Women’s Health: Principles and Clinical Practice. Pregler JP, DeCherny AH editors. B. C. Decker, Inc., London, 2002, pp. 697-707.

68

148. Mendez MF, Cummings JL. Neuropsychiatric aspects of aphasia and related disorders. In: The American Psychiatric Publishing Textbook of Neuropsychiatry and Clinical Neurosciences, 4th edition. Yudofsky SC, Hales RE editors. American Psychiatric Publishing, Inc., Washington, DC, 2002, pp. 565-578.

149. Askin-Edgar S, White KE, Cummings JL. Neuropsychiatric aspects of Alzheimer’s disease and other dementing illnesses. In: The American Psychiatric Publishing Textbook of Neuropsychiatry and Clinical Neurosciences. Yudofsky SC, Hales RE editors. American Psychiatric Publishing, Inc., Washington, DC, 2002, pp. 953-988.

150. McPherson S, Cummings JL. The frontal lobes and frontal-subcortical circuits in neuropsychiatric disorders. In: Handbook of Neuropsychology, 2nd edition. Boller F, Grafman J editors. Elsevier, Amsterdam, 2002, pp. 99-116.

151. Cummings JL. Behavioural characteristics in diagnosis. Qizilbash N editors. Blackwell Science, Oxford, England, 2002, pp. 124-129.

152. Tingus K, McPherson S, Cummings JL. Neuropsychological examination of executive functions. In: Vascular Cognitive Impairment. Erkinjuntti T, Gauthier S editors. Martin Dunitz, London, England, 2002, pp. 339-363.

153. Swanberg MM, Foti D, Cummings J. Neurobehavioral aspects of movement disorders. In: Movement Disorders. Wests RL, Koller WC (eds.) McGraw Hill, New York, 2002.

154. Swanberg MM, Cummings JL. Diagnosis and treatment of dementia. In: Neurological Disorders: Course and Treatment, 2nd edition. Elsevier Science, 2003, pp. 311-325.

155. Clark DG, Cummings JL. Aphasia. In: Neurological Disorders: Course and Treatment, 2nd edition. Elsevier Science, New York 2003, pp. 265-275.

156. Cummings JL. Trouble with speech and language. In: The Dana Guide to Brain Health. Bloom FE, Beal MF, Kupfer DJ. The Dana Press, New York, 2003, pp. 643-647.

157. Assal F, Cummings JL. Neurological signs in old age. In: Neurological Disorders: Course and Treatment, 2nd edition. Elsevier Science, New York, 2003, pp. 541-548.

158. Tekin S, Cummings JL. Hallucinations and related conditions. In: Clinical Neuropsychology, 4th edition. Heilman KM, Valenstein E editors. Oxford University Press, Oxford, pp. 479-494.

159. Cummings JL. Neuropsychiatric symptoms. In: Mild Cognitive Impairment. Petersen RC editor. Oxford University Press, Oxford, 2003, pp. 41-61.

160. Assal F, Cummings JL. Classification of dementias and cognitive disorders. In: Handbook of Medical Psychiatry. Marcel Dekker, Inc., New York, 2003, pp. 99-115.

161. Swanberg MM, Nasreddine ZS, Mendez MF, Cummings JL. Speech and language. In: Textbook of Clinical Neurology. Goetz CG editor. Saunders, Philadelphia, 2003, pp. 77-97.

162. Assal F, Cummings JL. Cortical and frontosubcortical dementias. In: Dementia: Presentations, Differential Diagnosis, and Nosology. Emery VOB, Oxman TE editors. The John Hopkins University Press, Baltimore, 2003, pp. 239-262.

163. Tekin S, Cummings JL. Hallucinations, Visual and Auditory. In: Encyclopedia of the Neurological Sciences. Di-L Volume 2. Academic Press, San Diego, 2003, pp.501-503.

164. Guy SK, Cummings JL. The mental status exam. In: Behavioral Neurology and Neuropsychology. Feinberg TE, Farah MJ editor. McGraw-Hill, New York, 2003, pp. 23-32.

165. Kaufer DI, Cummings JL. Delirium and Dementia: An Overview. In: Behavioral Neurology and Neuropsychology. Feinberg TE, Farah MJ editor. McGraw-Hill, New York, 2003, pp. 495-514.

166. Hwang TJ, Cummings JL. Neuropsychiatric symptoms of mild cognitive impairment. In: Alzheimer’s Disease and Related Disorders Annual 2004. Gauthier S, Scheltens P, Cummings JL editors. Martin Dunitz, London, 2003, pp. 71-80. 69

167. Askin-Edgar S, White KE, Cummings JL. Neuropsychiatric aspects of Alzheimer’s disease and other Dementing Illnesses. In: Essentials of Neuropsychiatry and Clinical Neuroscience. Yudofsky SC, Hales RE editor. American Psychiatric Publishing, Washinton, D.C., 2003, pp. 421-456.

168. Mendez M, Cummings JL. Neuropsychiatric aspects of aphasia. In: Essentials of Neuropsychiatry and Clinical Neuroscience. Yudofsky SC, Hales RE editor. American Psychiatric Publishing, Washinton, D.C., 2003, pp. 189-200

169. Hwang TJ, O’Conner S, Cummings JL. The use of the Neuropsychiatric Inventory in severe dementia. In: Research and Practice in Alzheimer’s Disease: Severe Dementia. Vellas B, Winblad B, Grundman M, Fitten LJ, Feldman H, Giacobini E, Kurtz A, Eds. Vol. 8, Serdi Publisher, Paris, France. 2003, pp. 100-106.

170. Swanberg MM, Foti D, Cummings JL. Neurobehavioral aspects of movement disorders. In: Movement Disorders: Neurologic Principles & Practice Second Edition. Watts RL, Koller WC. Eds. McGraw-Hill, New York, NY. 2004, pp. 17-33.

171. Gustavson AR, Cummings JL. Assessment and treatment of neuropsychiatric symptoms in Alzheimer’s disease. In: Current Clinical Neurology, Alzheimer’s disease: A Physicians Guide to Practical Management. Richter RW, Richter BZ. Eds. Human Press Inc., Totowa, NY. 2004, pp. 371-385.

172. Pakkar A, Cummings JL. Mental status and neurologic examination in the elderly. In: Principles of Geriatric Medicine and Gerontology Fifth Edition. Hazzard WR, Blass JP, Halter JB, Ouslander JG, Tinetti ME editors. McGraw-Hill, New York, NY. 2003, pp. 111-119.

173. Cummings JL. Diagnosis of regional cerebral dysfunction. In: Cecil Textbook of Medicine. Goldman L, Ausiello D editors. Saunders; 2004, pp. 2243-2257.

174. Chen S, Cummings JL. Tratamiento de los trastornos conductuales en la demencia. In: Demencia, Enfoque Multidisciplinario. Mangone CA, Allegri RF, Arizaga RL, Ollari JA, editors. Editorial Polemos; 2005:509-521.

175. Apostolova L, Cummings JL. Neuropsychiatric features of dementia with Lewy bodies. In: Dementia with Lewy Bodies and Parkinson’s Disease Dementia. O’Brian J, McKieth I, Ames DA, editors. Taylor & Francis; 2006, pp. 73-94.

176. Chiappelli F, Prolo P, Iribarren J, Neagos N, Fiala M, Concepcion E, Grasso E, Mocellini C, Salvatico F, Rosso MG, Mondino F, Fanto F, Santoro M, Dovio A, Sartori ML, Frattini P, Manfrini E, Angeli A, Provinciali L, Fiorucci A, Cummings JL. Alzheimer’s disease: New frontiers for the XXI century. In: Trends in Alzheimer’s Disease Research. Welsh EM, editor. Nova Science Publishers; 2006, pp. 233-258.

177. Cummings JL. Definitions and diagnostic criteria. In: Clinical Diagnosis and Management of Alzheimer’s Disease, 3rd edition. Gauthier S, editor. Informa Healthcare; 2006, pp. 3-15.

178. Teng E, Cummings JL. Behavior. In: Clinical Diagnosis and Management of Alzheimer’s Disease, 3rd edition. Gauthier S, editor. Informa Healthcare; 2006, pp.177-189.

179. Rogers SA, Lu PH, Cummings JL. Global cognitive impairment: the dementias. In: Guide to Neuropsychiatric Therapeutics. Coffey CE, McAllister TW, Silver JM, editors. Lippincott Williams & Wilkins; 2007, pp. 79-108.

180. Lu PH, Khanlou N, Cummings JL. Frontotemporal dementia and the orbitofrontal cortex. In: The Orbitofrontal Cortex. Zald DH, Rauch SL, editors. Oxford University Press; 2006. pp. 621-642.

181. Cummings JL, Miller BL. Conceptual and clinical aspects of the frontal lobes. In: The Human Frontal Lobes. Miller BL, Cummings JL (editors). Taylor & Francis Group; 2007, pp. 12-21.

182. Marshall GA, Cummings JL. Affective disorders. In: Neurology and Clinical Neuroscience. Schapira AHV, editor; Byrne E, DiMauro S, Frackowiak RSJ, Johnson RT, Mizuno Y, Samuels MA, Silberstein SD, Wszolek ZK, associate editors. Mosby Elsevier; 2007, pp. 235-247.

70

183. Apostolova LG, Cummings JL. The pathogenesis of Alzheimer’s disease: general overview. In: Protein Misfolding, Aggregation, and Conformational Diseases. Part B: Molecular Mechanisms of Conformational Diseases Volume 6. Atassi MZ, editor in chief; Uversky VN, Fink AL editors. Springer; 2007, pp. 3-29.

184. Cummings JL. Progress in neurotherapeutics and neuropsychopharmacology. In: Progress in Neurotherapeutics and Neuropsychopharmacology Volume 2. Cummings JL, editor in chief. Cambridge University Press; 2007, pp. 1-12.

185. Raya-Ampil E, Cummings JL. Clinical trials in dementia. In: Progress in Neurotherapeutics and Neuropsychopharmacology Volume 2. Cummings JL, editor in chief. Cambridge University Press; London. 2007, pp. 39-78.

186. Marshall GA, Cummings JL. Behavioral syndromes and their treatment. In: Blue Books of Neurology/The Dementias 2. Schapira AHV, Samuels MA, series editors, Growdon JH, Rossor MN, volume editors. Butterworth Heinemann Elsevier, 2007, pp. 441-428.

187. Reichman, WE, Cummings JL. Dementia. In: Practice of Geriatrics, Fourth Edition. Duthie EH, Katz PR, Malone ML, editors. Saunders Elsevier 2007, pp. 319-334.

188. Swanberg MM, Nasreddine ZS, Mendez MF, Cummings JL. Speech and Language. In: Textbook of clinical neurology, 2nd ed. Goetz CG, editor. Saunders Elsevier 2007, pp. 79-98.

189. Apostolova LG, Cummings JL. Neuropsychiatric aspects of Alzheimer’s disease and other dementing illnesses. In: The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences, Fifth Edition. Yudofsky SC, Hales RE, editors. American Psychiatric Publishing, Inc.; Washington, DC. 2007, pp. 935-967.

190. Marshall, GA, Cummings JL. Neuropsychiatric evaluation in dementia. In: Handbook of Clinical Neurology. Volume 89. Aminoff MJ, Boller F, Swaab DF (editors). Elsevier, Amsterdam; 2008, pp. 53-61.

191. Ringman JM, Cummings JL. Pharmacologic interventions for cognition in dementia. In: Cognitive Neurorehabilitation, Second Edition: Evidence and Application. Stuss DT, Winocur G, Robertson IH, editors. Cambridge University Press, 2008, pp. 334-347.

192. Mc Pherson S, Cummings J. Neuropsychological aspects of Parkinson’s disease and Parkinsonism. In: Neuropsychological Assessment of Neuropsyciatric and Neuromedical Disorders, Third Edition. Grant I, Adams KM, editors. Oxford University Press, New York, 2009, pp. 199-222.

193. Ringman JM, Cummings JL. The genetic basis for the cognitive deterioration of Alzheimer’s disease. In: The Genetics of Cognitive Nuroscience. Goldberg TE, Weinberger DR, editors. Massachusetts Institute of Technology, Cambridge, MA. 2009, pp. 221-244.

194. Hemrungrojn S, Cummings JL. Dementia in nursing home patients: assessment and management. In: Psychiatry in Long-Term Care, Second Edition. Reichman WE, Katz PR, editors. Oxford University Press, New York. 2009, pp. 17-53.

195. Teng E, Marshall GA, Cummings JL. Neuropsychiatric features of dementia. In: The Behavioral Neurology of Dementia. Miller BL, Boeve BF, editors. Cambridge University Press, New York. 2009, pp. 85-100.

196. Apostolova LG, Cummings JL. Neuropsychiatric aspects of Alzheimer’s disease and other dementing illnesses. In: Essentials of Neuropsychiatry and Behavioral Neurosciences. Yudofsky SC, Hales RE, editors. American Psychiatric Publishing, Inc., Arlington, VA. 2010, pp. 409-432

197. Mendez MF, Vinters HV, Cummings, JL. Frontotemporal dementia and related syndromes. In: Clinical Neurology of Aging, Third Edition. Albert ML, Knoefel JE, editors. Oxford Univesity Press, New York. 2011, pp. 197-211.

198. Apostolova LG, Cummings JL. Alzheimer’s disease and other dementing illnesses. In: Clinical Manual of Neuropsychiatry. Yudofsky SC, Hales RE, editors. American Psychiatric Publishing, Inc., Arlington, VA. 2012, pp. 311-338.

199. Aisen PS, Cummings JL, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. In: The Biology of Alzheimer Disease. Selkoe DJ, Mandelkow E, Holtzman DM, editors. Cold Spring Harb Perspect Med. 2012, pp. 475-496.

71

200. Grill J, Cummings JL. Alzheimer’s disease. In: Clinical Trials in Neurology. Ravina B, Cummings Jl, McDermott M, Poole RM, editors. Cambridge University Press, New York. 2012. pp 227-241.

201. Wint D, Cummings J. Comorbid Neurological Illness. In: Late-Life Mood Disorders. Laveretsky H, Sajatovic M, Reynolds III C, editors. Oxford University Press, New York. 2013. pp 295-314.

202. Cummings JL, Dubois B, Molinuevo JL, Scheltens P. International Work Group Criteria for the Diagnosis of Alzheimer Disease. In: Early Diagnosis and Intervention in Predementia Alzheimer’s Disease. Molinuevo JL, Cummings JL, Dubois B, Scheltens P, editors. Elsevier, Pennsylvania. 2013. pp.363-368.

203. Grill JD, Cummings J. Disease Modifying Therapies For Alzheimer’s Disease. In: Neurobiology of Mental Illness. Charney DS, Sklar P, Buxbaum JD, Nestler EJ, editors. Oxford University Press, New York. 2013. pp 854 – 871.

204. Walsh R, Cummings J. Clinical trials for psychotropic agents in Parkinson’s disease using psychosis as a model. In: Neuropsychiatric and Cognitive Changes in Parkinson’s Disease and Related Movement Disorders: Diagnosis and Management. Aarsland D, Cummings J, Weintraub D, Chaudhuri KR, editors. Cambridge University Press, New York. 2013. pp244 – 253

205. Cummings J, Aarsland D. Treatment of neuropsychiatric disturbances in Parkinson’s disease: future prospects and strategies. In: Neuropsychiatric and Cognitive Changes in Parkinson’s Disease and Related Movement Disorders: Diagnosis and Management. Aarsland D, Cummings J, Weintraub D, Chaudhuri KR, editors. Cambridge University Press, New York. 2013. pp 285 – 253

206. Cummings J, Zhong K. Challenges and opportunities to conduct global Alzheimer’s disease clinical trials. In: Global Clinical Trials for Alzheimer’s Disease. Bairu M, Weiner M, editors. Elsevier, New York. 2014. pp 61-75

207. Tsai P, Cummings JL. Treatment of Alzheimer’s Disease. In: The Behavioral Neurology of Dementia, 2nd ed. Miller B, Boeve B, editors. Cambridge University Press, United Kingdom. 2016. pp 415-424

208. Cummings JL, Zhong K. Symptomatic cognitive enhancing agents. In: Developing Therapeutics for Alzheimer’s Disease Progress and Challenges. Wolfe MS editor. Elsevier, New York. 2016. pp459-475

209. Wint D, Cummings JL. Neuropsychiatric aspects of cognitive impairment. In: Oxford Textbook of Cognitive Neurology and Dementia. Husain M, Schott JM editors. Oxford University Press, United Kingdom. 2016. pp197-201

Monographs 1. Cummings JL, Benson DF. Alzheimer's disease: A practitioner's guide. French Foundation for Alzheimer's Research, Los Angeles, l994.

2. Cummings JL. Treatment of Alzheimer’s disease. Pfizer Pharmaceuticals, New York, 1996.

3. Cummings JL, Booss J, Dickinson BD, Hazelwood MG, Cooley SG, Jarvik LF, Matuszewski KA, Mohs RG, Goodwin ME. Dementia identification and assessment: guidelines for primary care practitioners. US Department of Veterans Affairs at the University Health System Consortium, Washington, DC, 1997.

4. Cummings JL, Kaufer DI. Brief screening tools for dementia assessment. Center for Advanced , Lambertville, New Jersey, 1998.

5. Sunderland T, Cummings JL, Christensen DD. Understanding and managing behavioral problems in Alzheimer’s disease. Maricopa Integrated Health System, 1998.

6. Cummings JL, Raskind MA, Lin P, Galasko D. Clinical trial outcome measures to evaluate potential disease-modifying therapies in Alzheimer’s disease: Application in clinical practice. CNS News Special Report, Myriad Pharmaceuticals, May 2006.

Abstracts 1. Cummings JL, Oppenheimer EY. Tuberous sclerosis presenting with gynecomastia and sexual precocity. Proceed 6th Nat’l Meet Child Neurol Soc. Abstract 52 (1977).

2. Cummings JL, Benson DF, Walsh MJ, Levine HL. Left to right transfer of cerebral dominance: a case study. Neurol 29:599 (l979); American Academy of Neurology, Chicago, April, l979. 72

3. Obler LK, Cummings JL, Albert ML. Subcortical dementia: speech and language functions. Am Geriatric Soc, April l979.

4. Adams D, Cummings J, Hart E, Rosman NP. An idiot Savant calendar calculator: case report and review of explanations. Neurol 30: 390 (l980). American Academy of Neurology, New Orleans, April, 1980.

5. Cummings JL, Duchen LW. The Kluver-Bucy syndrome in Pick's disease. Neurol 3l (No 4, Pt 2):82 (l98l). American Academy of Neurology, Toronto, Canada, April, l98l.

6. Benson DF, Cummings JL, and Kuhl DE. Dementia: Cortical-Subcortical. Neurol 3l (no 4, Pt 2):l0l (l98l). American Academy of Neurology, Toronto, Canada, l98l.

7. Benson DF, Kuhl DE, Phelps ME, Cummings JL, and Tsai SY. Positron emission computed tomography in the diagnosis of dementia. Am Neurol Assoc., San Francisco, September, l98l; Trans Am Neurol Assoc l06:68-70 (l98l).

8. Cummings JL, Benson DF, and Tsai SY. Angular gyrus syndrome simulating Alzheimer's disease. American Academy of Neurology, Washington, DC, April l982, Neurol 32(2):A96 (l982).

9. Lilly R, Cummings JL, Benson DF, and Frankel M. Clinical occurrence of the Kluver-Bucy syndrome. American Academy of Neurology, Washington, DC, April l982; Neurol 32(2):A96 (l982).

10. Horowitz S, Benson DF, Kuhl DE, and Cummings JL. FDG scan to confirm Creutzfeldt-Jakob diagnosis. American Academy of Neurology, Washington, DC, April l982; Neurol 32(2):Al67 (l982).

11. Cummings JL, Landis T, and Benson DF. Environmental disorientation: clinical and radiologic findings. American Academy of Neurology, San Diego, April l983; Neurol 33(2):l03-l04 (l983).

12. Cummings JL, Benson DF, Hill MA, and Read S. Aphasia in Alzheimer's disease. American Academy of Neurology, Boston, April l2, l984. Neurol 34(l):l03 (l984).

13. Syndulko K, Pettler-Jennings P, Cohen SN, Cummings J, Halgren E, and Tourtellotte WW. P300 in memory disorders of diverse etiology. American Academy of Neurology, Boston, Massachusetts, April l2, l984. Neurol 34(l):PP298 (l984).

14. Landis T, Christen L, and Cummings JL. Prosopagnosia and associated symptoms in unilateral right posterior lesions: clinical and radiological findings in five patients. 2nd European Workshop in Cognitive Neuropsychology, Bressanone, Italy, January, l984.

15. Landis T, Christen L, and Cummings JL. Prosopagnosie bei unilateral rechts-posterioren Lasionen: Klinische und radiologischne Befunde von funf Patienten. Swiss Neurological Society, May, l984. Schw Arch Neurol Psychiat l36:79 (l985).

16. Miller BL, Cummings JL, McIntyre H, Grode M, and Ebars G. Hypersexuality and changes in sexual preference following brain injury. Am Acad Neurol, Dallas, Texas, April l985. Neurol 35(l):162 (l985).

17. Cummings JL, Frankel M, Robertson M, Trimble MR, Hill MA, and Benson DF. Obsessions and compulsions in Gilles de la Tourette syndrome. Am Acad Neurol, Dallas, Texas, April l985. Neuro 35:239 (l985).

18. Mendez MF, Cummings JL, Benson DF, and Hill MA. Depression in epilepsy: prevalence and phenomenology. Am Acad Neurol, Dallas, Texas, April, l985. Neurol 35(l):230-23l (l985).

19. Cohen SN, Syndulko K, Osterweil D, Pettler-Jennings P, Hirschman J, Cummings JL, Solomon D, and Tourtellotte WW. Event- related potential and neuropsychological testing in non-demented hypothyroid patients. Am Acad Neurol, Dallas, Texas, April, l985. Neurol 35(l):98 (l985).

20. Osterweil D, Cohen SN, Syndulko K, Cummings JL, Solomon D, Hirschman J, and Tourtellotte WW. Cognitive function in hypothyroid elderly. Western Society of Clinical Investigation. Carmel, CA, February 7, l985.

21. Osterweil D, Cohen SN, Syndulko K, Cummings JL, Solomon D, Hirschman J, and Tourtellotte WW. Cognitive Probabilistic Brain Atlases. Society For Neuroscience 1997;23: 2173. Function in hypothyroid elderly. International Congress of Gerontology, New York, New York, July, l985. 73

22. Van Lancker DR, Kreiman J, and Cummings JL. Voice recognition and discrimination: New evidence for a double dissociation. International Neuropsychological Society. Denver, Colorado, l986. J Clin Exp Neuropsych 7:609 (l985).

23. Shapira J and Cummings JL. Dementia of the Alzheimer type: family reactions to progressive impairment. Sigma Theta Tau Annual Research Day (Gamma Tau Chapter). Duarte, CA, February 28, l986.

24. Cummings JL. Multi-infarct dementia. Dementia Symposium. Am Psychiatr Assn Washington, D.C., May l6, l986.

25. Read SL, Frazee JG, Smith C, Shapira J, Cummings JL, and Satz P. Intraventricular bethanechol for Alzheimer's disease. Am Psychiatr Assn, Washington D.C., May l3, l986.

26. Neshkes R, Cummings JL, Miller BL, and Hill MA. Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer type. Am Geriatr Soc, Philadelphia, November, l986.

27. Smith CA, Read SL, Satz P, Frazee JG, Shapira J, and Cummings JL. Neuropsychological response to cholinergic stimulation in five patients with Alzheimer's disease (AD). International Neuro-psychological Society, J Clin Exp Neuropsych 1987;9:l7. Washington, DC, February, l987.

28. Mendez M, Cleveland OH, Cummings JL, Darkins AW. Alzheimer’s disease and Parkinson’s disease: Comparison of speech and language alterations. Am Acad Neurol, New York City, March 1987 Neurology 37 (Suppl 1): 227, 1987.

29. Powell A, Brunswick NJ, Cummings JL, Hill MA, Benson DF. Multi-infarct dementia and Alzheimer’s disease: Abnormalities of verbal output. Am Acad Neurol, New York City, March 1987. Neurology 37 (Suppl 1):226, 1987.

30. Davis J and Cummings JL. Clinical variants of tardive dyskinesia. Am Acad Neurol, New York City, April l987. Neurology 37 (l):26l, l987.

31. Powell A, Cummings JL, Hill MA, and Benson DF. Speech and language alterations in Parkinson's disease: comparison with dementia of the Alzheimer type. Am Acad Neurol, New York City, April, l987. Neurology 37 (Suppl l):227, l987.

32. Aharon J, Cummings JL. Periventricular lucencies in Alzheimer's disease and vascular dementia. Am Acad Neurol, New York City, April l987. Neurology 37 (Suppl l):329, l987.

33. Van Lancker DR, Kreiman J, Cummings JL. Phonagnosia: neuroanatomical correlates and moropsychological model of voice perception. Am Acad of Aphasia, Phoenix, Arizona, October 26, l987.

34. Shapira J and Cummings JL. Sexual alterations in dementia of the Alzheimer type. Octoberquest Nursing Research Conference, Los Angeles, California, October 23, l987.

35. Pahl JJ, Bartzokis G, Mazziotta JC, Cummings JL, Altshuler L, Phelps ME. Positronenemissiontomographia (PET) in der schizophrenieforschung: l980-l987. Symposium: D/C Schizophrenien Biologishe und familiendynamische Konzept zur Pathogense. Koln, Germany, November 6, l987.

36. Pahl JJ, Mazziotta JC, Cummings JL, Bartzokis G, Marder S, Schwab R, Sumida R, Kuhl DE, Baxter L, Phelps ME. Positron emission tomography in tardive dyskinesia and Huntington's disease: LCMRG/c in two patient populations with chorea. J Cereb Blood Flow Metab 7 (Suppl l), S373, l987.

36. Freidenberg DL, Cummings JL, Bartzokis G, Wirshing W. Anticholinergic effects on mixed-frequency drug-induced movement disorders. Neurology 38 (Suppl 1):362, March 1988

37. Pahl JJ, Bartzokis G, Mazziotta JC, Cummings JL, Altshuler L, Marder S, Phelps ME. PET studies in tardive dyskinesia. Am Acad Neurol, Cincinnati, Ohio, April l988, Neurology 1988;38(Suppl l):400.

38. Wirshing WC, Cummings JL. The electromechanical characteristics of tardive dyskinesia. Winter Workshop on Schizophrenia. Badgastein, Austria. January 26, l987. Schizophrenia Res 1989;3:240.

74

39. Pahl JJ, Mazziotta JC, Bartzokis G, Cummings JL, Baxter LR, Sumida R, Phelps ME. Metabolic dysfunction in tardive dyskinesia and Huntington's disease. Am Acad Neurol, Cincinnati, Ohio, April, l988, Neurology 1988;38 (Suppl l):30l.

40. Freidenberg D, Cummings JL, Bartzokis G, Wirshing W. Anticholinergic effects of mixed-frequency drug-induced movement disorders. Am Acad Neurol, Cincinnati, Ohio, April, l988.

41. Cummings JL. Depression in multi-infarct dementia. Depression Symposium; M. Dysken, Chairman, Am Psychiatric Assoc, Montreal, Canada, May, 1988.

42. Pahl JJ, Bartzokis G, Mazziotta JC, Cummings JL, Altshuler L, Marder S. Pallidal hypermetabolism in schizophrenics with TC. Am Psychiatric Assn, Montreal, Canada, May l0, l988.

43. Pahl JJ, Mazziotta JC, Bartzokis G, Cummings JL, Altshuler L, Marder S, Phelps ME. PET studies of the motor system in tardive dyskinesia. Soc Nuc Med, San Francisco, June l5, l988.

44. Pahl JJ, Mazziotta JC, Hawkins RA, Bartzokis G, Cummings JL, Altshuler L, Marder S, Phelps ME. PET in hyperkinetic movement disorders. Soc Nuc Med, San Francisco, June l5, l988.

45. Cummings JL. Neuropsychiatric aspects of neurologic disease. Neurology 39 (Suppl 1): 86, 1989.

46. Flynn F, Cummings JL, Gornbein J. Neuropsychological and behavioral correlates of delusions in dementia syndromes. Am Acad Neurol, April l990, Miami, Florida.

47. Liu CK, Miller BL, Cummings JL, Benson DF, Villanueva-Meyer J, Mehringer CM, Goldberg M, Mena I, Garrett K. MRI and SPECT in stroke and vascular dementia. Neurology 40 (Suppl l): l74-l75, l990.

48. Miller BL, Cummings JL, Lesser IM, Boone K, Villanueva-Meyer J, Pugliese G, Garrett K, Mena I. Frontal lobe degeneration: neurobehavioral and cerebral blood flow characteristics with SPECT. Neurology 40 (Suppl l):l74, l990.

49. Reichman WE, Cummings JL, Flynn F, McDaniel K, Gornbein J. Analysis of visuoconstructional impairment in dementia syndromes. Neurology 40 (Suppl l):449, l990.

50. Flynn FG, Cummings JL, Gornbein J. Neuropsychological and behavioral correlates of delusions in Alzheimer's disease and multi- infarct dementia. Neurology 40 (Suppl l):449, l990.

51. Hinkin CH, Van Gorp WV, Cummings JL, Mitrushina M, Satz P, Freeman D. HIV-l encephalopathy and normal aging: pattern of neuropsychological test performance. Paper presented at the Conference on Neurological and Neuropsychological Complications of HIV Infection: A Satellite Conference of the VI International AIDS Conference, Monterey, California, l990.

52. Mahler ME, Sultzer D, Hinkin C, Cummings JL, Mandelkern M, Shapira J, Van Gorp W, Klonsary A, Blahd W. Glucose PET in dementia. DAT and MID compared. Neurology l99l; 4l (Suppl l):ll9 (abstract presented at AAN).

53. Ross W, Engel P, Cummings JL. Mini-Mental State and Neurobehavior Cognitive Status Examinations in vascular and Alzheimer's dementias. Neurology l99l; 4l (Suppl l):406 (abstract presented at AAN).

54. Wirshing W, Ames D, Van Putten T, Marder SR, Bartzokis G, Cummings JL. Selegiline in the treatment of akathisia. American Psychiatric Association, Annual Meeting, New Orleans, May, l99l.

55. Ames D, Wirshing WC, Lee MA, Cummings JL, Van Putten T, Marder SR, Bartzokis G. Selegiline in the treatment of akathisia, tardive dyskinesia, and negative schizophrenic symptoms. Presented at Winter Workshop on Schizophrenia, Strausburg, Austria, l/30/92. Schizo Bull 1992;6:ll0-lll.

56. Cummings JL. Depression in Parkinson's disease. Biol Psychiatry Annual Meeting, Washington, 4/30/92. Biol Psychiatry l992;3l:GlA.

57. Cummings JL. Neurological disorders with obsessive-compulsive disorder. American Psychiatric Association, Washington, D.C., 5/2/92.

75

58. Cummings JL. Neurology of mood and affect. American Psychiatric Association, Washington, D.C., 5/5/92.

59. Cummings JL. Neuropsychiatric aspects of Parkinson's disease. American Psychiatric Association, Washington, D.C., 5/5/92.

60. Cummings JL. Neuropsychiatric aspects of Alzheimer's disease. American Psychiatric Association, Washington, D.C., 5/7/92.

61. Wirshing WC, Cummings JL, Ames D, Marder SR, Van Putten T, Bartzokis G. Instrumental quantification of tardive dyskinesia: Is it practical, feasible, or useful? American Psychiatric Association, Washington, D.C., 8/7/92 (Poster N60E).

62. Wirshing WC, Ames D, Cummings JL, Van Putten T, Marder SR, Bartzokis G, Lee MA. Selegiline and akathisia, tardive dyskinesia, and negative schizophrenic symptoms. Clin Neuropharm 1992;l5l (Suppl l): 27lB.

63. Sultzer DL, Mahler ME, Hinkin C, Mandelkern MA, Cummings JL, Van Gorp WG, Quonnones N, Khonsori A, Ropchan JR, Blahd WH. Psychiatric symptoms are associated with cortical hypometabolism in patients with Alzheimer's disease. Presented at the annual meeting of the American Association for Geriatric Psychiatry, New Orleans, February, l993.

64. Moore LH, Cummings JL, Van Gorp W, Hinkin C, Mahler M, Perlman S, Cederbaum S. Patterns of neuropsychological performance among forms of subcortical dementia. American Psychological Association, Toronto, Canada, August, l993.

65. Chang L, Miller BL, Scharre DW, Cummings JL, Vigo-Pelfry C, Schenk D. B-amyloid protein in cerebrospinal fluid of Alzheimer's disease: correlation with MMSE. American Academy of Neurology. Washington, D.C., l994 Neurology 1994;44, (Suppl. 2):A206;.

66. Mega MS, Cummings JL. Behavioral changes in Alzheimer's disease. American Academy of Neurology, Washington, D.C., l994 Neurology 44, (Suppl. l): A240.

67. Ponton MO, Miller BL, Darcourt J, Cummings JL, Schumann SW, Mena I. SPECT in Capgras syndrome: evidence for right temporal dysfunction. American Academy of Neurology, Washington, D.C., l994 Neurology 1994;44 , (Suppl. 2): A402.

68. Cummings JL. Frontal-subcortical dysfunction and neuro-psychiatric illness. J Neuropsychiatry Clin Neurosci 1994; 6:299-300.

69. Hinkin CH, Sultzer DL, Mahler ME, Mandelkern MA, Cummings JL, Van Gorp WG, Durvasula R, Ropchan JR, Beahd WW. Frontal hypometabolism and executive dysfunction in Alzheimer's Disease. J Internat Neuropsychological Soc 1:146, 1995.

70. Miller BL, Cummings JL, Boone K, Chang L, Schuman S, Pachana N, Darby A. Clinical and neurobehavioral 1995.characteristics of fronto-temporal dementia and Alzheimer's Disease. Neurology 45 (Supplement 4): A318-319:

71. Masterman DL, Cummings JL. Sensitivity and specificity of Tc99-HMPAO SPECT in discriminating Alzheimer's Disease patients from other patients with memory complaints. Neurology 45 (Supplement 4): A405: 1995.

72. Kaufer DI, Cummings JL. Does dementia severity predict response to Tacrine in Alzheimer's Disease? Neurology 45 (Supplement 4): A471-472: 1995.

73. Cummings JL. Frontal-subcortical circuits: anatomic, clinical, and pharmacologic aspects. J Psychopharmacol 3 (Supplement to Vol. 9), A3-12: 1995.

74. Kaufer DI, Cummings JL. Response of behavioral symptoms in Alzheimer's disease (AD) to tacrine. J Neuropsychiatry Clin Neurosci 7:397: 1995.

75. Mega MS, Xu TJ, Karaca LL, Altshuler LL, Payne BA, Cohen MS, Small GW, Cummings JL, Toga AW. Standardization of MRI volumetric studies: Hippocampal atrophy predates clinical symptoms in individuals at risk for Alzheimer's Disease. Neurology 46 A133: 1996.

76. Edwards-Lee T, Miller B, Cummings JL, Boone K. The temporal lobe variant of frontotemporal dementia. Neurology 46 A178: 1996.

77. Miller BL, Ikonte C, Cummings JL, Levy M, Darby A, Schuman S. Evaluation of the Lund Manchester criteria for frontotemporal dementia. Neurology 46 A185: 1996.

76

78. Cherrier MM, Mendez MF, Perryman KM, Miller BL, Cummings JL. Frontotemporal dementia versus Alzheimer's Disease: Differential Cognitive Features. Neurology 46 A186: 1996.

79. Kaufer D, Itti L, Miller B, Fairbanks J, Li J, Fishman J, Cummings JL. Midline cerebral morphometry discriminates frontotemporal dementia and Alzheimer's Disease. Neurology 46A186: 1996.

80. Sultzer DL, Cummings JL, Mahler ME, Berisford MA, Mandelkern MA, Hinkin CH. Depression and PET imaging in Alzheimer's disease.

81. Van Lancker D, Pachana NA, Cummings JL, Erickson C, Sidtis J. Dysprosodic speech following basal ganglia stroke: role of frontosubcortical circuits. J Internat Neuropsychological Society. 1996;83.

82. Cummings JL, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate in Alzheimer's disease - results of a dose-finding study. International Conference on Alzheimer's Disease and Related Disorders, Fifth. Osaka, Japan, July, 1996.

83. Cummings JL. Cholinergic treatment of behavioral disturbances in Alzheimer's disease. International Conference on Alzheimer's Disease and Related Disorders, Fifth. Osaka, Japan, July, 1996.

84. Thompson PM, Mega MS, Moussai J, Zohoori S, Goldkorn A, Khan AA, Coyrell J, Small G, Cummings JL, Toga AW. probabilistic atlas and average surface representation of the Alzheimer’s brain, with local variability and probability maps of the ventricles and deep cortex. Neurosci Abs 1996;22:1105.

85. Thompson PM, MS, Blanton RE, Moussai J, Khan AA, Zohoori S, Mogy J, Aron J, Goldkorn A, Holmes CJ, Small G, Cummings JL, MacDonald D, Evans AC, Collins RC, Toga AW. A detection system for mapping abnormal structure, anatomic variability and brain symmetry in Alzheimer’s disease and aging with 3D deformable probabilistic brain atlases. Neurosci Abs 1997;23:2173.

86. Mendez MF, Engebrit B, Doss R, Miller BL, Cummings JL. Clinical characteristics of epileptic auras with cognitive manifestations. J Neuropsychiatry Clin Neurosci 1997;9:145.

87. Ponton MO, Miller BL, Urrutia C, Mares M, Cummings JL. Clinical validity of the Neuropsychological Screening Battery for Hispanics (NeSBHIS) with an elderly demented population. J Neuropsychiatry Clin Neurosci 1997;9:166.

88. Kaufer D, Cummings J, Christine D, Bray T, Castellon S. Assessing the caregiver impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale. J Neuropsychiatry Clin Neurosci 1997;9:173.

89. Mendez MF, Miller BL, Cummings JL. Compulsions and hoarding behavior in frontotemporal dementia. J Neuropsychiatry Clin Neurosci 1997;9:174.

90. Wang AY, Mega MS, Pourrabbani S, Cheng Y, Brooks AJ, Vinters HV, Cummings JL. Divergent Lewy Body Burden in Limbic Versus Neocortex Across Alzheimer's Disease Severity Stages. Ann Neurol 1997;Vol 42 No 3.

91. Aarsland D, Larsen JP, Tandberg E, Cummings JL. Depression, psychosis, and dementia in Parkinson's disease: a community-based study. J Neuropsychiatry Clin Neurosci 1997;9:177.

92. Russell GL, Miller BL, Mena I, Cummings JL. Frontotemporal degeneration: frontal lobe variant vs. temporal lobe variant. J Neuropsychiatry Clin Neurosci 1997;9:180.

93. Tom TW, Cummings JL. Posterior cortical atrophy. J Neuropsychiatry Clin Neurosci 1997;9:180.

94. Tom TW, Wang AY, Mega MS, Tomiyasu U, Vinters HV, Masterman DL, Cummings JL. The relationship between Lewy bodies, neurofibrillary tangles, and senile plaques in hippocampi from patients with dementing disorders. Neurology 1997;48:A141.

95. Wang AY, Mega MS, Pourrabbani H, Vinters V, Cummings JL. Limbic And Neocortical Subgroups in Alzheimer's Disease With Lewy Bodies Based On Braak & Braak Plaque Staging. Society For Neuroscience, 1997;Vol 23.

97. Thompson PM, Mega MS, Blanton RE, Moussai J, Khan AA, Zohori S, Mogv J, Goldkorn A, Holmes CJ, Small G, Cummings JL, Macdonald D, Evans AC, Collins RC, Toga AW. A Detection System For Mapping Abnormal Structure, Anatomic Variability &

77

Brain Asymmetry In Alzheimer's Disease & Aging With 3D Deformable Probablistic Brain Atlases. Society for Neuroscience 1997;23: 2173.

98. Fuh JL, Mega MS, Thompson PM, Cummings JL, Toga AW. Cortical complexity maps and cognition in Alzheimer's disease. J Neuropsychiatry 1997;9: No 4.

99. Paulsen JS, Mega MS, Cummings JL. The spectrum of behavioral changes in Huntington's disease. J Neuropsychiatry 1997.

100. Thompson PM, Mega MS, Blanton RE, Moussai J, Zohori S, Goldkorn A, Holmes CJ, Macdonald D, Small W, Cummings JL. Three-dimensional patterns of abnormal brain structure, anatomic variation, and asymmetry in Alzheimer's disease. J Neuropsychiatry 1997.

101. Masterman DL, Bronstein J, Desalles AF, Foti DF, Cummings JL. Cognitive and behavioral performance following unilateral ventroposterior pallidotomy. Neurology 1997;48:A252-253.

102. Miller BL, Swartz JR, Koras NL, Suarez R, Kushi J, Cummings JL. Early symptoms in frontotemporal dementia. Neurology 1997;48:A50.

103. Cummings JL. Cholinergic treatment of behavioral disturbances in Alzheimer's disease. Biol Psychiatry 1997;42:124S.

104. Cummings JL. Non-cognitive manifestations of Alzheimer's disease: effects of cholinergic therapy. Alzheimer's Disease International, 13th. Helsinki, Finland, September 29 - October 2, 1997.

105. Litvan I, Cummings Jl, Mega M, Neuropsychiatric Features of Corticobasal Degeneration. American Neurological Association 1998.

106. Back C, McPherson S, Cummings JL, Fairbanks L. Functional ability in frontal variant AD and conventional AD. J Internat Neuropsychological Soc 1998;4:31.

107. Wilkins S, White K, Cummings JL. Utility of the Neuropsychiatric Inventory in a geriatric medical population. J Internat Neuropsychological Soc 1998;4:33.

108. Cummings JL, Cyrus PA, Bieber F, Orazem J, Mas J, Gulanski B. The effect of metrifonate on the cognitive, functional and behavioral symptoms of Alzheimer's disease. American Association for Geriatric Psychiatry, 11th. San Diego, California, March 8 - 11, 1998.

109. Leon J, Neumann PJ, Hermann RC, Hsu M-A, Cummings JL, Marin D, Doraiswamy PM. A cross-sectional study on the health related quality of life and health service utilization for mild, moderate, and severely impaired Alzheimer’s disease patients. Neurology 1998;50:A303.

110. Cummings JL, Cyrus PA, Ruzicka BB, Gulanski B. The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer’s disease patients. Neurology 1998;50:A251.

111. Mega MS, O’Connor SM, Lee L, Dinov ID, Cummings JL. Orbital frontal and anterior cingulate pretreatment perfusion defects on 99m Tc-HMPAO-SPECT are associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer’s disease. Neurology 1998;50:A250.

112. Lee L, Mega MS, Dinov ID, Cummings JL, Toga AW. Dorsolateral frontal and anterior cingulate perfusion defects on 99mTc- HMPAO-SPECT are associated with delusional behavior in Alzheimer’s disease. Neurology 1998;50:A362.

113. Miller BL, Cummings JL, Koras N, Mishkin F, Boone K, Read SL, Prince F, Cotman C. Emergence of visual or musical talent in frontotemporal dementia. Neurology 1998;50:A410.

114. Cummings JL. Organic disorders with psychotic features in the elderly. American Psychiatric Association, Toronto. Industry Symposia, pp. 310-311, 1998.

115. Cummings JL. Pathogenesis of Alzheimer’s disease. American Psychiatric Association, Toronto. Industry Symposia pp. 333, 1998.

78

116. Rozzini L, Frisoni GB, Gozzetti A, Binetti G, Zanetti O, Bianchetti A, Trabucchi M, Cummings JL. Behavioral syndromes in Alzheimer’s disease: description and correlates. Neurobiol Aging 1998;S24, 101. 117. Cummings JL. Fronto-temporal dementias vs. Alzheimer’s disease: distinctions in life. Workshop H: Hereditary fronto-temporal dementia and Pick’s disease. Neurobiol Aging 1998;S294, 1232.

118. Cummings JL. Cortical-subcortical networks related to behavioral disturbances. Int J Neuropsychopharmacol 1998;1(S1):S92.

119. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Lopez OL, DeKosky ST. Assessing neuropsychiatric symptoms in clinical practice: The Neuropsychiatric Inventory Questionnaire (NPI-Q). J Neuropsychiatry Clin Neurosci 1999;11:145-146.

120. Ringman JM, Cummings JL. Treatment of parasomnia with donepezil. J Neuropsychiatry Clin Neurosci. 1999; 11:145-146.

121. Ercoli LM, Huang S-C, Komo S, Bookheimer SY, Saxena S, Silverman DHS, Mega MS, Mazziotta JC, Wu HM, Cummings JL, Phelps ME. PET and genetic risk for Alzheimer disease. Society of ’s 46th Annual Meeting. June 6, 1999.

122. Bethesda JL, Neumann PJ, Hermann RC, Hsu M-A, Cummings JL, Marin D, Doraiswamy M. A cross-sectional study on the health related quality of life and health service utilization for mild, moderate, and severely impaired Alzheimer’s disease patients. American Academy of Neurology 50th Annual Meeting Program. Neurology 50:A303 (1998).

123. Miller BL, Cummings JL, Koras N, Mishkin F, Boone K, Read SL, Prince F, Cotman C. Emergence of visual or musical talent in frontotemporal dementia. American Academy of Neurology 50th Annual Meeting Program. Neurology 1998 50:A410.

124. Mega MS, O’Connor SM, Lee L, Dinov ID, Cummings JL, Toga A. Orbital frontal and anterior cingulate pretreatment perfusion defects on 99mTc-HMPAO-SPECT are associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer’s disease. American Academy of Neurology 50th Annual Meeting Program. Neurology 1998;50 (4):A250.

125. Cummings JL, Cyrus PA, Ruzicka BB, Gulanski B. The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer’s disease patients. American Academy of Neurology 50th Annual Program. Neurology 1998;50 (4):A251.

126. Lee L, Mega MS, Dinov ID, Cummings JL, Toga AW. Dorsolateral frontal and anterior cingulate perfusion defects on 99mTc- HMPAO-SPECT are associated with delusional behavior in Alzheimer’s disease. American Academy of Neurology 50th Annual Program. Neurology 1998 l;50 (4):A362.

127. Mega MS, Woods RP, Thompson PM, Dinoy ID, Lee L, Aron J, Zoumalan CI, Cummings JL, Toga A. Detecting metabolic patterns associated with minimal cognitive impairment using FDG-PET analysis within a probabilistic brain atlas based upon continuum mechanics. Society for Neuroscience 28th Annual Meeting. Society for Neuroscience Abstracts 1998 Nov;24 (2):1269.

128. Thompson PM, Mega MS, Woods RP, Blanton RE, Moussai J, Zoumalan CI, Cummings JL, MacDonald D, Evans AC, Toga AW. Detecting 3D patterns of Alzheimer’s disease pathology with probabilistic brain atlas based on continuum mechanics. Annual Conference of the American Academy of Neurology, Neurology 1999;52(6): A368 Suppl.

129. Thompson PM, Mega MS, Woods RP, Blanton RE, Moussai J, Zoumalan CI, Aron J, Cummings JL, Toga AW. 3D probabilistic atlas of the in Alzheimer’s disease: emerging patterns of variability, asymmetry and degeneration. NeuroImage 1999;9(6):S597.

130. Mega MS, Cummings JL, Dinov ID, Masterman DM, Felix J, O'Connor MO, Reback ER, Toga AW. Metrifonate clinical benefits are correlated with activation of specific neuronal networks. American Neurological Association 1999.

131. Kwong EM, Mega MS, Thompson PM, Mina LX, Ercoli LM, Cummings JL, Small GW, Felix J, Toga AW. Three Dimensional Hippocampal Maps in Normal Aging, Older Persons with Mild Cognitive Impairment and Patients with Alzheimer's Disease. Neurology 1999;52.

132. Felix J, Mega MS, Dinov ID, Toga AW, Cummings JL. Perfusion in the Parietal Cortex and Dorsolateral Bilaterally are Associated with Depressed Mood in Alzheimer's Disease Patients: A 99mTc-HMPAO SPECT Analysis. NeuroImage 1999;9.

79

133. Thompson PM, Mega MS, Woods RP, Blanton RE, Moussai J, Zoumalan CI, Aron J, Cummings JL, Toga AW. A Probablistic Atlas of the Human Brain in Alzheimer's Disease: Emerging Patterns of Variability, Asymmetry and Degeneration. NeuroImage 1999;9, No 6, 5597.

134. Small GW, Ercoli LM, Huang SC, Komo S, Bookheimer SY, Saxena S, Silverman DH, Mega MS, Mazziotta JC, Wu HM, Cummings JL, Phelps ME. Pet And Genetic Risk For Alzheimer's Disease. J Nuclear Med 1999;No. 283.

135. Thompson PM, Mega MS, Woods RP, Blanton RE, Moussai J, Zoumalan CI, Cummings JL, MacDonald D, Evans AC, Toga AW. Detecting 3D patterns of Alzheimer’s disease pathology with a disease-specific population-based probabilistic brain atlas. Neurosci Abs 1999;25: 1801.

136. Thompson PM, Mega MS, Woods RP, Blanton RE, Moussai J, Zoumalan CI, Cummings JL, MacDonald D, Evans AC, Toga AW. Detecting 3D patterns of Alzheimer’s disease pathology with disease-specific population-based probabilistic brain atlas. Proc. Society for Neuroscience, Miami, FL. October 1999.

137. Cummings JL. Behavior management over the course of Alzheimer's disease. American Psychiatric Association 152nd Annual Meeting. Washington D.C. (May 16, 1999).

138. Cummings JL. Assessment of neuropsychiatric disorders. American Psychiatric Association 152nd Annual Meeting. Washington D.C. (May 17, 1999).

139. Cummings JL. Assessment of behavioral disorders in dementia patients. World Psychiatric Association: Current Opinion in Psychiatry 12:34 (July 1999).

140. Cummings JL. Management of psychosis in neurologic disorders. World Psychiatric Association: Current Opinion in Psychiatry July 1999;12:94.

141. Halbreich U, Giorgio R, Shridhar S, Cummings J, Trimble M. Integration of Neurology and Psychiatry (and Round Table) World Psychiatric Association: Current Opinion in Psychiatry July 1999;12:446.

142. Mega MS, Felix J, Dinov ID, McPherson SM, Cummings JL, Toga AW. Anterior conulate and frontal polar hypoperfusion is associated with declines in verbal fluency in older persons with mild cognitive impairment: A 99mTc-HMPAO SPECT study. NeuroImage Abs 1999;9: p S350.

143. Mega MS, Thompson PM, Woods RP, Dinov ID, Zoumalan CI, Cummings JL, Mazziotta JC, Toga AW. Functional imaging analysis within an Alzheimer’s disease atlas: Cortical variability maps of anatomic and PET registration errors. Neurosci Abs 1999;25:15.

144. Thompson PM, Mega MS, Woods RP, Zoumalan CI, Lindshield CJ, Blanton RE, Moussai J, Holmes CJ, Dinov ID, Cummings JL, Toga AW. Early cortical change in Alzheimer’s disease detected with a disease-specific, population-based, probabilistic brain atlas. American Academy of Neurology, 2000.

145. Cummings JL. Neuropsychiatry in the elderly. The 3rd International Congress of Neuropsychiatry. Kyoto, Japan (April 9-13, 2000).

146. Cummings JL, Anand R, Koumaras B, Hartman R. Behavioral benefits in Alzheimer’s disease patients residing in a nursing home following 52 weeks of rivastigmine treatment. American Psychiatric Association 153rd Meeting. Chicago, IL (May 13-18, 2000).

147. Senanarong V, Harnphadugkit K, Udompunpurak S, Punthumchinda K, Poungvarin N, Cummings JL. Clock drawing test and activities of daily living questionnaires as a short screening test for dementia in Thai population. The 3rd International Congress of Neuropsychiatry. Kyoto, Japan (April 9-13, 2000).

148. Thompson PM, Mega MS, Woods RP, Zoumalan CI, Lindshield CJ, Blanton RE, Moussai J, Holmes CJ, Dinov ID, Cummings JL, Toga AW. Early cortical change in Alzheimer’s disease detected using cortical pattern matching and a disease-specific, population- based, probabilistic brain atlas. 6th International Conference on Functional Mapping of the Human Brain, San Antonio, Texas, June 2000.

149. Cummings JL. Update on pharmacologic management of behavioral disturbances in Alzheimer’s disease. Symposium Therapeutic Approaches. Neurobiol Aging July 9, 2000;21:S1-304. 80

150. Senanarong V, Vannasaeng S, Poungvarin N, Ploybutr S, Udompunthurak S, Chamjuras P, Cummings JL. Estrogen: associations for dementia risks and neuropsychiatric symptoms. Poster Presentation: Alzheimer’s disease and related dementias IV. Neurobiol Aging July 9, 2000;21: S1-304.Porter VR, Panossian L, Valenzuela HF, Zhu X, Rausch HR, Cummings JL, Effros RB. The role of telomere length and telomerase in the immunopathogenesis of Alzheimer’s disease. The 30th Annual Meeting of the Society for Neuroscience, New Orleans, LA, November 4-9, 2000.

151. Mega MS, Cummings JL, Masterman DM, Dinoz ID, Felix J, O’Connor SM, Toga AW. Metabolic responses to donepezil therapy in Alzheimer's disease. Neurology 2000; 54 (suppl 3).

152. Porter VR, Panossian L, Valenzuela HF, Zhu X, Rausch HR, Cummings JL, Effros RB. The role of telomere length and telomerase in the immunopathogenesis of Alzheimer’s disease. The 30th Annual Meeting of the Society for Neuroscience, New Orleans, LA, November 4-9, 2000.

153. Crabtree EC, Mega MS, Lindshield C, Dinov ID, Thompson PM, Felix J, notestine-Fennema C, Archibald SL, Jernigan TL, Cummings JL, Toga AW. Alzheimer grey matter loss across time: assessment using a probablistic Alzheimer brain atlas. Society for Neuroscience, 2000; 26.

154. Toga AW, Thompson PM, Mega MS, Cummings JL. Detecting dynamic (4D) profiles of degenerative rates in Alzheimer's disease patients, using tensor mapping and a population-based brain atlas. Society for Neuroscience, 2000; 26.

155. Geula C, Farlow M, Cummings JL, Morris J, Scheltens P, Anand R. Alzheimer’s disease: translating neurochemical insights into clinical benefits. J Clin Psychiatry 2000;61:791-802.

156. Dinov ID, Mega MS, Manese M, Feliz J, Tran N, Lindshield C, Cummings JL, Toga AW. Construction of the first rest-state functional subvolume probabilistic atlas of normal variability in the elderly and demented brain. Neurology 2001;56;A248.

157. Reichman WE, Menza M, Mulsant BH, Cummings JL. Depression in the neuropsychiatric disorders of aging: toward a unified understanding of pathogenesis. Am J Geriatr Psychatry, Annual Meeting, Summer 2001; pp.36.

158. Cummings JL. Depression: toward a unified understanding of pathogenesis. Am J Geriatr Psychiatry, Annual Meeting, Summer 2001; pp.37.

159. Cummings JL, Duttagupta S, Wade S, Goldberg G, Mosso A, Patton M, Haberman M. cost savings associated with use of donepezil in managed care. Am J Geriatr Psychatry, Annual Meeting, Summer 2001; pp.53.

160. Cummings JL, Kavanagh S, Hammond G. Galantamine (Reminyl) prevents behavioural symptoms and caregiver distress in Alzheimer’s disease. 1st European Union of Geriatric Societies, August 2001.

161. Mega MS, Dinov ID, Manese M, Felix J, Tran N, O’Connor SM, Masterman DM, Toga AW, Cummings JL. Laboratory of imaging and Alzheimer’s disease. Anterior cingulate activation occurs across cholinesterase inhibitor therapy in Alzheimer’s disease. Int Psychogeriatr 2001;13 (suppl 2).

162. Senanarong V, Punthumchinda K, Somprakit P, Udompunthurak S, Jamjumras P, Poungvarin N, Cummings JL. Seven item cognitive screening test (7ICST) for dementia in Thai elderly. J Neurol Sci 2001;187:S43.

163. Street JS, Clark WS, Cummings JL, Kadam DL, Mitan SJ, Sanger TM, Bymaster FP, Tamura RN, Feldman PD, Gannon KS, Tollefson GD, Breier A. Olanzapine in the treatment of psychosis and behavioural disturbances associated with Alzheimer’s disease. J Neurol Sci 2001;187:PO131.

164. Cummings JL. Neuropsychiatric aspects of Parkinson’s disease. J Neurol Sci 2001;187:54.01.

165. Cummings JL. Neural pathways mediating behaviors in dementia. The American Journal of Geriatric Psychiatry March-April 2002. AAGP 15th Annual Meeting, Orlando, Florida: February 24-27, 2002.

166. Cummings JL. Cholinergic treatment of neuropsychiatric symptoms in Alzheimer’s disease. 7th International Geneva/Springfield Symposium on Advances in Alzheimer Disease, April 3-6, 2002.

81

167. Mega M, Dinov II, Manese M, Felix J, O’Connor SM, Toga AW, Cummings JL. Cerebral metabolic activation with cholinesterase inhibitor therapy in Alzheimer disease. 7th International Geneva/Springfield Symposium on Advances in Alzheimer Disease, April 3- 6, 2002.

168. Prolo P, Mondino F, Rosso MG, Salvatico F, Grasso E, Angeli A, Cummings JL, Masterman DL, Fanto F, Tisci C. A comparison of life satisfaction and mood in subjects with Alzheimer’s disease and their caregivers. Neurobiology of Aging July-August 2002. 8th International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden: July 20-25, 2002:S43.

169. Mega M, Dinov I, O’Connor SM, Toga A, Cummings J, Felix J. Cerebral metabolic activation with cholinesterase inhibitor therapy in Alzheimer’s disease. Neurobiology of Aging July-August 2002. 8th International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden: July 20-25, 2002:S114.

170. Senanarong V, Poungvarin N, Prayoonwiwat N, Udompunthurak S, Cummings JL. Frontal behaviors and executive function in Thai patients with Alzheimer’s disease. Neurobiology of Aging July-August 2002. 8th International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden: July 20-25, 2002:S160.

171. Sultzer D, Chen S, Monserratt L, Brown C. Mandelkern M, Cummings JL. Exeuctive skills and frontal cortical metabolism in Alzheimer’s disease. Neurobiology of Aging July-August 2002. 8th International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden: July 20-25, 2002:S470.

172. Mega M, Dinov I, Cummings JL. Confirmation of dementia subtypes using functional neuroimaging. Neurobiology of Aging July- August 2002. 8th International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden: July 20-25, 2002:S472.

173. Cummings JL. Non-cognitive symptoms in dementia. Neurobiology of Aging July-August 2002. 8th International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden: July 20-25, 2002:S145.

174. Cummings JL. The neuropsychiatric burden of geriatric neurologic disorders. Int Psychogeriatr Assoc Prog & Abstract Book October 23-26, 2002. IPA’S Asia Pacific Regional Meeting, Hong Kong, SAR PR China: October 23-26, 2002:16.

175. Cummings JL. Clinical syndromes in dementia. Report of T. S. Srinivasan Institute of Neurological Sciences and Research Centre 2003;18.

176. Cummings JL. 23rd T. S. Srinivasan endowment oration: dementia: from science to patient. Report of T. S. Srinivasan Institute of Neurological Sciences and Research Public Health Centre 2003;13.

177. Cummings JL, Lilienfeld S, Mahableshwarkar AR. The effect of galantamine on behavior: maintenance of effects with long-term treatment of mild-to-moderate Alzheimer’s disease. New Research Program for the American Psychiatric Association 156th Annual Meeting. San Francisco, CA: May 17-22, 2003:63 (Poster session).

178. Cummings JL. Depression in Parkinson’s disease. Syllabus and Proceedings Summary for the American Psychiatric Association 156th Annual Meeting. San Francisco, CA: May 17-22, 2003:88.

179. Cummings JL. Depression in dementing disorders. Syllabus and Proceedings Summary for the American Psychiatric Association 156th Annual Meeting. San Francisco, CA: May 17-22, 2003:261.

180. Cummings JL. Apathy in neuropsychiatric disorders. Syllabus and Proceedings Summary for the American Psychiatric Association 156th Annual Meeting. San Francisco, CA: May 17-22, 2003:272.

181. Cummings JL. Geriatric neuropsychiatry. Sehat sejahtera di usia lanjut. Kongress Pertama API. Jakarta, Indonesia. May 14-16, 2003:4-6.

182. Cummings JL. Galantamine: a new dimension in Alzheimer dementia therapy. Sehat sejahtera di usia lanjut. Kongress Pertama API. Jakarta, Indonesia. May 14-16, 2003:7-8.

183. Michael S. Mega, I. Dinov, JL. Cummings, A.W. Toga. Utilization of functional neuroimaging to confirm dementia subtypes. Advances in Geriatric Psychiatry: Translating Research into Care. Proceedings of the 16th Annual Meeting of the American Association for Geriatric Psychiatry. Honolulu, Hawaii: March 1-4, 2003:90. 82

184. Bartzokis G, Cummings JL, Sultzer D, Nuechterlein KH, Mintz J. Heterogeneous age-related breakdown of white matter structural integrity: Implications for “disconnection” in aging and Alzheimer’s disease. Ann Neurol 2003; 54: 7: S29-S30.

185. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effects of memantine in Alzheimer’s disease (abstract). Neurology 2004;62(7 Suppl 1):A104.

186. Cummings J, Schmitt F, Tariot P, et al. Effect of memantine on behavioral outcomes in moderate to servere Alzheimer’s disease. Poster presented at: 43th American Collecge of Neuropsychopharmacology Annual Meeting; December 12-16, 2004; San Juan, Puerto Rico.*

187. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effects of memantine in Alzheimer’s disese (abstract). J Am Geriatr Soc 2004;52(4):S1-S246. (ORAL Presentation by J Olin)

188. Cummings JL. Alzheimer’s disease and normal aging: keeping our minds healthy. The Egyptian Society of Neurology Psychiatry and Neurosurgery. 5th CNC Cairo International Neurology Conference. Cairo, Egypt: January 14-16, 2004:15.

189. Cummings JL. The neuropsychiatry of Alzheimer’s disease: assessment and treatment. The Egyptian Society of Neurology Psychiatry and Neurosurgery. 5th CNC Cairo International Neurology Conference. Cairo, Egypt: January 14-16, 2004:19-20.

190. Cummings JL, Finkel S, Zhang R, Burt T, McRae R. Donepezil improves behavioral symptoms in patients with Alzheimer’s disease. American Association for Geriatric Psychiatry’s 17th Annual Meeting. Baltimore, MD: February 21-24, 2004: PO62.

191. Cummings JL, Tariot P, Gergel I, Graham SM, Jin J. Effect of memantine on behavioral outcomes in moderate to severe Alzheimer’s disease. American Association for Geriatric Psychiatry’s 17th Annual Meeting. Baltimore, MD: February 21-24, 2004: PO63.

192. Cummings JL. NamanedaTM shows benefits in behavioral disturbances associated with moderate to severe Alzheimer’s disease. American Association for Geriatric Psychiatry’s 17th Annual Meeting. Baltimore, MD: February 21-24, 2004.

193. Cummings JL. Cholinisterase inhibitors: behavioral and neuropsychiatric effects. Neurobiology of Aging. 2004;25:S6.

194. Cummings JL, Tariot P, Graham SM, Bell J, Jin J. Effects of memantine on behavioral outcomes in moderate to severe Alzheimer’s disease. 8th International Montreal/Springfield Symposium on Advances in Alzheimer Therapy. Montreal, Canada: April 14-17, 2004:52.

195. Nasreddine ZS, Chertkow H, Phillips NA, Whitehead V, Bergman H, Collin I, Cummings JL, Herbert L. The moderate cognitive assessment (MOCA): A brief cognitive screening tool for detection of mild cognitive impairment. 8th International Montreal/Springfield Symposium on Advances in Alzheimer Therapy. Montreal, Canada: April 14-17, 2004:90.

196. Apostolova LG, Dinov II, Toga AW, Cummings JL. Mapping apathy in Alzheimer’s disease: a structural MRI study. American Academy of Neurology 56th Annual Meeting Program. San Francisco, CA: April 24-May 1, 2004; P02.043.

197. Mega MS, Dinov II, Porter V, Chow G, Reback E, Davoodi P, O’Connor SM, Carter MF, Felix J, Amezcua H, Cummings JL, Toga AW. Metabolic patterns associated with the clinical response to galantamine therapy: an FDG-PET study. American Academy of Neurology 56th Annual Meeting Program. San Francisco, CA: April 24-May 1, 2004; P02.047.

198. Lu PH, Masterman D, Swerdoff R, Cotman C, Miller B, Mulnard R, Wang C, Yaffe K, Carter M, Cummings JL. Effects of testosterone on cognition and mood in male patients with mild Alzheimer’s disease and normal volunteers. American Academy of Neurology 56th Annual Meeting Program. San Francisco, CA: April 24-May 1, 2004; P02.057.

199. Nasreddine Zs, Cherkow H, Phillips N, Whitehead V, Collin I, Cummings JL. The Montreal Cognitive Assessment (MoCA): a brief cognitive screening tool for detection of mild cognitive impairment. American Academy of Neurology 56th Annual Meeting Program. San Francisco, CA: April 24-May 1, 2004; P02.063.

200. Cummings JL, van Dyck CH, Schmitt FA, Graham SM, Olin JT, Jin J, Tariot PN. Functional and behavioral effects of memantine in Alzheimer’s disease. American Academy of Neurology 56th Annual Meeting Program. San Francisco, CA: April 24-May 1, 2004; P04.107.

83

201. Cummings JL, Zhang R, McRae T. Effects of donepezil therapy on behavioral symptoms in patients with Alzheimer’s disease. American Academy of Neurology 56th Annual Meeting Program. San Francisco, CA: April 24-May 1, 2004; P04.112.

202. Cummings JL. Director, Non-Alzheimer’s Dementias. Education Program Syllabus, American Academy of Neurology 56th Annual Meeting. San Francisco, CA: April 26, 2004; 3AC.005.

203. Cummings JL, Zhang R, McRae T. Donepezil therapy improves behavioral symptoms in patients with Alzheimer’s disease. Syllabus & Proceedings Summary: American Psychiatry Association 2004 Annual Meeting. New York, NY: May 1-6, 2004;NR238.

204. Tariot PN, van Dyck CH, Schmitt FA, Graham SM, Olin JT, Jin J, Cummings JL. Functional and behavioral effects of memantine in Alzheimer’s disease. Syllabus & Proceedings Summary: American Psychiatry Association 2004 Annual Meeting. New York, NY: May 1-6, 2004;NR872.

205. Cummings JL. Diversity of neuropsychiatric impairment: cognitive and behavioral implications. Syllabus & Proceedings Summary: American Psychiatry Association 2004 Annual Meeting. New York, NY: May 1-6, 2004; 32B.

206. Cummings JL. Depression in Parkinson’s disease. Syllabus & Proceedings Summary: American Psychiatry Association 2004 Annual Meeting. New York, NY: May 1-6, 2004; 57B

207. Schmitt F, Tariot P, Cummings JL, Bell J, Jia D, Olin J. Robust response to memantine treatment when functional and behavioral efficacies are combined with cognition. Neurobiology of Aging 9th international conference on Alzheimer’s disease and related disorders. Philadelphia, PA: July 17-22, 2004; S93, P1-002.

208. Cummings JL, van Dyke C, Schmitt F, Graham SM, Olin JT, Jin J, Tariot P. Functional and behavioral effects of memantine in Alzheimer’s disease. Neurobiology of Aging 9th international conference on Alzheimer’s disease and related disorders. Philadelphia, PA: July 17-22, 2004; S186, P1-315.

209. Mega M, Dinov II, Porter V, Chow G, Reback E, Davoodi P, O’Connor S, Carter M, Felix J, Amezcua H, Cummings JL, Toga AW. Metabvolic patterns associated with the clinical response to galantamine therapy: an FDG-PET study. Neurobiology of Aging 9th international conference on Alzheimer’s disease and related disorders. Philadelphia, PA: July 17-22, 2004; S187, P1-318.

210. Schmitt FA, Tariot PN, Cummings JL, Bell JM, Jia D, Olin T. Robust response to memantine treatment when functional and behavioral efficiencies are combined with cognition. 8th Congress of the European Federation of Neurological Societies. Paris, France: September 4-7, 2004;11: S2, P1014.

211. Cummings JL, van Dyke C, Schmitt F, Graham SM, Olin JT, Jin J, Tariot P. Functional and behavioral effects of memantine in Alzheimer’s disease. 8th Congress of the European Federation of Neurological Societies. Paris, France: September 4-7, 2004; 11: S2, P1031.

212. Senanarong V, Harnphadungkit K, Poungvarin N, Udomthanthurak S, Phanthumchinda K, Cummings JL. Combined clock drawing test and Thai activities of daily living scale as a screening test for dementia in elderly Thai. 8th Congress of the European Federation of Neurological Societies. Paris, France: September 4-7, 2004; 11: S2, P2031.

213. Cummings JL. Protein misfolding and the proteotype – phenotype relationship. Ipsen Foundation, Genotype-Proteotype-Phenotype Relationships in Neurodegenerative Diseases. Parris, France: September 13, 2004.

214. Schmitt FA, Tariot PN, Cummings JL, Bell JM, Jia D, Olin JT. Robust response to memantine treatment when functional and behavioral efficacies are combined with cognition. The International Journal of Neuropsychopharmacology. XXIV CINP Congress, Paris France June 20-24, 2004;S208:P01.288.

215. Cummings JL, van Dych C, Schmitt FA, Graham SM, Olin JT, Jin J, Tariot PN. Functional and behavioral effects of memantine in Alzheimer’s disease. The International Journal of Neuropsychppharmacology. XXIV CINP Congress, Paris France June 20-24, 2004;S208:P01.289.

216. Il-Seon S, Carter M, Masterman D, Fairbanks Lynn, Cummings JL. Neuropsychiatric symptoms and quality of life in Alzheimer’s disease. IPA Asia Pacific Regional Meeting, Seoul. September 8-11, 2004.

84

217. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effects of memantine in Alzheimer’s disease. Neurology 2004;62(7 Suppl 5): A318.

218. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effects of memantine in Alzheimer’s disease. J Am Geriatr Soc 2004;52S1-S246.

219. Cummings J, Tariot P, Graham S, et al. Effect of memantine on behavioral outcomes in moderate to severe Alzheimer’s disease. 157th Annual meeting of the American Psychiatric Association, New York, NY: May 1-6,2004.

220. Schmitt FA, Tariot PN, Cummings JL, et al. Robust response to memantine treatment when functional and behavioral results are combined with cognition. The American Neurological Association 129th Annual Meeting, Toronto, Ontario, Canada: October 3-6, 2004.

221. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effects of memantine in Alzheimer’s disease. The American Psychiatric Association 56th Institute on Psychiatric Services, Atlanta, Georgia: October 6-10, 2004.

222. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effets of memantine in Alzheime’rs disease. 35th Annual Meeting of the American Society of Consultant Pharmacists, San Francisco, CA: November 3-6, 2004.

223. Cummings J, Schmitt F, Tariot P, et al. Effect of memantine on behavioral outcomes in moderate to severe Alzheimer’s disease. 43th American College of Neuopsychopharmacology Annual Meeting, San Juan, Puerto Rico: December 12-16, 2004.

224. Cummings J, Tariot P, Graham S, et al. Effect of memantine on behavioral outcomes in moderate to severe Alzheimer’s disease. International Journal of Neuropsychopharmacology 2004;7: S208.

225. Schmitt F, Tariot P, Cummings J, et al. Response to memantine treatment based on multiple definitions of responders. International Journal of Neuropsychopharmacology 2004;7:S380.

226. Schmitt FA, Tariot PN, Cummings JL, et al. Robust response to memantine treatment based on multiple definitions of responders. J Eur Neuropsychopharm 2004;14(Suppl 3): S331.

227. Van Dyck C, Cummings J, Schmitt F, et al. Functional and behavioral effects of memantine in Alzheimer’s disease. J Eur Neuropsychopharm 2004;14(Suppl 3):S334.

228. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effects of memantine in Alzheimer’s disease. Eur J Neurology 2004;11(Suppl2):45.

229. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effects of memantine in Alzheimer’s disease. Neurobiology Aging 2004;25(S2):S186.

230. Cummings JL. Dementia: clinical evaluation. Molecular Imaging and Biology, scientific abstracts of the 2005 Annual Conference of the Academy of Molecular Imaging. Orlando, FL, March 18-23, 2005;p84, No. 20.

231. Cummings JL, Schneider E, Peskind ER, Tariot P, Graham S, Bell JM. Effects of memantine on behavioral outcomes in mild to severe Alzheimer’s disease. American Academy of Neurology 57th Annual Meeting. Miami Beach, FL April 9-16, 2005; pA104, No. P02.093.

232. Marshall GA, Fairbanks L, Tekin S, Park F, Vinters HV, Cummings JL. Age correlates negatively with pathological burden in Alzheimer’s disease. American Academy of Neurology 57th Annual Meeting. Miami Beach, FL, April 9-16, 2005; pA362, No. P06.075.

233. Cummings JL, Marshall GA, Tekin S, Park F, Fairbanks L, Vinters HV. Neuropathologic correlates of apathy in Alzheimer’s disease. American Academy of Neurology 57th Annual Meeting. Miami Beach, FL, April 9-16, 2005; pA136, No. S11.002.

234. Marshall GA, Fairbanks L, Tekin S, Park F, Vinters HV, Cummings JL. Neuropathologic correlates of activities of daily living in Alzheimer’s disease. American Academy of Neurology 57th Annual Meeting. Miami Beach, FL, April 9-16, 2005; pA137, No. S11.003.

85

235. Cummings JL. Neuropsychiatric and behavioral aspects of mild cognitive impairment. American Academy of Neurology 57th Annual Meeting. Miami Beach, FL, April 9-16, 2005; 2PC.001-21-25.

236. Bartzokis G, Lu PH, Geschwind DH, Edwards N, Mints J, Cummings JL. The impact of ApoE alleles on age-related myelin breakdown. Alzheimer’s Association International Prevention of Dementia Conference. Washington DC, June 19, 2005.

237. Bartzokis G, Tishler T, Lu PH, Oh LS, Lieu CA, Mintz J, Cummings JL. Brain ferritin iron as a risk factor for age of onset in neurodegenerative diseases. Alzheimer’s Association International Prevention of Dementia Conference. Washington DC, June 19, 2005.

238. Cummings JL. Behavioral and neuropsychiatric outcomes in Alzheimer’s disease. American Psychiatric Association Annual Meeting. Atlanta, GA, May 21-26, 2005; p28, No. 20E.

239. Cummings JL, Weintraub D, Jackson-Segel J, Tariot PN, Sultzer DL. Treament of psychosis in Parkinon’s disease. American Psychiatric Association Annual Meeting. Altalanta, GA, May 21-26, 2005; p43, No. 31C.

240. Cummings J, Schneider E, Tariot P, et al. Effect of memantine on behavioral outcomes in moderate to severe Alzheimer’s disease. 18th Annual meeting of the American Association for Geriatric Psychiatry, San Diego, CA: March 3-6, 2005.

241. Cummings J, Schneider L, Peskind E, et al. Effect of memantine on behavioral outcomes in Alzheimer’s disease. 8th annual meeting of the College of Psychiatric and Neurologic Pharmacists, San Diego, CA: March 10-13, 2005.

242. Cummings J, Schneider E, Peskind E, et al. Effect of memantine on behavioral outcomes in mild to severe Alzheimer’s disease. 158th Annual Meeting of the American Psychiatric Association, Atlanta, GA: May 21 to 26, 2005.

243. Cummings J, Schneider E, Peskind E, et al. Effect of memantine on behavioral outcomes in mild to severe Alzheimer’s disease. Alzheimer’s Association 1st International Conference on Prevention of Dementia, Washington, D.C.: June 18-21, 2005.

244. Cummings J, Schneider E, Peskind E, et al. Effect of memantine on behavioral outcomes in mild to severe Alzheimer’s disease. Neurology 2005;64(Suppl 1):A104.

245. Cummings J, Schneider E, Peskind E, Tariot P, et al. Effect of memantine on behavioral outcomes in mild to severe Alzheimer’s disease. J Am Geriatr Soc 2005;53:S77.

246. Bartzokis G, Tishler T, Lu PH, Oh LS, Lieu CA, Mintz J, Cummings JL. Brain ferritin irons as a risk factor for age at onset in neurodegenerative diseases. Alzheimer’s Association international conferene on prevention of dementia: early diagnosis and intervention. July 18-21, 2005, Washington, DC. J Alzheimer’s Association 2005; S26: P-057.

247. Bartzokis G, Lu PH, gescwind DH, Edwards N, Mintz J, Cummings JL. The impact of apoe alleles on age related myelin breakdown. Alzheimer’s Association international conferene on prevention of dementia: early diagnosis and intervention. July 18- 21, 2005, Washington, DC. J Alzheimer’s Association 2005; S28: P-063.

248. Cummings JL, Schneider E, Peskind ER, Tariot PN, Graham SSM, Bell JM. Effect of memantine on behavioral outcomes in Alzheimer’s disease. Alzheimer’s Association international conferene on prevention of dementia: early diagnosis and intervention. July 18-21, 2005, Washington, DC. J Alzheimer’s Association 2005; S70: P-194.

249. Tariot P, Cummings JL, Olin J. Benefits of memantine/donepezil treatment on behaiour in moderate to severe AD using factor- analytically derived subscales. December 11-15, 20005, Waikoloa, Hawaii. Neuropsychopharmacology: 30; 16: S83.

250. Apostolova LG, Thompson PM, Toga AW, Cummings JL. Gray matter atrophy patterns in mild cognitive impairment endophenotypes. 130th Annual Meeting of the American Neurological Association. San Diego, CA: September 2005.

251. Apostolova LG, Thompson PM, Dutton RA, Dinov ID, Cummings JL. Hippocampal atrophy maps can predict conversion of mild cognitive impairment to Alzheimer’s disease. 130th Annual Meeting of the American Neurological Association. San Diego, CA: September 2005.

86

252. Apostolova LG, Thompson PM, Hayashi K, Dinov ID, Cummings JL. Cortical atrophy can predict conversion from mild cognitive impairment to Alzheimer’s disease. 130th Annual Meeting of the American Neurological Association. San Diego, CA: September 2005.

253. Apostolova LG, Thompson PM, Hayashi KM, Dinov ID, Cummings JL. Neocortical atrophy pattern predictive of conversion of mild cognitive impairment to Alzheimer dementia. 11th Annual Meeting of the Organization for Human Brain Mapping. Toronto, Canada: July, 2005.

254. Apostolova LG, Thompson PM, Hayashi K, Dinov ID, Cummings JL. Neocortical atrophy pattern predictive of conversion of mild cognitive impairment to Alzheimer dementia. The Beeson Scholar Meeting: June, 2005.

255. Apostolova LG, Thompson PM, Dutton RA, Dinov ID, Cummings JL. Hippocampal size can predict outcome in mild cognitive impairment. 11th Annual Meeting of the Organization for Human Brain Mapping. Toronto, Canada: July, 2005.

256. Apostolova LG, Thompson PM, Dutton RA, Dinov ID, Cummings JL. Hippocampal size can predict outcome in mild cognitive impairment. The Beeson Scholar Meeting: June, 2005.

257. Cummings JL, Apostolova LG, Akopyan GG, Steiner CA, Partiali N, Toga AW, Thompson PM. Structural correlates of apathy in Alzheimer’s disease. American Academy of Neurology 58th Annual Meeting Program. San Diego, CA: April 1-8, 2006; P02.127.

258. Teng E, Lu PH, Cummings JL. Neuropsychiatric symptoms in subtypes of mild cognitive impairment. American Academy of Neurology 58th Annual Meeting Program. San Diego, CA: April 1-8, 2006; P02.181.

259. Steiner CA, Akopyan GH, Toga AW, Cummings JL, Thompson PM. Gray matter atrophy in mild cognitive impairment and mild Alzheimer’s disease. American Academy of Neurology 58th Annual Meeting Program. San Diego, CA: April 1-8, 2006; P02.182.

260. Marshall GA, Tsang SWT, Pomakian J, Cummings JL, Vinters HV, Lai MKP. Neuropathologic and cholinergic correlates of education and dementia severity in Alzheimer’s disease. American Academy of Neurology 58th Annual Meeting Program. San Diego, CA: April 1-8, 2006; P05.079.

261. Marshall GA, Tsang SWT, Pomakian J, Cummings JL, Vinters HV, Lai MKP. Early onset Alzheimer’s disease is associated with cholinergic deficits. American Academy of Neurology 58th Annual Meeting Program. San Diego, CA: April 1-8, 2006; P05.085.

262. Cummings JL, Olin JT. The effects of memantine on distinct behavior syndromes in moderate to severe AD patients. American Academy of Neurology 58th Annual Meeting Program. San Diego, CA: April 1-8, 2006; P06.053.

263. Apostolova LG, Dinov ID, Toga AW, Cummings JL, Thompson PM. 3D comparison of hippocampal impairment and Alzheimer’s disease. American Academy of Neurology 58th Annual Meeting Program. San Diego, CA: April 1-8, 2006; S01.005.

264. Meador KJ, (Director). Cummings JL, Kaufer D, Meador JL (Lecture/Faculty). Management of common behavioral disturbances in dementia. American Academy of Neurology 58th Annual Meeting Program. San Diego, CA: April 1-8, 2006; 2DS.003.

265. Cummings JL, (Director). DeCarli CS, Kaufer D, Miller BL, Cummings JL (Lecture/Faculty). Non-Alzheimer’s dementia. American Academy of Neurology 58th Annual Meeting Program. San Diego, CA: April 1-8, 2006; 3PC.005.

266. Miller BL, (Director). Miller BL, Sperling RA, Rosen HJ, Cummings JL, (Lecture/Faculty). Primer of cognitive neurology. American Academy of Neurology 58th Annual Meeting Program. San Diego, CA: April 1-8, 2006; 8AC.004.

267. Olin JT, Cummings JL. Meta-analysis of neuropsychiatric inventory (NPI) domains in three 6-month trials of memantine in moderate to severe AD. 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. Geneva, Switzerland: April 19- 22, 2006; p.50, No. 20B.

268. Cummings JL, Olin JT. The effect of memantine on distinct behavior syndromes in moderate to severe AD patients. 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. Geneva, Switzerland: April 19-22, 2006; p.51, No. 21B.

269. Cummings JL, (Expert Panel). Corey-Bloom J, Francis P, Jones R, Lopez O (Panelists). Controversies in cholinergic therapy for mild cognitive impairment and Alzheimer disease. Neurobiology of Aging 9th International Geneve/Springfield Symposium on Advances in Alzheimer Therapy. Geneva, Switzerland: April 19-22, 2006. Neurobiology of Aging 2006; 27: S5, No. 19. 87

270. Apostolova LG, Lu P, Rogers S, Dutton RA, Toga AW, Cummings JL, Thompson PM. 3D mapping of language impairments in clinical and pre-clinical Alzh eimer’s disease. 12th Annual Meeting of the Organization for Human Brain Mapping. Florence, Italy: June, 2006.

271. Apostolova LG, Lu P, Rogers S, Dutton RA, Toga AW, Cummings JL, Thompson PM. 3D mapping of Mini-mental State Examination performance in clinical and pre-clinical Alzheimer’s disease. 12th Annual Meeting of the Organization for Human Brain Mapping. Florence, Italy: June, 2006 (manuscript in preparation).

272. Apostolova LG, Steiner CA, Akopyan GG, Toga AW, Cummings JL, Thompson PM. Gray matter atrophy in mild cognitive impairment and mild Alzheimer’s disease. 58th American Academy of Neurology Meeting. San Diego, CA: April, 2006.

273. Cummings JL, Olin JT. The effect of memantine on distinct behavior syndromes in moderate to severe attention deficit patients. 159th American Psychiatric Association Annual Meeting. Toronto, Canada: May 20-25, 2006: NR907.

274. Olin JT, Cummings JL. Meta-analysis of Neuropsychiatric I nventory domains in three, six-month trials of memantine in moderate to severe attention deficit. 159th American Psychiatric Association Annual Meeting. Toronto, Canada: May 20-25, 2006; NR969.

275. Tariot PN, Cummings JL, Olin JT. NPI subscale analysis of memantine/donepezil treatment in moderate-to-severe attention deficit. 159th American Psychiatric Association Annual Meeting. Toronto, Canada: May 20-25, 2006; NR993.

276. Cummings J, Schneider E, Tariot PN, Graham SM. Effect of memantine on behavioral outcomes in moderate to severe Alzheimer’s disease. 46th American Society of Clinical Psychopharmacology Annual Meeting. Boca Raton, Florida: June 12-15, 2006; 239.

277. Ringman JM, Wardak M, Kepe V, Barrio J, Huang SC, Yu C-L, Geschwind D, Schaffer B, Rodriguez Y, Small GW, Cummings JL. [18F]FDDNP-PET imaging in persons at-risk for familial AD. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15-20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S66.

278. Simon ES, Doniger GM, Cummings JL, Fillit H. A hierarchical approach to practical assessment of cognitive decline in the elderly. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15-20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S82.

279. Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. PET metabolic correlates of apathy in Alzheimer’s disease. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15-20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S224.

280. Cummings JL, Olin JT. The effect of memantine on distinct behavior syndromes in moderate to severe AD patients. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15-20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S231.

281. Cummings JL, Olin JT. Meta-analysis of neuropsychiatric inventory (NPI) domains in three 6-month trials of memantine in moderate to severe AD. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15-20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S231.

282. Ringman JM, Cole G, Geschwind D, Schaffer B, Rodriguez Y, Fein J, Medina L, Pratico D, Younkin S, Cummings JL. Biochemical markers in blood and cerebrospinal fluid of persons with or at-risk for familial AD. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15-20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S282.

283. Barrio JR, Kepe V, Huang S-C, Ercoli L, Siddarth P, Cole GM, Satyamurthy N, Cummings JL, Phelps ME, Small GW. In vivo quantification of neuronal loss and neuropathological deposition in Alzheimer’s disease with PET. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15-20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S328.

284. Bartzokis G, Lu PH, Tingus K, Edwards N, Lieu CA, Mendez MF, Mintz J, Cummings JL. Cognitive processing speed and myelin breakdown in older individuals. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15- 20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S348.

285. Apostolova LG, Clark DG, Zoumalan C, Steiner CA, McMurtray A, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Mendez MF, Thompson PM. 3D mapping of gray matter atrophy in semantic dementia and frontal variant frontotemporal dementia. 10th 88

International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15-20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S354.

286. Apostolova LG, Dinov ID, Thompson PM, Zoumalan C, Steiner CA, Siu E, Dutton RA, Hayashi KM, Small GW, Cummings JL, Toga AW, Phelps ME, Silverman DHS. MR-guided 3D PET mapping of longitudinal changes in regional cerebral metabolism of normal subjects. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15-20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S354.

287. Ringman JM, O’Neill J, Apostolova L, Geschwind D, Tseng B, Schaffer B, Rodriguez Y, Medina L, Cummings JL, Bartzokis G. Decreased fractional anisotropy in the fornix of presymptomatic carriers of FAD mutations. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15-20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S680.

288. Bartzokis G, Lu PH, Tingus K, Edwards N, Lieu CA, Mendez MF, Mintz J, Cummings JL. Cognitive processing speed and myelin breakdown in older individuals. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15- 20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S682.

289. Ringman JM, O’Neill J, Tseng B, Rodriguez Y, Geschwind D, Schaffer B, Medina L, Thixton T, Cummings JL. Elevated hippocampal myo-inositol in subjects with or at-risk for familial AD. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain:July 15-20, 2006. Alzheimer’s & Dementia 2006;2(Suppl 1):S689.

290. Cummings JL. Neuropsychiatric aspects of Alzheimer’s disease. III Expert Meeting on Dementia. Madrid, Spain: September 22-23, 2006. Alzheimer 100 años recordando 2006.

291. Winblad B, Cummings J, Zechner S, Ros J, Nagel J, Bernhard G, Lane R. IDEAL: a 6-month placebo-controlled study of the first transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. 131st Annual Meeting of the American Neurological Association. Hyatt Regency Chicago, Chicago, IL: October 8-11, 2006;75.

292. Apostolova LG, Lu PH, Rogers S, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. 3D mapping of verbal memory performance in clinical and pre-clinical Alzheimer disease. 131st Annual Meeting of the American Neurological Association. Chicago, IL: October 8-11, 2006;22.

293. Tariot PN, Cummings JL, Olin JT. NPI subscale analysis of memantine/donepezil treatment in moderate-to-severe AD. 131st Annual Meeting of the American Neurological Association. Chicago, IL: October 8-11, 2006;26.

294. Teng E, Lu PH, Cummings JL. Instrumental activities of daily living in mild cognitive impairment and mild Alzheimer’s disease. 131st Annual Meeting of the American Neurological Association. Chicago, IL: October 8-11, 2006; 26.

295. Cummings JL, Farlow M, Grossberg G, Green P, Tocco M, Resnick EM, Olin J, Graham S. A review of the safety and tolerability of treatments for moderate to severe Alzheimer’s disease. 45th Annual Meeting of the American College of Neuropsychopharmacology. Hollywood, FL: December 3-7, 2006;S70.

296. Grossberg G, Winblad B, Cummings J, Andreasen N, Onofrj M, Zechner S, Ros J, Tekin S, Nagel J. IDEAL: a 1-year study of the first transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Annual Meeting of the American Association for Geriatric Psychiatry. New Orleans, LA: March 1-4, 2007.

297. Cummings JL, Grossberg G, Green P, Tocco M, Resnick M, Olin J, Graham S. A review of the safety and tolerability of treatments for moderate to severe AD. Annual Meeting of the American Academy of Neurology, Boston, MA: April 28- May 5, 2007.

298. Ringman JM, Teng E, Schneider L, Galasko D, Yaffe K, Mulnard R., Dick M, Davies H, Ross L, Cummings JL. Major depression is independently associated with poorer activities of daily living in persons with Alzheimer Disease. Annual Meeting of the American Academy of Neurology, Boston, MA: April 28- May 5, 2007.

299. Cummings JL. Management of behavioral disturbances in Alzheimer disease. Annual Meeting of the American Psychiatric Association, San Diego, CA: May 19-24, 2007

300. Cummings JL, Gautheir S. Specific benefits of memantine on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. 20th ECNP Congress (European College of Neuropsychopharmacology), Vienna, Austria: October 13-17.2007.

89

301. Alva G, Cummings, JL, Resnick M, Tocco M, Graham, SM. Comparative safety and tolerability of Alzheimer’s disease treatments. Abstracts from the 2008 APA Annual Meeting. Washington DC, May 3-8, 2008

302. Alva G, Cummings JL, Resnick M, Tocco M, Graham, S. comparative safety and tolerability of Alzheimer’s disease treatments. American Journal of Geriatric Psychiatry. Abstracts from the 2008 AAGP Annual Meeting. 2008;16:SA109-SA110.

303. Cummings, JL, Doody R, Gavrilova SI, Sano M, Aisen PS, Seely L, Hung D. Dimebon stabilizes neuropsychiatric symptoms in Alzheimer’s disease: one-year clinical trial results. American Journal of Geriatric Psychiatry. Abstracts from the 2008 AAGP Annual Meeting. 2008;16:SA111.

304. Cummings JL, Mackell JA, Murthy A, Zhang R. Donepezil for Severe Alzheimer’s Disease: Behavioral Effects in Patients with Multi-Domain Responses. American Journal of Geriatric Psychiatry. Abstracts from the 2008 AAGP Annual Meeting. 2008;16:SA109-SA110.

305. Cummings JL. Effect of Cholinesterase inhibitors on behavior. Neurobiology of Aging. 2008;29:S6.

306. Ringman JM, Seltzer W, Worcester MA, Cole G, Medina LS, Rodriguez Y, Varpetian A, Downey CA, Sokolow S, Fitten J, Ortiz F, Cummings JL. Elevated CSF P-tau181 and total-tau and teduced P-tau181/T-tau ratio in pre-symptomatic familial Alzheimers disease. Neurology 2008;70:S183.

307. Apostolova L, Beyer MK, Green AE, Avedissian C, Hwang K, Stavanger DA, Janvin CC, Larsen JP, Cummings JL, Thompson PM. Hippocampal atrophy in Parkinsons disease patients with mild cognitive impairment. Neurology 2008;70:S285.

308. Cummings, JL, Emre, M, Tekin S, Dronamraju, N, Lane, R. Effects of rivastigmine in Alzheimer’s disease patients with and without hallucinations. Abstracts from the 2008 APA Annual Meeting. Washington DC, May 3-8, 2008

309. Andrawis JP, Hwang KS, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR, Weiner MW, Thompson PM, Apostolova LG. 3D mapping of associations amongst amyloid-pet and CSF biomarkers and hippocampal morphology. ICAD, Vienna Austria 2009.

310. Apostolova LI, Hwang KS, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski J, Shaw L, Jack CR, Weiner MW, Thompson PM. CSF Abeta and Tau associations with 3D hippocampal radial distance mapped in 282 ADNI subjects.

311. Apostolova LG, Green AE, Babakchanian S, Hwang KS, Chou YY, Cummings JL, Toga AW, Thompson PM, UCLA, Los Angeles, CA, USA. Effect of age on ventricular enlargement when comparing cognitively normal elderly, mild cognitive impairment and Alzheimer’s disease subjects.

312. Lu P, Apostolova LG, Beyer MK, Hwang, KS, Green AE, Ching C, Thompson PM, Leow A, Lee G, Janvin CC, Larsen, JP, Cummings, JL, Aarsland D. A Tensor Based Morphometry study of patients with cognitive impairment and dementia in Parkinson’s disease.

313. Lu P, Mendez M, Thompson PM, Alex Leow A, Lee G, Shapira J, Jimenez E, Lee AD, Lee H, Khoo T, Cummings JL, Bartzokis G. Differential patterns of atrophy in behavioral versus language subtypes of frontotemporal lobar degeneration: a tensor-based morphometry study.

314. Flores D, Liang LJ, Medina LD, Rodriguez Y, Schaffer B, Macias-Islas MA, Fitten J, Ortiz F, Cummings JL, Ringman J. Behavioral disturbances in Early Familial Alzheimer’s Disease.

315. Ringman JM, Medina LD, Rodriguez Y, Schaffer B, Varpetian A, Macias-Islas MA, Cummings JL, Bookheimer S. Effects of ApoE Genotype but not of FAD Mutation Status in BOLD Activation during a Novelty Encoding Task.

316. Srivanitchapoom P, Cummings JL, Senanarong V. Glomerular filtraton rate and cognitive impairment in adults: data from the dementia and disability project in Siriraj Hospital, Thailand. 19th World Congress of Neurology. Bangkok, Thailand: October 24-30, 2009;FP46-TH-05.

317. Cummings J. Disease-modifying drugs and vaccines for Alzheimer’s disease. 19th World Congress of Neurology Bangkok, Thailand: October 24-30. J Neurol Sci 2009;IN54-TH-03.

90

318. Apostolova LG, Babakchanian S, Hwang KS, Green AE, Zlatev D, Chou YY, Jack C, Petersen RC, Thal LJ, Aisen PS, Cummings JL, Toga AW, Thompson PM. Ventricular atrophy and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. 2nd Conference: Clinical Trials on Alzheimer’s Disease. Cleveland Clinic, Las Vegas. 2009: Oct. 29- 30.

319. Andrawis J, Hwang KS, Green Ae, Morra JH, Kotlerman J, Ramirez A, Elashoff D, Cummings JL, Thompson PM, Apostolova LG. Accelerated hippocampal atrophy in subjects with maternal history of alzheimer’s disease. 2nd Conference: Clinical Trials on Alzheimer’s Disease. Cleveland Clinic, Las Vegas. 2009: Oct. 29-30.

320. Farlow M, Cummings JL, Olin JT. Skin tolerability associated with rivastigmine transdermal patch: results rom a large placebo- controlled multicenter trial in mild to moderate Alzheimer’s disease. Abstracts form the American Association for Geriatric Psychiatry Annual Meeting, Honolulu, Hawaii, March 5-8, 2009.

321. Farlow M, Cummings JL, Olin JT. Skin tolerability associated with rivastigmine transdermal patch: results from a large placebo- controlled multicenter trial in mild to moderate Alzheimer’s disease. Abstracts from the American Psychhiatric Association Annual Meeting, San Francisco, California, May 1-21, 2009.

322. Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Influence of rivastigmine capsule on subscales of the Clinical Interview- Based Impression of Change (CIBIC-Plus) rating scale in Alzheimer’s Disease. Abstracts from the American Society of Consultant Pharmacists Annual Meeting, Anaheim, California, 18-21 November, 2009.

323. Ferris SH, Farlow MR, Cummings JL, Olin JT, Meng X. Influence of rivastigmine on subscales of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) in mild to moderate Alzheimer’s disease. American College of Neuropsychoparmacology Annual Meeting, Hollywood, Florida, 6-10 December, 2009.

324. Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on specific cognitive abilities in patients with mild to moderately severe Alzheimer’s disease: A pooled analysis. American Association for Geriatric Psychiatry Annual Meeting, Savannah, Georgia, March 5-8, 2010.

325. Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on specific cognitive abilities in patients with mil to moderately severe Alzheimer’s Disease: A pooled analysis. American Academy of Neurology Annual Meeting, Toronto, Canada, April 10-17, 2010.

326. Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on specific cognitive abilities in patients with mild to moderately severe Alzheimer’s disease: A pooled analysis. American Geriatric Society Annual Meeting, Orlando, Florida, May 12-15, 2010.

327. Cummings JL. Defining and labeling disease-modifying treatments for Alzheimer's disease. Alzheimers Dement 2009;5(5):406-418.

328. Senanarong V, Harnphadongkit K, Wannasaeng S, Poungvarin N, Chawalparit O, Raksathapat A, Udompanthurak S, Cummings JL. Apathy as a risk of cognitive decline and dementia. Int Psychogeriatr 2009; 21(2):S68-69.

329. Braskie MN, Medina LD, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Cummings JL, Bookheimer SY, Ringman JM. Increased fMRIsignal with age in familial Alzheimer’s disease mutation carriers. Neurobiol Aging. December 1, 2010.

330. Cummings JL. Behavioural symptoms and cognitive impairment in late life. VII European Congress Health and Active Ageing for All Europeans II, Aging Clin Exp Res, Vol. 23, Suppl. to No 1.

331. Apostolova LG, Hwang K, Omid K, Copolla G, Gao F, Ringman J, Cummings JL, Thompson P. Automated diagnostic classifiers for cognitively normal and mild cognitive impairment subjects using imaging, genotyping, and gene expression. American Academy of Neurology 63rd Annual Meeting. Honolulu, HI: April 9-April 16, 2011; SC01.003.

332. Apostolova LG, Klein E, Cummings JL, Thompson P, Hwang K, Kohannim O, Coppola G, Gao F. Automated diagnostic classifiers for cognitively normal and mild cognitive impairment subjects using imaging, genotyping and gene expression. Alzheimer’s Association International Conference 2011, Paris, France, July 16-21, 2011;P1-058.

91

333. Babakchanian S, Hwang K, Coppola G, Klein E, Lane J, Johnson S, Thompson P, Lee J, Cummings JL, Apostolova L. TOMM40 rs2075650, TOMM40 rs157580 and TOMM40 PolyT polymorphism effects on ventricular enlargement in individuals with and without mild cognitive impairment. Alzheimer’s Association International Conference 2011, Paris, France, July 16-21, 2011;P1-209.

334. Apostolova L, Hwang K, Copolla G, Lane J, Gao F, Cummings JL, Thompson P. Peripheral blood gene expression correlates of cortical atrophy across cognitively normal elderly and MCI. Alzheimer’s Association International Conference 2011, Paris, France, July 16-21, 2011;P2-016.

335. Hwang K, Gylys K, Taylor K, Thompson P, Cole G, Cummings JL, Apostolova L. Plasma BDNF associations with cortical thickness in normal controls and mild cognitive impairment. Alzheimer’s Association International Conference 2011, Paris, France, July 16-21, 2011;P2-037.

336. Yu H, Shen J, Shen Q, Zhang Z, Kim SY, Kwok T, Chen C, Wang SJ, Lee DY, Wang H, Cummings JL, Harrison J, Black R. Alzheimer’s disease instrument validation study in Asia. Alzheimer’s Association International Conference 2011, Paris, France, July 16-21, 2011;P4-170.

337. Boxer A, Cummings J, Gold M, Feldman H, Knopman D, Mackenzie I, Huey T, Rosen H, Kramer J, Hu W. Clinical trials in frontotemporal degeneration and related disorders. 4th Conference: Clinical Trials on Alzheimer’s Disease. San Diego, California. Nov 3-5, 2011;S9.

338. Gril JD, Di L, Elashoff D, Lu PH, Kohannim O, Apostolova L, Ringman JM, Cummings JL, Thompson P and the Alzheimer’s Disease Neuroimaging Initiative. Estimating sample sizes for predementia Alzheimer’s disease clinical trials based on the Alzheimer’s disease Neuroimaging initiative. 4th Conference: Clinical Trials on Alzheimer’s Disease. San Diego, California. Nov 3- 5, 2011;P24.

339. Cummings J, Hendrix S, Miller M, Pejović V, Graham S, Michael T. Extended-release mematine (28 mg, Once Daily) and sustained behavioral improvement: Post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer’s disease. The American Association for Geriatric Psychiatry 2012. Washington, DC. March 16 – 19, 2012: NR 12.

340. Cummings J. Managing functional and cognitive decline in patients with mild-to-moderate Alzheimer’s disease: A 48-week, randomized, double-blind evaluation of 13.3 mg/24 h (15 cm²) versus 9.5 mg/24 h (10 cm²) rivastigmine patch. 64th Annual Meeting American Academy of Neurology. New Orleans, LA. April 21 – 28, 2012: P04.

341. Cummings J, Frölich L, Black S, Bakchine S, Bellelli G, Molinuevo J, Kressig R, Downs P, Caputo A, Strohmaier C. A new option to reach maximum dose efficacy with rivastigmine, patch in the treatment of Alzheimer’s disease: results of a 48-week, randomized, double-blind evaluation of the comparative efficacy, safety and tolerability of 9.5 mg/24 h and 13.3 mg/24 h. 12th International Stolkholm/Springfield Symposium on Advances in Alzheimer Therapy. Stolkholm, Sweden. May 9 – 12, 2012.

342. Shen J, Shen Q, Yu H, Zhang Z, Wang H, Kim S, Kwok T, Chen C, Wang S, Lee D, Cummings J, Harrison J, Beaumont J, Lai J, Cella D, Black R. Alzheimer’s disease instruments validation study in Asia. Alzheimer’s Association International Conference. Vancouver, BC, Canada. July 14 – 19, 2012.

343. Hwang K, Coppola G, Klein E, Thompson P, Cummings J, Apostolova L. Microtubule-associated protein tau H2 haplotype is associated with frontotemporal atrophy in cognitively normal elders. Alzheimer’s Association International Conference. Vancouver, BC, Canada. July 14 – 19, 2012.

344. Apostolova L, Jie Di L, Tseng C, Fairbanks L, Elashoff D, Cummings J. Behavioral reserve in mild cognitive impairment and mild Alzheimer’s disease. Alzheimer’s Association International Conference. Vancouver, BC, Canada. July 14 – 19, 2012.

345. Apostolova L, Jei Di L, Tseng C, Fairbanks L, Elashoff D, Cummings J. Comparison of the prevalence of neuropsychiatric behaviors between amnestic and nonamnestic MCI subjects. Alzheimer’s Association International Conference. Vancouver, BC, Canada. July 14 – 19, 2012.

346. Dilley M, Mason K, Silverman D, Quach J, Beigi M, Ringman J, Cummings J, Grill J. Ketogenic medical food consumption in Alzheimer’s disease enhances the acute cerebral blood flow response in specific frontocortical and basal ganglia regions. Alzheimer’s Association International Conference. Vancouver, BC, Canada. July 14 – 19, 2012.

92

347. Doody R, Winblad B, Cummings J, Tariot P, Sano M, Aisen P, Selby B, Seely L, International CONCERT Study Team. Dimebon in Alzheimer’s disease: Summary and contrast of three efficacy trials. Alzheimer’s Association International Conference. Vancouver, BC, Canada. July 14 – 19, 2012.

348. Cummings J, Grossberg G, Alva G, Caputo A, Downs P, Strohmaier C. High-dose 13.3 MG/24 H rivastigmine transdermal patch demonstrates efficacy on instrumental activities of daily living: Individual item analysis. Alzheimer’s Association International Conference. Vancouver, BC, Canada. July 14 – 19, 2012.

349. Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Mackell J, Fain R. Evaluating the cognitive effects of Donepezil 23 mg/d in Moderate and Severe Alzheimer’s Disease: A patient subgroup analysis. Clinical Trials Conference on Alzheimer’s Disease. Monte Carlo. October 29-31, 2012.

350. Ferris S, Cummings J, Christensen D, Doody R, Farlow M, Sabbagh M, Mackell J, Fain R. Donepezil 23 mg/d for moderate to severe Alzheimer’s disease: Assessing subdomains of the severe impairment battery. Clinical Trials Conference on Alzheimer’s Disease. Monte Carlo. October 29-31, 2012.

351. Harrison J, Altman J, Kempler G, Angua D, Herd C, Targum S, Cummings J, Ritchie C. ADAS-EXEC: A cognitive composite derviced from the ADAS-cog and NTBA. Clinical Trials Conference on Alzheimer’s Disease. Monte Carlo. October 29-31, 2012.

352. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Bahr D, Dhall R, Ballard C. Antipsychotic efficacy and motor tolerability in a phase III placebo-controled study of pimavanserin in patients with Parkinson’s disease psychosis (Study ACP-103- 020). American Academy of Neurology Conference. San Diego, CA. March 21, 2013.

353. Molinuevo J, Cummings J, Froelich L, Galvin J, Tillman K, Stroheimer C. High-dose 13.3 mg/24h rivastigmine patch efficacy and safety in mild-to-moderate Alzheimer’s disease with and without concomitant memantine use. World Congress of Neurology. Vienna, Austria. September 21-26, 2013.

354. Alva G, Cummings J, Galvin J, Meng X, Somogyi M. Infrequent skin reactions at the application site of rivastigmine patch (4.6. 9.5 or 13.3 mg/24 h): analysis of two clinical studies revealed most were tolerable and manageable across all doses. American Society of Consultant Pharmacists Conference. Seattle, WA. November 20-22, 2013

355. Alva G, Cummings J, Galvin J, Meng X, Somogyi M. Infrequent skin reactions at the application site of rivastigmine patch (4.6. 9.5 or 13.3 mg/24 h): analysis of two clinical studies revealed most were tolerable and manageable across all doses. Alzheimer’s Association International Conference. Boston, MA. July 13 – 18, 2012

356. Cummings J, Bellelli G, Black S, Bakchines S, Krahnke T, Strohmaier C. The Rivastigmine high-dose, 13 mg/24h (15 cm²), transdermal patch provides daily living benefits to people with severe Alzheimer’s disease: Retrospective analysis of the optimising transdermal Exelon in mild-to-moderate Alzheimer’s disease (OPTIMA) study. Alzheimer’s Association International Conference. Boston, MA. July 13 – 18, 2013

357. Langbaum J, High N, Aisen P, Albert M, Brown K, Comer M, Cummings J, Manly J, Petersen R, Sperling R, Strobel G, Weiner M, Tariot P, Reiman E. Development and Implementation of the National Alzheimer’s Prevention Registry. Alzheimer’s Association International Conference. Boston, MA. July 13 – 18, 2013

358. Ballard C, Mills R, Williams H, Chi-Burris K, Bahr D, Cummings J. Antipsychotic efficacy and good tolerability in a Phase III placebo-controlled study of Pimavanserin in patients with Parkinson’s disease psychosis (ACP-103-020.) Alzheimer’s Association International Conference. Boston, MA. July 13 – 18, 2013

359. Alva G, Cummings J, Galvin J, Meng X, Somogyi M. Skin reactions at the application site of rivastigmine patch (4.6, 9.5 or 13.3 mg/24 h): a qualitative analysis of two clinical studies. Alzheimer’s Association International Conference. Boston, MA. July 13 – 18, 2013

360. Shen J, Shen Q, Lai J, Beaumont J, Yu H, Zhang Z, Wang H, Kim S, Kwok T, Chen C, Wanf S, Lee D, Harrison J, Cummings J. Sensitivity to change of validated Alzheimer’s disease instruments in an Asian sample. Clinical Trials on Alzheimer’s Disease Conference. San Diego, CA. November 14 – 16, 2013

93

361. Alva G, Cummings J, Galvin J, Meng X, Somogyi M. Skin reactions at the application site of rivastigmine patch (4.6, 9.5 or 13.3 mg/24 h): a qualitative analysis of two clinical studies. American Society of Consultant Pharmacists. Seattle, WA. November 20-22, 2013

362. Ballard C, Mills R, Williams H, Corbett A, Cummings J. Treatment of psychosis in Parkinson’s disease and Parkinson’s disease dementia. 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. Geneva, Switzerland. March 26- 29, 2014

363. Cummings J, Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, Clayton D, Mortensen D, Ho C, Paul R. A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer’s disease. Alzherimer’s Association International Conference. Copenhagen, Denmark. July 12 – 17, 2014

364. Liu-Seifert H, Siemers E, Price K, Han B, Selzler K, Henley D, Sundell K, Aisn P, Cummings J, Raskin J, Mohs R. Cognition impairment precedes and predicts functional impairment in mild Alzheimer’s disease. Alzheimer’s Association International Conference. Copenhagen, Denmark. July 12 – 17, 2014

365. Grill JD, Raman R, Ernstrom K, Dowsett S, Hake A, Aisen P, Doody R, Cummings J. Comparing recruitment among geographic regions in multinational Alzheimer’s disease clinical trials. Alzheimer’s Association International Conference. Copenhagen, Denmark. July 12 – 17, 2014

366. Henley DB, Dowsett SA, Chen Y, Liu-Seifert H, Grill JD, Doody R, Aisen P, Raman R, Miller DS, Hake AM, Cummings J. Regional variation in Alzheimer’s disease progressin in a clinical trial setting. Alzheimer’s Association International Conference. Copenhagen, Denmark. July 12 – 17, 2014

367. Molinuevo JL, Cummings J, Frolich L, Galvin JE, Krahnke T, Strohmaier C. Up-titration to high-dose 13.3 mg/24 h rivastigmine transdermal patch may provide greater benefit to Alzheimer’s disease patients compared to concomitant use of 9.5 mg/24 h patch and memantine. Results from the OPTIMA study. Alzheimer’s Association International Conference. Copenhagen, Denmark. July 12 – 17, 2014

368. Cummings J, Lyketsos C, Tariot P, Peskind E, Nguyen U, Knowles N, Shin P, Siffert J. Dextromethorphan/Quinidine (AVP-923) efficacy and safety for treatment of agitation in Alzheimer’s disease (AD): Results from a Phase 2 Study. 139th Annual Meeting of the American Neurological Association. Baltimore, Maryland. October 12 – 14, 2014

369. Cummings J. Advances in neuropsychiatric drug development. 7th Conference Clinical Trials on Alzheimer’s Disease. Philadelphia, PA. November 20 – 22, 2014

370. Dubois B, Feldman H, Hampel H, Scheltens P, Cummings JL. The added-value of the IWG-2 criteria. 7th Conference Clinical Trials on Alzheimer’s Disease. Philadelphia, PA. November 20 – 22, 2014

371. Liu-Seifert H, Siemers E, Selzler K, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. Correlation between cognition and function across the spectrum of Alzheimer’s disease. 7th Conference Clinical Trials on Alzheimer’s Disease. Philadelphia, PA. November 20 – 22, 2014

372. Cummings JL, Gavrilova SI, Tribanek M, Hoerr R. Sensitivity to change and discriminative power of composite and frequency scores of the neuropsychiatric inventory (NPI) in amnestic mild cognitive impairment, mild dementia and moderate dementia. 7th Conference Clinical Trials on Alzheimer’s Disease. Philadelphia, PA. November 20 – 22, 2014

373. Tariot P, Langbaum J, Reiman E, High N, Aisen P, Albert M, Comer M, Cummings JL, Manly J, Petersen R, Reisa S, Strobel G, Weiner M. Alzheimer’s Prevention Registry: A Shared Resource to the Scientific Community to Facilitate Enrollment in Studies. American College of Neuropsychopharmacology 53rd Annual Meeting. Phoenix, AZ. December 7 – 11, 2014

374. Cummings J. Dextramethorphan/quinidine (AVP-923) efficacy and safety for treatment of agitation in persons with Alzheimer’s disease: results from a phase 2 study (NCT01584440). American Association of Geriatric Psychiatry Annual Meeting, New Orleans, LA. March 29, 2015

375. Goukasian N, LeClair H, Hwang KS, Ringman JM, Cummings JL, Apostolova LG. Behavioral correlates of cognitive decline in normal aging and prodromal Alzheimer’s disease. Alzheimer’s Association International Conference. Washington, DC. July 18-23, 2015 94

376. Langbaum JB, High N, Reiman EM, Aisen PS, Albert MS, Comer M, Cummings JL, Manly JJ, Petersen RC, Srerling RA, Strobel G, Weiner MW, Tariot PN. Alzheimer’s prevention registry: a shared resource to the scientific community to facilitate enrollment in studies. Alzheimer Association International Conference. Washington, DC. July 18-23, 2015

377. Goukasian N, LeClair H, Porat S, Hwang KS, Ringman JM, Silverman D, Cummings JL, Apostolova LG. Anxiety is associated with brain in cognitively normal and mild cognitive impairment subjects: a [18F] flutemetamol PET study. Alzheimer Association International Conference. Washington, DC. July 18-23, 2015

378. Cummings J, Dubé S, Cui H, Siffert J. NPI agitation/aggression domain as a useful clinical trial measure: validity and correlation with other NPI and global outcomes. 8th Conference Clinical Trials on Alzheimer’s Disease. Barcelona, Spain. November 5-7, 2015

379. Dube S, Cummings J, Cui H, Siffert J. NPI agitation/aggression domain scores demonstrate clinically meaningful changes in a phase 2 study of dextromethorphan/quinidine (DM/Q) in patients with agitation in Alzheimer’s disease. American College of Neuropsychopharmacology (ACNP) 2015 Annual Meeting. Hollywood, Florida. December 7, 2015

380. Abushakra S, Vellas B, Cummings J, Hey J, Tolar M, Power A. Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous AD patients: efficacy and safety analyses from two phase 3 trials. 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy. Athens, Greece. March 9-12, 2016

381. Tolar M, Vellas B, Cummings J, Porsteinsson A, Abushakra S, Hey J. Efficacy of tramiprosate in APOE4 heterozygous patients with mild to moderate AD: combined sub-group analyses from two phase 3 trials. 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy. Athens, Greece. March 9-12, 2016

382. Lubarda J, Hanley K, Cummings J. Important concepts in Parkinson’s disease: Can online education improve physician knowledge on neuropsychiatric complications? American Academy of Neurology Annual Meeting. Vancouver, Canada. April 16, 2016

383. Sethanandha C, Dilley M, Grill J, Lee J, Cummings J, Ossindale C, Parker E, Silverman D. Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer’s disease: results of a randomized, double-blinded, pilot study. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. San Diego, CA. June 13, 2016

384. Atri A, Boneva N, Cummings JL, Frolich L, Tariot PN, Windfeld K. Idalopirdine, a 5-HT6 antagonist in phase III development as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: baseline data from the ongoing STARSHINE study. Alzheimer Association International Conference. Toronto, Ontario, Canada. July 24, 2016

385. Cummings J. GAP-NET: Site networks for efficient trials recruitment. Alzheimer’s Association International Conference. Toronto, Ontario, Canada. July 28, 2016

386. Ritchie CW, Webster SP, Cummings J, Masters CL, Ruffles VS, Seckl JR, Walker BR. Xanamem: a novel 11β-HSD1inhibitor with potential to provide durable symptomatic and disease modifying benefits in Alzheimer’s disease. Alzheimer’s Association International Conference. Toronto, Ontario, Canada. July 27, 2016

387. Cummings J, Winfeld K, Odergren T. Idalopirdine, a 5-HT6 antagonist in phase III development as adjunctive therapy to cholinesterase inhibitors in patients with mild-to moderate Alzheimer’s disease: the observed case analyses of the phase II study. International Psychogeriatric Association International Congress. San Francisco, CA. September 6-9, 2016

388. High N, Nichols J, Gordon D, Walsh T, Aggarwal R, Aisen PS, Albert MS, Comer M, Cummings JL, Manly JJ, Petersen RC, Sperling RA, Strobel G, Weiner MW, Reiman EM, Tariot PN, Langbaum JB. Alzheimer’s Prevention Registry:Lessons learned in developing a shared resource to the scientific community. 9th Clinical Trials on Alzheimer’s Disease Congress. San Diego, CA. December 8, 2016.

389. Cummings J, Dube S, Shin P, Megerian T, Wu S, Nguyen U, Lyketsos C. Phase 3 efficacy, safety, and tolerability studies of AVP- 786 (deuterated (d6)-dextromethorphan hydrobromide plus quinidine sulfate) for the treatment of agitation in Alzheimer’s disease (NCT02442765, NCT02442778, NCT02446132). 9th Clinical Trials on Alzheimer’s Disease Congress. San Diego, CA. December 9, 2016

95

390. Voss T, Li J, Cummings J, Doody R, Farlow M, Assaid C, Froman S, Leibensperger H, Snow-Adami L, McMahon K, Egan M, Michelson D. MK7622, a positive of the M1 acetylcholine receptor, does not improve symptoms in Alzheimer’s disease: A randomized, double-blind, placebo-controlled proof of concept trial. 9th Clinical Trials on Alzheimer’s Disease Congress. San Diego, CA. December 9, 2016

Book Cover Citations 1. Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR. Psychiatric Aspects Of Neurologic Diseases: Practical Approaches To Patient Care. Oxford University Press, New York, 2008

2. Budson AE, Solomon PR. Memory Loss: A Practical Guide For Clinicians. Elsevier Saunders, China, 2011

3. Arciniegas DB, Zasler ND, Vanderploeg RD, Jaffee MS. Management Of Adults With Traumatic Brain Injury. American Psychiatric Publishing, Washington, 2013

4. Taylor MA. Hippocrates Cried: The Decline Of American Psychiatry. Oxford Univeristy Press, New York, 2013

5. Stuss DT, Knight RT. Principles Of Frontal Lobe Function. Oxford University Press, New York, 2013

6. Comer M. Slow Dancing with a Stranger. Harper Collins Publishers, New York, 2014

Book Reviews 1. Cummings JL. Review of Differential Diagnosis in Neuropsychiatry. By Roberts JKA. John Wiley and Sons, New York, l984. Neurology l985; 35:l088.

2. Cummings JL. Review of Senile Dementia of the Alzheimer Type. Hutton JT and Keany AD editors. Alan R Liss, Inc., New York, (l985).

3. Cummings JL. Review of Behavioral Neurology, 3rd editor. Pincus JH and Tucker GJ editors. Oxford University Press, New York, l985. Psychosomatics l986;37:806.

4. Cummings JL and Arthur RJ. Review of Behavioral Neurology: A Practical Approach. By Kershner H., Churchill Livingstone, New York, l986. Military Med l5l6l7 1987.

5. Cummings JL. Review of The Exceptional Brain: The Neuropsychology of Exceptional Abilities. Obler L, Fein D, editors. Guilford Press, New York, l987. In Am J Psychiatry 1989; l46:l067-l068.

6. Cummings JL. Review of Geriatric Neuropsychology (Albert M, Moss M, editors). In Neuropsychiatry Neuropsychol Behav Neurol 1989; 2:23l-232.

7. Cummings JL. Review of Time and the Nervous System (Gooddy W, editor). In: Am J Psychiatry 1991;l48:l30-l3l.

8. Cummings JL. Review of Acquired aphasia, 2nd edition. Sarno MT editor. Academic Press, New York, l99l. In: Arch Neurol 1992;49:2l6.

9. Cummings JL. Review of Alzheimer's disease: Current research in early diagnosis. Becker RE, Giacobini E editors. New York, Taylor and Francis, l990. In: J Clin Psychiatry 1992;53:l05.

10. Cummings JL. Review of Neurobiology of memory, 2nd ed. Squire LR, Butters, N editors. In: Am J Psychiatry 1994;151:1514- 1515.

11. Cummings JL. Review of The neurological side of neuropsychology. By Cytowic RE. MIT Press, Cambridge, Mass, 1996. Neurology 1997;48:301-302.

12. Cummings JL. Review of Melancholia: a disorder of movement and mood: a phenomenological and neurobiological review. Parker G, Hadzi-Pavlovic D editors. Cambridge University Press, New York, 1996. In: Psychiatric Services 48:1603- 1604.Cummings JL. Review of how the brain talks to itself: a clinical primer of psychotherapeutic neuroscience. By Harris

96

JE, Haworth Press, New York, 1998. Am J Psychiatry 1999;156: 491-492.

13. Cummings JL. Review of dementia with Lewy bodies: clinical, pathological and treatment issues. Perry RH, McKeith IG, Perry EK editors. Cambridge University Press, New York, 1996. In: Am J Psychiatry 156: 492-493.

14. Cummings JL. Review of Principles of behavioral and cognitive neurology, 2nd ed. M. -M. Mesulam. Oxford University Press, 2000. In: Ann Neurology 49:280.

15. Cummings JL. Review of Neurocorrelates of Consciousness: Empirical and Conceptual Questions. Metzinger T. editor. MIT Press, Cambridge, MA (2000). Published in Am J Psychiatry, 2000.

16. Cummings JL. Review of The Dementias: Diagnosis, Treatment and Research, 3rd ed. Weiner MF, Lipton AM editors. In: Arch Neurol 2004; 61: 1623.

Forewords 1. Cummings JL. Getting Through: Communicating When Someone You Care For Has Alzheimer's Disease. Ostuni E and Santo Pietro MJ. The Speech Bin, Plainsboro, New Jersey, l986.

2. Cummings JL. Visual Fields: Clinical Case Presentations with Photography. Carson et al. Butterworths, Boston, l99l.

3. Cummings JL. Dementia with Lewy Bodies. Perry R, McKeith I, Perry E editors. Cambridge University Press. Cambridge, England, 1996.

4. Cummings JL. Dementia: Management of Behavioural and Psychological Symptoms. Ballard C, O’Brien JO, James I, Swann A. Oxford University Press, Oxford, 2001.

5. Cummings JL. When the Doctor Says “Alzheimer’s”: Your Caregiver’s Guide to Alzheimer’s & Dementia. Weiss, Betty. 1st Books, 2004.

6. Cummings JL. Psychiatric Issues in Parkinson’s Disease: A Pratical Guide. Menza M, Marsh L. (Eds.) Taylor & Francis, London, 2006.

7. Cummings JL. Memory Loss: A Practical Guide for Clinicians. Budson AE, Solomon PR. Elsevier, Inc., Amsterdam, 2011.

8. Cummings JL, Zhong K. Bexarotene for Alzheimer disease: Innovative clinical trial could open the door to disease-modifying. Neuroscience Pathways 2013;4-5

Other 1. Cummings JL. Investigation of the anticonvulsant activity of the biogenic monoamine precursors. Thesis Award. University of Washington School of Medicine, l974.

2. Cummings JL. Rapidly progressive brainstem syndrome. Clini-Pearls l978;2(8):3.

3. Cummings JL. Binswanger's disease. Journal Club Neurology l98l;2(2).

4. Cummings JL. Alzheimer's that isn't. Interview in Transition: Medicine and the Aging Process l982;l(4): 5l-55.

5. Cummings JL. Implications of neurologic research for dyslexia and the reading teacher. Reading Game News l983;11(l):2.

6. Heilman KM, Ross ED, Brumback R, Cummings JL. Editorial: Behavioral Neurology Society. Neuropsychiatry Neuropsychol Behav Neurol l993.

7. Cummings JL, Benson DF. Dementia of the Alzheimer type. An inventory of diagnostic clinical features. Geriatric Digest l986;5:2l-22.

97

8. Cummings JL. The evaluation and management of dementia. Audio-Digest Internal Medicine l993;40(l9).

9. Yudofsky SC, Cummings JL, Hales RE. Advances in neuropsychiatry. ACP Psychiatric Update l993;l3(9):l-9. Text and audiotape.

10. Cummings JL. New drug improves symptoms in Alzheimer's. The Menninger Letter. 1994;6:2(4):7.

11. Cummings JL. Pathogenesis and potentials for prevention. In Advances in Alzheimer's disease. Audio-Digest Internal Medicine l994;4l(8).

12. Miller BL, Ponton M, Benson DF, Cummings JL, Mena I. Enhanced artistic creativity with temporal lobe degeneration. Letter to editor, Lancet 1996;348:1744.

13. Cummings JL. Commentary and recognition and initial assessment of Alzheimer's disease and related disorders. Abstract of Clinical Care Guidelines 1997;9(5):11-12.

14. Relkin NR. Diagnosis of AD: use of genetic/biological markers: a roundtable discussion with Jeffrey L. Cummings, MD, and Richard Margolin, MD. In Alzheimer’s disease and diagnosis: a self-study supplement for neurologists and primary care physicians. A Supplement to Neurology Reviews Advances. January 1999.

15. Cummings JL. The memory impairment screen: a brief test for dementia. In: Journal Watch Neurology. Sample Issue. 1999.

16. Cummings JL. Galantamine is effective for mild-to-moderate Alzheimer’s disease. In: Journal Watch Neurology 2001;(3):90.

17. Cummings JL. New Practice Parameters for Dementia. Psychiatric Times 2001;45-46.

18. Cummings JL, Grossman M, Mayeux R, Scharre D. How to treat dementia in its early stages. Practical Neurology 2002:60.

19. Cherry DL, Cummings JL. Update primary care practice guidelines for Alzheimer’s disease management. Medical Board of California Action Report 2002;6-9.

20. Cummings JL. US Neurology 2013:6

21. Hsain MM, Cummings JL, McKeith IG. Neurobiology of behavioral disturbances in dementia: implications for clinical practice. AAGP 15th Annual Meeting, February 23-27, 2002, Orlando, Florida (Audio cassette).

22. Cummings JL. Cognition and behavior: the role of receptors and transmitters. In: Cognitive and Behavioral Aspects of Neuropsychiatric Disorders. Potkin SG, Alva G, Cummings JL, Glazer WM, Juncos JL, Kanner AM, Pearl PL, Schatzberg AF, Spencer T editors. 2002.

23. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwan EM, Whalen E. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. J Am Geriatr Psychiatry 2003;(51):132-141. (letter to the editor).

24. Cummings JL, Silverman D, Small S, Phelps M. The role of positron emission tomography in the diagnosis of Alzheimer’s disease. J Am Geriatric Soc 2004;(52):467-468.

25. Cummings JL. Medical Reviewer and Editor. New Therapeutic Options Expand the Armamentarium for the treatment of Alzheimer’s Disease. Year in Review. University of Florida, 2004.

26. Cummings JL, Forstl H, Peskind ER, Tangalos EG, Tariot PN (panelists) Salgo PL. (Moderator). Medical Crossfire: Debates, peer exchange, and insights in medicine. Special edition. Alzheimer’s disease continuum: an exchange of diagnosis and treatment strategies. Medical Crossfire 2004;(5).

27. Kaplan A. Through the Times with Jeffrey L. Cummings, M.D. Psychiatric Times 2005; 22, issue 2.

28. Cummings JL, Farlow MR, Olanow CW, Sethi KD (panelists) Salgo PL. (Moderator). Medical Crossfire: Debates, peer exchange, and insights in medicine Special edition. Spotlight on Parkinson’s disease: confronting issues and opportunitites in management. Medical Crossfire 2005;(9):22-30.

98

29. Cummings JL. Meeting review: Genotype, proteotype, phenotype relationships in neurodegenerative diseases. Highlights from the 21st Ipsen Foundation Alzheimer’s Disease Symposium, September 13, 2004, Paris, France. Rev Neurol Dis 2005;2:80-84.

30. Cummings JL. Matters of the mind: Evaluation of patient with dementia. Audio-Digest Family Practice, Sep 7, 2007 55:33.

31. Cummings JL. Alzheimer’s disease redefined. Geriatric Times Fall 2011

32. Cummings J. How much is your brain really worth? The Washington Examiner. May 20, 2011:23

33. Cummings JL. Foreward. US Neurology 2013

34. Zhang Z-X, Cummings J. The China memory clinic guide: Best practices for the care of patients with Alzheimer’s disease and their families. Novartis Pharmaceuticals 2014

35. Cummings JL. From wrong turns to the right stuff: a strategy for clinical trial success in Alzheimer disease. Cleveland Clinic Geriatric Times, Fall 2015

36. Cummings J, Leverenz J, Tousi B. Immunotherapeutic approaches to Alzheimer’s: How we got here and where insights are leading. Cleveland Clinic Neuroscience Pathways 2016:6-7

MEDIA/VIDEOS: 1. Cummings JL. Post-traumatic aphasia. In: Traumatic Brain Injury. A Video Presentation. Head Trauma Support. Project, Inc., 1983.

2. Cummings JL. Alzheimer's disease. Hospital Satellite Network video program, l986.

3. TriAD video, 1997.

4. CNBC Health Update, April 1997.

5. Today Show, November 9, 1997.

6. AirTalk, KPCC, August 26, 1998.

7. Today Show, October 5, 6, 1998.

8. Cummings JL. Communicating the impact of Alzheimer’s disease to patients and caregivers. Video (1998). Winner, Gorden Hugo Award.

9. Cummings JL. Understanding diagnostic scales in Alzheimer's disease. Pfizer Pharmaceuticals. Video (1999).

10. Cummings JL. For a cure for dementia: interview with Dr. Jeffrey L. Cummings. Frontline Vol. 20, No. 6, March 15-28, 2003. Printed and published by S. Rangarajan on behalf of Kasturi & Sons Ltd., at the National Press, Chennai.

11. Cummings JL. Curing Alzheimer’s. BBC Documentary. 2016

12. PBS Nova. Can Alzheimer’s Be Stopped? April 13, 2016.

SELECTED NATIONAL PRESENTATIONS/NAMED LECTURESHIPS:

November 8, 1996; Santa Barbara, California Corinne Precourt Rubottom Lecture; Advances in Alzheimer's disease

November 13, 1996; Hartford, Connecticut Benjamin Wiesel Lectureship; Frontal-subcortical circuits and behavior 99

March 3, 1997; Loma Linda, California Cyril B. Courville Memorial Lectureship; Behavioral manifestations of neurological illness

April 4, 1998; University of Vermont Alexander Nies Lecture; Neuropsychiatric aspects of Alzheimer’s disease

August 4, 1998; Sacramento, California Testified at Hearing on Alzheimer’s disease in California for Joint Committee of the California State Legislature

November 19, 1998; Arlington, Virginia The Dolan Lecture

February 11, 2000; Dallas, Texas The Tobolowsky Lecture

November 14, 2000; Boston, Massachusetts Matthew and Marcia Simons Lectureship, (Alzheimer's Association, Massachusetts Chapter)

March 1, 2003; Boston, Massachusetts

March 11, 2006; American Association Geriatric Psychiatry Pseudobulbar palsy; outcomes of clinical trials of antiamyloid agents

March 25, 2006; Northridge Hospital, California Alzheimer’s Disease Research Update

April 8, 2006; American Academy of Neurology Treatment of frontotemporal dementia

April 27, 2006; Rochester, New York Meyerowitz lecture: Neuropsychiatric aspects of Alzheimer’s disease

June 5, 2006; Los Angeles, California; UCLA Family Medicine Course Evaluation of the patient with dementia; treatment of Alzheimer’s disease

June 29, 2006; Washington, D.C Atypical antipsychotics in Alzheimer’s disease

October 25, 2006; New York, New York Alzheimer’s disease research update

November 18, 2006; Scottsdale, Arizona Alzheimer’s disease research update

November 30, 2006; Toledo, Ohio Neuropschiatric aspects of Alzheimer’s disease

November 9, 2007; Houston, TX Chevas Smyth Lecture “Preventing, delaying and treating Alzheimer’s disease”

December 2, 2007; Las Vegas, NV Preventing Alzheimer’s disease

February 26, 2009; San Diego, CA West Coast College Geriatric Psychiatry “Emerging Treatments of AD: Opportunities and Challenges” 100

March 6-7, 2009; Arlington, VA American Society of Experimental Neuro-Therapeutics. “Fundamentals of Clinical Trials in Neurotherapeutics: Endpoint Validation”

February 7. 2012; Galveston, Texas Vaccines in Chronic Diseases “Disease-Modifying Treatment in Alzheimer’s Disease”

March 22, 2012; New Orleans, Louisianna American Neuropsychiatric Association Annual Meeting 2012 “Developing New Psychiatric Medications for Neuropsychiatric Disorders”

Preventing, delaying and treating Alzheimer’s disease September 10, 2013: New York, NY Alzheimer’s Disease Drug Discovery Foundation Annual Meeting 2013 “Opportunities for Repurposing Approved Drugs for Treatment of Alzheimer’s Disease”

October 19, 2013: San Diego, CA National Assocation of Neuropsychology “Alzheimer Disease Update”

October 26, 2013: Cleveland, OH From Neurodegeneration to Brain Health “Alzheimer’s Disease Drug Development and Clinical Trials”

October 29, 2013: Philadelphia, PA Institute on Aging – Visiting Scholar Series “Alzheimer’s Disease Drug Development and Clinical Trials”

November 15, 2013: San Diego, CA 6th Clinical Trials Conference in Alzheimer’s Disease “Designing Drug Trials Taking into Account Neuropsychiatric Symptoms of Alzheimer’s Disease”

SELECTED INTERNATIONAL PRESENTATIONS:

December 28 - January 10, 1988; Soviet Union (Moscow, Tashkent, Leningrad, Samarkand, Bukhara) February 23 - 24, 1989; Mexico City, Mexico January 22 - 24, 1992; Mexico City, Mexico October 10 - 12, 1992; Montevideo, Uruguay April 3, 1993; Sao Paolo, Brazil April 5, 1993; Rio de Janeiro, Brazil August 18 - 21, 1993; Stockholm, Sweden October 20 - 24, 1993; Amsterdam, Holland November 20 - 24, 1993; Oslo, Norway March 8, 1994; Padua, Italy March 10, 1994, Florence, Italy September 18 - 22, 1994; Cape Town, South Africa October 14, 1994; Brescia, Italy March 29 - April 2, 1995; Nice, France April 21 - 23, 1995; Paris, France July 19, 1995; Cambridge, England July 25 - August 3, 1995; Australia (Perth, Sydney, Brisbane, Melbourne, Adelaide) October 8 - 13, 1995; Guatemala City, Guatemala October 26-29, 1995; Seville, Spain November 16 -19, 1995; Jakarta, Indonesia April 22 - 24, 1996; Bangkok, Thailand 101

July 22 - 27, 1996; Osaka, Japan August 28 - 31, 1996; Seville, Spain June 8 - 13, 1997; University of Chile, Santiago September 29 - October 2, 1997; Helsinki, Finland January 21 - 22, 1998; Oslo, Norway March 19 - 20, 1998; London, England (Stokes Court) July 15, 1998; Glasgow, Scotland July 19 – 23, 1998; Amsterdam, The Netherlands September 1-3, 1998, Hong Kong September 21-24, 1998; Buenos Aires, Argentina October 19-20, 1998; London, England February 1-4, 1999; Bangkok, Thailand March 3-5, 1999; Cape Town, South Africa April 7-10, 1999; Taipei, Taiwan August 6-9, 1999; Hamburg, Germany October 24-27, 1999; Izmir, Turkey December 14, 1999; Barcelona, Spain January 27-28, 2000; Manila, Philippines; Kuala Lumpur, Malaysia; Singapore October, 2000; Cambridge, England February, 2001; Madrid, Spain April 19, 2001; Cyprus May, 2001; Istanbul, Turkey June 18-21, 2001; London, England September 19-21, 2001; Bangkok, Thailand October 25-27, 2001; Christ Church, New Zealand January 9, 2002; Cairo, Egypt February 28-March 2, 2002; Prague, Czechoslovakia March 16, 2002; Rome, Italy April 3-6, 2002; Geneva, Switzerland July 20-29, 2002; Stockholm, Sweden October 25, 2002; Hong Kong, China February 13, 2003; Chennai, India June 13-17, 2003; Jakarta, Indonesia January 14-16, 2004; Sharm El-Sheikh, Egypt March 22-25, 2004; Bangkok, Thailand April 14-16, 2004; Montreal, Canada May 11-17, 2004; Shanghai, Hongzhou, Guangzhou, Shen Yang, Beijing, China August 3-6, 2004; Buenos Aires, Argentina September 5-7, 2004; Paris, France September 10-11, 2004; Odense, Denmark; Danish Neuropsychological Society October 28-30, 2004; Perth, Australia November 3-5, 2004; Bangkok, Thailand; Thai Neurological Society April 19-23, 2005; Santiago, Chile

April 20, 2006; Geneva Switzerland Controversies in cholinergic therapy

May 18, 2006; Copenhagen, Denmark Alzheimer’s disease

May 22, 2006; American Psychiatric Association; Toronto, Canada Advances in neuropsychiatry

June 24, 2006; Paris, France Neuropsychiatric features of mild cognitive impairment

July 18, 2006; Madrid Spain Transdermal rivastigmine for treatment of Alzheimer’s disease 102

September, 23, 2006; Madrid, Spain Neuropsychiatric aspects of dementia

January 6-14, 2007; India (Chennai, Bangalore, Calcutta, Lucknow, New Delhi) Defining treatment goals in dementia

March 18, 2007; Paris, France Memantine and behavioral disturbances in Alzheimer’s disease

July 2, 2007; Singapore, China Optimizing treatment for Alzheimer’s disease

July 4, 2007; Kuala Lampur, Thailand Optimizing treatment for Alzheimer’s disease

July 5, 2007; Bangkok, Thailand Behavioral aspects of Alzheimer’s disease

July 8, 2007; Phuket, Thailand Alzheimer’s disease: Pathophysiology and treatment

September 19, 2007; Stockholm Sweden Memantine treatment of Alzheimer’s disease

September 20, 2007; Copenhagen, Denmark Memantine and behavioral disturbances in Alzheimer’s disease

October 14, 2007; Vienna, Austria Memantine and behavioral disturbances in Alzheimer’s disease

August 25, 2008; Madrid, Spain European Federation of Neurological Societies Symposium “Future Treatment Approaches in Europe and US”

October 19, 2008; Naples, Italy “Mind & Movement” Symposium., “Trans-Dermal Patch for Alzheimer’s disease”

February 9-13, 2009; Luxor, Egypt 1st Annual Egyptian Con. “Advances in the Treatment of AD” “Drug Development CNS Disorder”

May 15, 2009; Copenhagen, Denmark Dementia Symposium – “Usability of the Neuropsychiatric Inventory in Assessing BPSD” “Dementia Treatment in Retrospect: Role of Cholinesterase Inhibitors in the Future”

May 24, 2009; Chengdu, China Asia Dementia Symposium “Advances in Treatment and Diagnosis of AD”

August 21, 2009; Santiago, Chile “Neuropsychiatric Aspects of Alzheimer’s Disease”

September 3, 2009; Montreal, Canada International Psychogeriatric Associations “Disease Modifying Therapies in Alzheimer’s Disease

103

September 12, 2009; Madrid, Spain Quenen Solin Alzheimer’s Foundation (Quenen Solin Attended) “Alzheimer’s Disease Therapeutics”

October 25, 2009; Bangkok, Thailand World Congress of Neurology Update: Alzheimer’s Disease Therapeutics

December 6, 2009; Bali “Memantine Mechanisms of Action”

January 23, 2010; Pusan, Korea “Behavioral Cholinesterase Inhibitor Effects”

February 5, 2010; Berlin, Germany “New Targets for Therapy in Alzheimer’s Disease”

March 26, 2010; Geneva, Switzerland “The Future of Alzheimer’s Disease Research”

April 24, 2010; Amman, Jordan “Update in Alzheimer’s Disease Research”

April 27, 2010; Pattaya, Thailand Vikert Vivanuatti Invited Lecturer “Biomarkers Insights into the Pattoyamesis of Alzheimer’s Disease”

May 28, 2010; Sorrento, Italy “Update on Alzheimer’s Disease Therapeutic Targets”

June 6, 2010; Hong Kong, China Rivastigmine patch as a treatment for Alzheimer’s disease Chinese Dementia Society Meeting

July 8, 2011; Bangkok, Thailand Dementia Expert Meeting “New Approaches to the Early Diagnosis of Alzheimer’s Disease”

July 9, 2011; Bangkok, Thailand Dementia Expert Meeting “Targets in Alzheimer’s Disease Research”

July 16-21, 2011; Paris, France Alzheimer’s Association International Conference “New Criteria for Alzheimer’s Disease”

September 22, 2011: Madrid, Spain Alzheimer’s International 2011 “Year of Research on Alzheimer’s”

February 28, 2012; Manchester, United Kingdom David Bowen Memorial Symposium “Disease-Modifying Treatment in Alzheimer’s Disease”

May 8 – 12, 2012: Stockholm, Sweden Advances Alzheimer’s Therapy (Springfield) 2012 “New Criteria for Alzheimer’s Disease”

104

November 8, 2012: Amsterdam, The Netherlands Dementia 2012 “Concept change in AD: Diagnosis before dementia – Review of guidelines and use of biomarkers”

November 10, 2013: Monte Carlo, Monaco Cleveland Clinic International Leadership Board Meeting “Alzheimer’s Disease and the Lou Ruvo Center for Brain Health “

105